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Summary 
DNA damage results from exposure to endogenous and environmental genotoxic agents such 
as alkylating agents. Base excision repair (BER) is a DNA repair process initiated by DNA 
glycosylases acting on DNA base damage. An example of such DNA glycosylases acting on 
alkylation base damage is the alkyladenine DNA glycosylase (AAG).  
AAG activity on alkylated DNA bases initiates BER and generates abasic sites (AP sites), 
which are further processed to form single strand breaks (SSBs). If left unrepaired, these 
BER intermediates are very toxic to the cell. Since BER is a multistep repair process, any 
imbalance in the pathway can lead to accumulation of these toxic intermediates and 
potentially trigger cell death via a mechanism postulated to involve hyperactivation of 
poly(ADP-ribose) polymerase (PARP). PARP uses energy in the form of NAD+ for the 
synthesis of poly(ADP-ribose) (PAR) polymers and therefore PARP hyperactivation may 
result in bioenergetics failure. 
This study characterised the BER pathway initiated by AAG and analysed cellular response 
to alkylation by using AAG proficient and deficient cells. The temporal changes in BER 
intermediate incidence were characterised. In addition, PAR synthesis and cellular levels of 
NAD+ and ATP as well as cell death were measured and the temporal changes were 
characterised. Moreover, the effects of alkylation treatment on cell cycle progression were 
investigated. 
The results show that the kinetics and magnitude of BER intermediate formation is similar 
in AAG proficient versus AAG deficient cells. Meanwhile, there were clear differences 
between these two genotypes in terms of PAR synthesis, bioenergetics, cell viability and cell 
cycle. This study shows that the processing of alkylated bases and formation of BER 
intermediates is rapid and concomitant with an increase in PAR synthesis. Importantly, this 
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increase in PAR synthesis is only observed in AAG proficient cells suggesting that AAG 
activity is necessary for PAR polymer formation after SSB induction. 
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1.1 DNA 
Deoxyribonucleic acid (DNA) is required for the expression and storage of genetic 
information. DNA is packaged into chromosomes in the nucleus of eukaryotic organisms 
and is also present in mitochondria (Champe and Harvey, 2005). Nucleotides are the building 
blocks of DNA and there are four types of nucleotides, adenine (A), thymine (T), guanine 
(G) and cytosine (C). Unless damage occurs, these four nucleotides pair with each other in 
a complimentary way, therefore A always pairs with T and G always pairs with C. Each 
nucleotide comprises of a phosphate group, a sugar molecule (a deoxyribose in DNA) and a 
nitrogen containing base. The complementary bases are paired through weak hydrogen 
bonds which hold the DNA in a double strand (Figure 1-1). However, this complex structure 
of the DNA is continuously attacked by various endogenous and exogenous agents lead to a 
diversity forms of DNA damage (Gidron et al., 2006). 
 
Figure 1-1: The structure of double-helix DNA. Double-stranded DNA is composed of two long intertwined 
polynucleotide chains held together by base pairing to form a double helix. Adenine and thymine pair via two 
hydrogen bonds between opposing chains, whereas guanine and cytosine pair via three hydrogen bonds. The 
arrows on the DNA chains show the polarities of the two long chains, which run antiparallel to each other in 
the DNA molecule (i.e. one runs 5' to 3', the other runs 3' to 5') (Alberts, 2010). Figure is adapted from (Alberts, 
2010). 
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1.2 DNA Damage 
DNA damage refers to any alteration (physical or chemical) in the double-helix structure of 
the DNA which is capable of causing cellular injury (Kaufmann and Paules, 1996, Freitas 
and de Magalhaes, 2011). Damage to the DNA is thought to play a major role in the ageing 
process, since DNA damage can be mutagenic or cytotoxic (De Bont and van Larebeke, 
2004).  
DNA damages can result in increased error-prone DNA synthesis during DNA repair or 
replication which consider as a major source of mutations. The accumulation of these 
mutations as a function of time could contribute to ageing by a decrease in cellular function 
because these mutations can lead to inactivates genes that are important for the cell 
functioning (Kennedy et al., 2012). In addition, the accumulation of unrepaired DNA 
damages can also contribute to ageing by inducing cells to undergo apoptosis or cellular 
senescence which eventually lead to reduced tissue homeostasis with age (Freitas and de 
Magalhaes, 2011, Maynard et al., 2015). These evidences indicate that accumulation of DNA 
damages is associated with ageing. However, DNA damage can arise from different sources 
which are known as DNA damage agents as discussed below. 
1.3 Classification of DNA Damage Agents 
DNA damage agents can be classified into two major classes, endogenous (or spontaneous) 
and exogenous (or environmental) (Friedberg et al., 2006). Endogenously, DNA damage can 
mostly result from hydrolytic and oxidative reactions (Friedberg et al., 2006). Indeed, one 
important source of endogenous DNA damage is unavoidable by-products of normal cellular 
metabolism, such as reactive oxygen species (ROS) (Houtgraaf et al., 2006). DNA damage 
can also result from the inherent instability of the DNA molecule or from replication errors 
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(Meira et al., 2005). Approximately 20,000 lesions per day per cell result from endogenous 
sources which lead to DNA damage (Drablos et al., 2004).  
In contrast, environmental DNA damaging agents include any external agent that causes 
damage to the DNA (Friedberg et al., 2006). Examples of these environmental agents are 
ionizing radiation, ultraviolet (UV) radiation in sunlight and numerous genotoxic chemicals 
(Houtgraaf et al., 2006). Although some agents such as UV light (photodynamic therapy), 
ionizing radiation and most chemotherapeutic agents can cause damage to the DNA, they 
are increasingly being used to treat common disorders, for example psoriasis, vitiligo and 
cancer (Houtgraaf et al., 2006, Jackson and Bartek, 2009, Carter et al., 1976). However, 
exposure to endogenous and environmental DNA damaging agents can lead to a wide 
diversity of lesions in the DNA as summarised in the next figure (Figure 1-2). 
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Figure 1-2: Summary of the most common types of DNA damaging agents (top) which can be generated by 
spontaneous or environmental damaging agents. Examples of the DNA lesions induced by those agents are 
shown (middle), where these lesions can affect a single strand or both strands of the DNA molecule. The 
assumed DNA repair pathway which is responsible for the removal of the lesions is indicated as well (bottom) 
(Houtgraaf et al., 2006). ROS, reactive oxygen species; HR, homologous recombination; NHEJ, 
nonhomologous end-joining. Figure is adapted from (Houtgraaf et al., 2006). 
1.4 Responses to DNA Damage 
The many types of DNA lesions which result from either endogenous metabolism 
(spontaneous) or from exposure to environmental agents are rapidly detected, with 
subsequent activation of a complicated web of cellular pathways which sense, signal and 
repair DNA damages. This network of cellular pathways is known as the DNA damage 
response which involves multiple mechanisms in cells (Barzilai and Yamamoto, 2004). 
These mechanisms result in either removal of the DNA damage or mitigation of the 
potentially lethal effects that result from interference with normal DNA metabolism 
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(Friedberg et al., 2006). Below, (Figure 1-3) shows a summary of different cellular 
mechanisms responding to damaged DNA.  
 
Figure 1-3: Summary of the different types of cellular responses to DNA damage (Friedberg et al., 2006). 
A more detailed description of cell cycle and checkpoint control can be found in chapter 5 
(page 170). 
1.5 Types of DNA Damage 
Several known types of DNA damage have been identified. Some of the most common types 
of DNA damage are already mentioned in Figure 1-2. Small base chemical alterations are 
alterations of the chemical structure of DNA bases which may not obstruct replication or 
transcription but they often induce miscoding, therefore can lead to mutagenesis. In addition, 
helix deforming lesions interfere with base pairing, normal replication and transcription and 
primarily arise from environmental sources. Finally, double strand breaks (DSBs) are breaks 
in both strands of the DNA molecule and render more serious damage and challenges for 
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repair (Gidron et al., 2006). However, this thesis will focus on the types of base damage 
which can be repaired by base excision repair (BER) pathway and a representative sampling 
of these types is discussed below.  
1.5.1 Deaminated DNA Bases 
Deamination of the DNA bases refers to the loss or removal of an amino group from the 
DNA bases which catalyses by enzymes called deaminases. Three of the four DNA bases 
(adenine, guanine and cytosine) undergo deamination in spontaneous reactions; deamination 
of adenine results in hypoxanthine (Hx), deamination of guanine gives rise to xanthine or 
oxanine and deamination of cytosine leads to uracil (U) (Figure 1-4) (Meira et al., 2005, 
Hitchcock et al., 2004). The exception of deaminated bases in DNA is thymine due to the 
absence of amino group in this DNA base (Freitas and de Magalhaes, 2011). 
Also, the base 5-methylcytosine can be found in the DNA molecule where some authors 
consider it as the fifth distinct base for the DNA (Friedberg et al., 2006, Freitas and de 
Magalhaes, 2011, De Bont and van Larebeke, 2004). It is a naturally occurring derivative of 
cytosine which base pairs with guanine. The deamination of 5-methylcytosine into thymine 
(Figure 1-4) leads to the production of a G-T base pair (mispair) (Freitas and de Magalhaes, 
2011).   
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Figure 1-4: The deamination of the DNA bases and their formed products. Deamination of adenine results in 
hypoxanthine, deamination of guanine will give rise to xanthine and deamination of cytosine leads to uracil. 
Also, the base 5-methylcytosine which is derived from cytosine can be deaminated into thymine. The numbers 
of the base ring atoms are shown (Friedberg et al., 2006). Figure is copied from (Friedberg et al., 2006). 
During replication, hypoxanthine pairs with cytosine leading to transitions of A:T to G:C 
(Schouten and Weiss, 1999, Hill-Perkins et al., 1986). Whereas, uracil pairs with adenine 
resulting in C:G to T:A transitions (Duncan and Miller, 1980, Coulondre et al., 1978). In 
contrast, because most types of deaminated bases form a base which does not occur in DNA 
naturally (deamination of 5-methylcytosine is the only exception), so this can facilitate the 
identification and excision of the deamination bases by DNA glycosylases enzymes (Freitas 
and de Magalhaes, 2011). However, all deaminated base lesions are mutagenic and they 
might be considered as the major source of endogenous mutagenesis in cells (Meira et al., 
2005). 
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1.5.2 Oxidised DNA Bases 
DNA damage by oxidation is the result of the interaction of reactive oxygen species (ROS) 
with DNA and it represents a major source of endogenous DNA damage (Kow, 2002, Meira 
et al., 2005). Despite oxygen (O2) being an essential component for energy production in 
aerobic organisms, it is also extremely dangerous to the organisms because of the high 
susceptibility of DNA to attack by ROS and this is referred to as the “Oxygen Paradox” 
(Barzilai and Yamamoto, 2004, Friedberg et al., 2006, Davies, 1999).     
The most important ROS include superoxide anions (O2•ˉ), hydrogen peroxide (H2O2) and 
hydroxyl radicals (•OHˉ). The mutagenic 8-oxo-7,8-dihydroguanine (8-oxoG) and thymine 
glycols (TG) and ring-opened forms of purines (formamidopyrimidines) are the major 
biologically relevant oxidative products, with all of them mutagenic and cytotoxic (Rouet 
and Essigmann, 1985, Marnett, 2000).  
ROS are produced constantly in the cells as a result from exposure to endogenous and 
environmental oxidant agents (Nelms et al., 1998, Shiloh and Kastan, 2001). The process of 
reducing molecular oxygen (O2) to water (H2O) where there is sequential transfer of single 
electrons is one main mechanism by which ROS are produced (Figure 1-5) (Gidron et al., 
2006). During this mechanism, the series of one electron O2 reduction steps has become 
known as the univalent pathway for O2 reduction (Figure 1-5) (Davies, 1999). 
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Figure 1-5: The univalent pathway for oxygen (O2) reduction. At first, O2 is reduced to the superoxide anion 
radical (O2•ˉ) and after that to the hydrogen peroxide (H2O2). A production of the extremely powerful oxidant 
of hydroxyl radical (•OH) is the third electron reduction. Finally, the production of water (H2O), following the 
fourth electron reduction is the last step in the dangerous univalent pathway for O2 reduction (Davies, 1999). 
Figure is copied from (Davies, 1999). 
The endogenous sources of ROS can be considered as natural by-products of cellular 
metabolism which include mitochondrial oxidative respiration and lipid peroxidation 
(Hoeijmakers, 2001, Gidron et al., 2006, Bartsch et al., 2002). Additionally, pathological 
conditions such as inflammation are another example where increased endogenous 
production of ROS is observed (Ohshima and Bartsch, 1994, Meira et al., 2008). On the 
other hand, environmental ROS sources may include exposure to ionising radiation or 
radiomimetic chemicals, alcohol and cigarette smoking (Moller et al., 1996). 
Molecules which can enhance the effects of ROS are termed pro-oxidants, while molecules 
that inhibit the effects of ROS are termed antioxidants (Gidron et al., 2006). Furthermore, 
oxidative stress can result when the concentration of pro-oxidants is greater than the 
concentration of antioxidants (Gidron et al., 2006, De Bont and van Larebeke, 2004). As 
reviewed by Meira et al. (2005), DNA damage by oxidative stress gives rise to damaged 
bases and also damage to the sugar-phosphate backbone which can cause single strand 
breaks (SSBs) or double strand breaks (DSBs) that can result in recombinational or lethal 
events. 
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1.5.3 Abasic Sites, Depurination and Depyrimidination 
The abasic site (also called AP site) is considered as one of the most frequent spontaneous 
lesions in DNA. AP site is the commonly used abbreviation, where AP symbolises 
apurinic/apyrimidinic. It is produced in the DNA when a DNA base is lost by hydrolytic 
cleavage of the N-glycosyl bond between the DNA base and its deoxyribose sugar, leaving 
the sugar-phosphate chain intact (Figure 1-6) (Friedberg et al., 2006). Under normal 
physiological conditions, the amount of AP sites is expected to persist at 50,000-200,000 
lesions per mammalian cell at steady state level (Nakamura and Swenberg, 1999). AP sites 
are potentially mutagenic and cytotoxic, which can block and prevent normal DNA 
transcription and replication (Boiteux and Guillet, 2004, Dianov et al., 2003). 
AP sites can be formed in the DNA by spontaneous depurination and depyrimidination 
(Freitas and de Magalhaes, 2011). Depurination includes the loss of purine bases (adenine 
or guanine) from the DNA molecule. The N-glycosyl bond to deoxyribose is broken in 
spontaneously occurring depurination reactions by hydrolysis, leaving the sugar-phosphate 
chain in the DNA molecule intact, forming an AP site (Freitas and de Magalhaes, 2011). 
On the other hand, depyrimidination results from the loss of pyrimidine bases (cytosine or 
thymine) from the DNA molecule (Freitas and de Magalhaes, 2011). Because the N-glycosyl 
bond between the pyrimidine base and the deoxyribose sugar in the DNA is more stable than 
the similar bond for the purine base, so depyrimidination is much less common than 
depurination (Lindahl, 1993, Freitas and de Magalhaes, 2011). 
Furthermore, AP sites can also be produced as an intermediate step of the base excision 
repair (BER) pathway by DNA glycosylases (to be discussed later in Section 1.6.1) (Boiteux 
and Guillet, 2004), as well as being formed by ROS (Nakamura and Swenberg, 1999, 
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Nakamura et al., 2000). Importantly, incomplete or inefficient BER may leave unrepaired 
AP sites in the DNA which are cytotoxic lesions to the cells (Freitas and de Magalhaes, 
2011). 
 
Figure 1-6: The origin of spontaneous abasic sites (AP sites) in the DNA. They are produced by spontaneous 
hydrolysis of the N-glycosyl bond of damaged bases or normal purines. Also, AP sites are formed by removal 
of damaged bases, inappropriate bases and also normal bases from the DNA by specific DNA N-glycosylases 
(Boiteux and Guillet, 2004). Figure is copied from (Boiteux and Guillet, 2004). 
1.5.4 Single Strand Breaks 
Single strand breaks (SSBs) are DNA strand breaks where one strand of the DNA double 
helix carries a breakage or interruption in the sugar-phosphate backbone. These DNA strand 
breaks are accompanied usually by loss of a single nucleotide and will contain either a 3' 
and/or 5' obstructive termini at the site of the DNA strand break (Dianov and Parsons, 2007, 
Caldecott, 2014). 
SSBs can arise in the DNA indirectly as an intermediate during the BER process when base 
damage is removed from DNA (will discuss later in more details). Also, they can arise 
directly via disintegration of the deoxyribose sugar of the DNA (Caldecott, 2014). These 
formation of SSBs in the DNA are induced by both endogenous and exogenous sources. An 
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example for endogenous source is oxidative attack by ROS. While, SSBs can also induced 
by exogenous sources such as alkylating agents and ionising radiation (Caldecott, 2004, 
Pascucci et al., 2005). 
SSBs formed in DNA must be repaired otherwise unrepaired SSBs can significantly impact 
cell fate (Caldecott, 2008). Single strand break repair (SSBR) is a collective term for the 
repair of both direct and indirect SSBs because it appears that the same group of proteins in 
SSBR are involved in the repair of both types of SSBs (Caldecott, 2004, Caldecott, 2014). 
1.5.5 Alkylated DNA Bases 
Alkylation of the DNA bases caused by alkylating agents is considered as one of the most 
common forms of DNA damage. This is because many alkylating agents are present in the 
environment and also within the cells. Alkylating agents are genotoxic chemicals and may 
be broadly defined as electrophilic compounds with affinity for nucleophilic centres in 
organic macromolecules. In other words, they can transfer alkyl carbon groups to over a 
dozen nucleophilic sites in the DNA and other cellular macromolecules (Friedberg et al., 
2006). Therefore, these agents can alter the structure of biological molecules and potentially 
disrupt their function (Fu et al., 2012). Some types of alkylation damage are cytotoxic due 
to the fact that they block the progression of replicative DNA polymerases (Larson et al., 
1985, Doublie et al., 1998, Beard et al., 1996). Whereas some of the other types can be 
mutagenic, if the methylated base mispairs during DNA duplication (Rebeck and Samson, 
1991). 
1.5.5.1 Reaction Sites 
Numerous potential reaction sites in all four bases of the DNA have been identified for 
alkylation, but not all of these reaction sites have equal reactivity (Friedberg et al., 2006). 
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Nitrogen and oxygen atoms in the four DNA bases and in phosphodiester bonds between the 
DNA bases are targets for attack by alkylating agents (Figure 1-7) (Middleton and Margison, 
2003). This is largely reliant on the type of mechanism by which the alkylating agents react 
(Meira et al., 2005). 
 
Figure 1-7: The nucleophilic centres in the DNA base-pairs which are the most highly reactive with alkylating 
agents. These sites of attack by alkylating agents are indicated in red. dR, deoxyribose residue. Adapted from 
(Middleton and Margison, 2003). 
Generally, the ring nitrogen of the DNA bases are more nucleophilic (reactive) than the ring 
oxygens (Friedberg et al., 2006). In addition, the most reactive and frequent sites of damage 
in DNA bases are the N3 position of adenine and the N7 and O6 positions of guanine (Figure 
1-7) (Singer, 1986, Middleton and Margison, 2003). The N7-position of guanine DNA base 
is the predominant target of alkylation in DNA bases which accounts for 70-90% of all DNA 
alkylation damages (Rinne et al., 2005). 
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1.5.5.2 Classification of Alkylating Agents 
Alkylating agents can be classified into two main categories depending on the number of 
reactive sites, monofunctional and bifunctional (Friedberg et al., 2006). Also, alkylating 
agents can be divided into two types SN1 (nucleophilic substitution, first order) and SN2 
(nucleophilic substitution, second order) agents on the basis of their particular chemical 
reactivity (the reaction with electron-rich atoms in biologic molecules to form covalent 
bonds) (Colvin, 2000). These different classifications of alkylating agents will be explained 
in detail in below. 
1.5.5.2.1 Monofunctional and Bifunctional Alkylating Agents 
Monofunctional alkylating agents have one active moiety (single reactive group) which 
covalently interacts with one of the nucleophilic centres in the DNA and then modifies single 
bases (Friedberg et al., 2006, Helleday et al., 2008). Bifunctional alkylating agents have two 
active moieties (two reactive groups), so each molecule can react with two sites in the DNA 
(Fu et al., 2012). The table below (Table 1-1) illustrates the reactive sites in DNA for many 
monofunctional alkylating agents.  
Table 1-1: The reactive sites of monofunctional alkylating agents in DNA. 
The Base The Sites of Reactions 
Adenine N1, N3, N6 and N7 
Guanine N1, N2, N3, N7 and O6 
Cytosine N3, N4 and O2 
Thymine N3, O2 and O4 
Note: exocyclic positions on the four bases of the DNA are nominated with a superscript 
(Friedberg et al., 2006). 
On the other hand, because bifunctional alkylating agents can react with two different sites 
(nucleophilic centres) in the DNA, they can form inter-strand DNA cross-links when the two 
sites are on opposite polynucleotide strands, and intra-strand cross-links if these two sites 
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are situated on the same polynucleotide strand of the DNA duplex (Figure 1-8). Inter-strand 
cross-links are an important class of chemical DNA damage because they can prevent the 
separation of the DNA chain and therefore can constitute severe and complete blocks to the 
DNA transcription and replication (Helleday et al., 2008, Friedberg et al., 2006).   
 
Figure 1-8: The effects of both monofunctional and bifunctional alkylating agents on the DNA bases. 
Monofunctional alkylating agents have one single reactive group which interacts with one of the nucleophilic 
centres in the DNA and then alkylates and modifies single bases (top). While, bifunctional alkylating agents 
have two reactive groups which can react with two different sites in the DNA molecule. If these two sites are 
situated on opposite polynucleotide strands, then inter-strand cross-link is generated (middle). While, intra-
strand cross-link is produced when the two sites are in the same polynucleotide strand of the DNA (bottom) 
(Hurley, 2002). Figure is copied from (Hurley, 2002). 
1.5.5.2.2 SN1 and SN2 Alkylating Agents 
The alkylating agents are broadly defined as electrophilic compounds which can react with 
electron-rich atoms in the biologic molecules to form covalent bonds with nucleophilic 
centres found not only in DNA but also in RNA and proteins. The SN1 alkylating agents 
directly react with biologic molecules. While, SN2 alkylating agents form a reactive 
intermediate which then reacts with the biologic molecules. In the SN1 alkylating agent, the 
reaction occurs in two steps and the rate of reaction is only dependent on the concentration 
of electrophile (the reactive intermediate). Therefore, this reaction follows first-order 
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kinetics. While in the SN2 alkylating agent, the reaction occurs in one step and the rate of 
reaction relies on the concentration of both electrophile (the alkylating agent) and 
nucleophile (the nucleophilic target). Thus, this reaction exhibits second-order kinetics. 
These differences have important implications in understanding the molecular and cellular 
pharmacology of particular alkylating agents (Colvin, 2000, Friedberg et al., 2006). 
1.5.5.3 Sources of Alkylating Agents 
Alkylating agents are abundantly present within living cells (endogenous) and in our 
environment, hence they are unavoidable. Also, these agents can be used in the clinic as 
chemotherapeutic agents such as the cytostatic drugs in cancer therapy (Fu et al., 2012). 
These different sources of alkylating agents will be discussed below in more detail. 
1.5.5.3.1 Endogenous Alkylating Agents 
There are several potential physiological sources of alkylating agents and many such 
alkylating compounds have been identified (Drablos et al., 2004). S-adenosylmethionine 
(SAM) is an example of an endogenous alkylating agent which is well defined and it is the 
major alkylating agent produced endogenously (Sedgwick et al., 2007). SAM is a methyl 
group donor in the great majority of in vivo enzymatic DNA methylation reactions including 
a wide variety of acceptor molecules (Sedgwick et al., 2007, Drablos et al., 2004). Also, it 
is a weak nonenzymatic DNA methylating agent in vitro that has been shown to induce DNA 
mutations (Barrows and Magee, 1982, Rydberg and Lindahl, 1982). 
SAM mainly alkylates the ring nitrogen of purines in the DNA, generating 7-methylguanine 
(7-meG) and 3-methyladenine (3-meA), but little and insignificant levels of O6–
methylguanine (O6–meG) (Rydberg and Lindahl, 1982, Barrows and Magee, 1982). SAM 
produces the same products on alkylation of the DNA as the experimental alkylating agent, 
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methyl methanesulfonate (MMS) but the reactivity of SAM is approximately 2000-fold 
weaker compared to MMS (Rydberg and Lindahl, 1982, Sedgwick et al., 2007). 
1.5.5.3.2 Environmental Alkylating Agents 
There are many direct acting methylating compounds which are present in the environment. 
An example of such environmental alkylating agents is methyl chloride (MeCl) which is also 
called chloromethane. MeCl is a gas and a very ubiquitous environmental carcinogen and 
mutagen as a result of DNA alkylation (Friedberg et al., 2006). MeCl is the most abundant 
atmospheric halocarbon which can be produced in many terrestrial environments such as by 
fungi and plants, also it can be generated industrially as well (Drablos et al., 2004). 
Moreover, bromomethane (or methyl bromide - MeBr) and other bromo-compounds are 
more abundant in marine environments. Also, iodomethane (or methyl iodide - MeI) can be 
produced in the environment as well (Ballschmiter, 2003). All of these halocarbons (MeCl, 
MeBr and MeI) are present in the ambient air (Mohamed et al., 2002) and they can alkylate 
DNA, therefore, being mutagenic and carcinogenic (Bolt and Gansewendt, 1993, Vaughan 
et al., 1993). 
In contrast, human exposure to N-nitroso compounds produced in tobacco smoke products 
might be the predominant source of exposure to the environmental alkylating agents 
(Drablos et al., 2004). Tobacco smoke products is including tobacco specific N-nitroso 
compounds and also many other nitroso compounds (Drablos et al., 2004). These compounds 
can lead to DNA alkylations after metabolic activation (Hecht, 1999) which can generate 
O6-meG and also other methylated bases (Drablos et al., 2004). 
Moreover, food compounds can be also nitrosated to agents which alkylate DNA (Drablos 
et al., 2004). Myosmine is present in a variety of foods, for example milk and also several 
vegetables and fruits, where it is nitrosated easily to alkylating DNA compounds (Tyroller 
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et al., 2002).  Additionally, fish and cured foods may significantly contain higher amounts 
of N-nitroso compounds (Goldman and Shields, 2003). 
1.5.5.3.3 Alkylating Drugs 
Alkylating drugs are the oldest class of anti-cancer drugs and they are commonly used for 
treatment of many different types of cancers (Chaney and Sancar, 1996, Hurley, 2002). 
These anti-cancer agents are unfortunately extremely toxic also to non-cancer tissue 
(Harrison and Fauci, 1998). The common feature of the alkylating drugs is their ability to 
alkylate nucleophilic sites in cellular macromolecules, favouring sulphur, nitrogen and 
oxygen (Middleton and Margison, 2003). DNA repair processes strongly modulate the 
effects of alkylating drugs, therefore, controlling and understanding of these repair processes 
might allow development of new therapies by potentiating effects in target tissues or by 
protecting normal tissues (Drablos et al., 2004, Middleton and Margison, 2003). 
Most alkylating drugs are monofunctional methylating agents, bifunctional alkylating agents 
or chloroethylating agents (Kondo et al., 2010). As discussed above, bifunctional alkylating 
agents can form inter-strand DNA cross-links and are therefore very effective cytotoxic 
agents since they can prevent DNA strand separation and completely block DNA 
transcription and replication. So, it is for this reason that many bifunctional alkylating agents 
have been extensively used in cancer chemotherapy (Friedberg et al., 2006). Table 1-2 shows 
some examples of these alkylating drugs. 
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Table 1-2: Some examples of alkylating drugs. 
Monofunctional 
Methylating Agents 
Bifunctional Alkylating 
Agents 
Chloroethylating Agents 
 Temozolomide (TMZ). 
 N-methyl-N'-nitro-N-
nitrosoguandine 
(MNNG). 
 Dacarbazine. 
 Nitrogen mustards (e.g., 
chlorambucil and 
cyclophosphamide). 
 Cisplatin. 
 Nimustine (ACNU). 
 Carmustine (BCNU). 
 Lomustine (CCNU). 
 Fotemustine. 
Adapted from (Kondo et al., 2010). 
1.5.5.4 Alkylating Agents Used in Laboratory Studies 
There are many types of alkylating agents which are widely used in the research studies. 
Simple methylating and ethylating agents in laboratory studies are shown in Table 1-3 which 
are frequently used in DNA repair studies. 
Table 1-3: Some of the methylating and ethylating agents used in DNA repair studies. 
Methylating Agents Ethylating Agents 
Methylnitrosourea (MNU) Ethylnitrosourea (ENU) 
N-methyl-N'-nitro-N-nitrosoguanidine (MNNG) Ethyl methanesulfonate (EMS) 
Methyl methanesulfonate (MMS)  
Adapted from (Friedberg et al., 2006). 
MNNG and MNU attack both oxygens and nitrogens, whereas MMS attacks mostly base 
nitrogens (Friedberg et al., 2006). Below, I will focus on MMS in more detail since it is the 
alkylating agent of choice for this study.  
1.5.5.4.1 Methyl Methanesulfonate (MMS) 
Methyl methanesulfonate (MMS) is one of the monofunctional alkylating agents which is 
widely used in research studies. MMS methylates DNA bases leading predominantly to the 
generation of 7-meG and 3-meA lesions within the DNA and also to a lesser extent O6-meG 
lesion (Figure 1-9). The total distribution of these lesions following MMS treatment are 
approximately 10% 3-meA and 70–80% 7-meG (Horton et al., 2003), whereas the potent 
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toxic and mutagenic lesion O6-meG is only formed at the very low frequency of 0.3% 
(Beranek, 1990). According to Sedgwick et al. (2007), MMS produces the same products as 
the endogenous alkylating agent SAM but the reactivity of SAM is approximately 2000-fold 
weaker comparing to MMS (Rydberg and Lindahl, 1982). 
 
Figure 1-9: The predominant DNA lesions formed by MMS. Figure modified from (Fu et al., 2012). 
These MMS-induced alkylated bases are primarily repaired by the base excision repair 
(BER) pathway initiated by an enzyme called alkyladenine DNA glycosylase (AAG). This 
enzyme recognises and removes a single damaged base to create an abasic site, which will 
be discussed later in this literature review (Fu et al., 2012). 
1.6 DNA Repair 
DNA repair is a collection of mechanisms acting on DNA damage with the goal of damage 
removal and repair. DNA repair must be well-coordinated in order to provide protection 
against neurodegeneration, premature ageing and also carcinogenesis (Hoeijmakers, 2009). 
This is because loss of DNA repair coordination leads to negative outcomes such as when 
the levels of certain DNA repair enzymes are increased within a particular DNA repair 
pathway which can then negatively impact cellular homeostasis (Fu et al., 2012). Also, 
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decreased DNA repair has been shown to increase cancer risk (Hoeijmakers, 2009, Calvo et 
al., 2013). 
There are different types of DNA repair pathways which have evolved to deal with the many 
different types of lesions that can occur in DNA. These evolved mechanisms for repairing 
the different types of DNA damage show a certain degree of specificity but also some 
overlap depending on the type of damage (Gidron et al., 2006). The next figure (Figure 1-
10) shows some of the different types of DNA damage and the possible DNA repair 
pathways for these DNA damages. 
 
Figure 1-10: Different types of DNA damage and their DNA repair mechanisms. The type of lesion in the DNA 
(top) plays a role in the choice of DNA repair mechanism (bottom) to repair the DNA damage. BER, base 
excision repair; NHEJ, non-homologous end-joining; NER, nucleotide excision repair. Figure modified from 
(Lord and Ashworth, 2012). 
The major DNA repair mechanisms for alkylation damages include the O6-methylguanine-
DNA methyltransferase (MGMT) repair protein and direct DNA repair by members of the 
AlkB homologue (ALKBH) family; and by the multistep pathways of nucleotide excision 
repair (NER) and base excision repair (BER) (Fu et al., 2012). However, in this thesis, out 
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of the major DNA repair mechanisms for alkylation damage, I will concentrate only on the 
multistep base excision repair pathway (BER). 
1.6.1 Base Excision Repair (BER) 
The base excision repair (BER) pathway is responsible for the repair of a large number of 
damage types such as single-strand DNA breaks, abasic sites and chemically altered bases 
which can occur spontaneously and/or by environmentally induced mechanisms (Meira et 
al., 2005). There are several lesions repaired by the BER pathway and some examples of 
these DNA lesions are shown in (Figure 1-11).  
 
Figure 1-11: Some examples of DNA lesions repaired by the BER pathway. Figure is copied from (Robertson 
et al., 2009). 
1.6.1.1 The Pathway of BER 
The BER pathway is initiated by a DNA glycosylase to remove the damaged base. The 
pathway of BER can be summarised as a process of five sequential steps: Firstly, recognition 
and excision of the DNA damaged base by a DNA glycosylase occurs to generate an AP site 
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intermediate; secondly, incision of the DNA backbone adjacent to the resulting AP site by 
an apurinic/apyrimidinic (AP) endonuclease or AP lyase; thirdly, end processing of the 
obstructive DNA termini (3′- and 5′- termini) to produce a 3′-hydroxyl group (3′-OH) and a 
5′-phosphate moiety (5′-P); fourthly, repair synthesis to fill the missing nucleotide(s) by 
DNA polymerase enzymes and finally, DNA ligation to seal the remaining nick by a DNA 
ligase enzyme (Jeppesen et al., 2011). 
1.6.1.2 The Initiation of BER 
DNA glycosylase enzymes initiate the BER pathway by recognising specific subsets of DNA 
damaged bases and excising these damaged bases from DNA. These DNA glycosylase 
enzymes cleave the N-glycosyl bond between the DNA base and the deoxyribose sugar; 
therefore, an AP site is created (Jacobs and Schär, 2012). There are 11 DNA glycosylases 
described and each one of these DNA glycosylases has a specific substrate range. This a 
specific substrate range of each one of the DNA glycosylases can be sometimes broad and 
largely overlapping to excise and remove a subset of alkylated, deaminated or oxidised DNA 
bases (Takao et al., 2002, Wood et al., 2001, Hazra et al., 2002b). Some of these known 
substrates for the DNA glycosylase enzymes are already mentioned in the previous figure 
(Figure 1-11) and also summarised in the next tables (Tables 1-4 and 1-5). 
However, most of the DNA glycosylase enzymes which initiate BER have been shown 
previously to be not essential at either the organismal level or the cell, although BER is 
responsible for removing many different types of DNA damages which are formed daily in 
the cells. This is because viable knockout for both animals and cell lines have been generated 
for the DNA glycosylase enzymes (Demple and Sung, 2005). The only one exception of 
these DNA glycosylase enzymes is the thymine DNA glycosylase (TDG). Knockout of the 
Tdg in mice has been found in studies to cause embryonic lethality which occurs at 
25 
 
embryonic day 11.5, so it is essential for embryonic development (Cortellino et al., 2011, 
Cortázar et al., 2011). 
1.6.1.2.1 The Classification of DNA Glycosylases 
DNA glycosylases may be divided into two main classes, monofunctional and bifunctional 
DNA glycosylases. The tables below (Tables 1-4 and 1-5) illustrate examples of the DNA 
glycosylases for both classes and the lesions repaired by BER pathway that initiated by these 
DNA glycosylases. 
Table 1-4: Examples of monofunctional DNA glycosylases and the type of DNA lesions that 
initiated by these monofunctional DNA glycosylases and repaired by BER pathway. 
DNA Glycosylases Type of Removal Lesions References 
Alkyladenine DNA 
Glycosylase (AAG) 
3-meA. 
7-meG. 
3-meG. 
Hypoxanthine (Hx). 
1,N6-ethenoadenine (εA). 
3,N2-ethenoguanine. 
Oxanine. 
(Dosanjh et al., 1994). 
(O'connor and Laval, 1990). 
(Saparbaev et al., 2002). 
(Saparbaev and Laval, 1994). 
(Hitchcock et al., 2004). 
Uracil DNA Glycosylases: 
UNG 
SMUG1 
Thymine DNA Glycosylase 
(TDG) 
MBD4 
Uracil. 
Thymine glycols (opposite G) 
by TDG and MBD4. 
(Krokan et al., 2002). 
(Jacobs and Schär, 2012). 
MutY DNA Glycosylase 
(MYH) 
Adenine (opposite 8-oxoG). 
2-Hydroxyadenine (2-OH-A). 
(Slupska et al., 1999). 
(Ohtsubo et al., 2000). 
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Table 1-5: Examples of bifunctional DNA glycosylases and the type of DNA lesions that initiated 
by these bifunctional DNA glycosylases and repaired by BER pathway. 
DNA Glycosylases Type of Removal Lesions References 
8-oxoguanine DNA 
Glycosylase 
(OGG1) 
8-oxoG. 
2,6-diamino-4-hydroxy-5-
formamidopyrimidine (FapyG). 
2,6-diamino-4-hydroxy-5-N-
methylformamidopyrimidine (N7-meFapyG). 
8-oxo-7,8-dihydroadenine (8-oxoA). 
(Dherin et al., 1999). 
(Girard et al., 1998). 
(Zharkov et al., 2000). 
(Hu et al., 2005). 
NTHL1 
5-hydroxycytosine. 
Thymine glycol (Tg). 
5-hydroxy-6-hydrothymine. 
5,6-dihydroxycytosine. 
5-hydroxyuracil residues. 
4,6-diamino-5-formamidopyrimidine 
(FapyA). 
(Dizdaroglu et al., 1999). 
(Hu et al., 2005). 
NEIL DNA 
Glycosylases: 
NEIL1 
NEIL2 
NEIL3 
4,6-diamino-5-formamidopyrimidine 
(FapyA). 
2,6-diamino-4-hydroxy-5-
formamidopyrimidine (FapyG). 
Dihydrouracil. 
8-oxoG. 
5-hydroxyuracil (5-OHU). 
5,6-dihydrouracil. 
5-hydroxycytosine. 
(Hu et al., 2005). 
(Hazra et al., 2002a). 
(Hazra et al., 2002b). 
(Jacobs and Schär, 2012). 
 However, the monofunctional DNA glycosylases hydrolyse simply the glycosidic bonds 
creating AP sites. While, the bifunctional DNA glycosylases have an intrinsic AP lyase 
activity and can cleave the AP site by one of two different mechanism (Meira et al., 2005). 
These different mechanisms between the monofunctional and bifunctional DNA 
glycosylases are shown in the next figure (Figure 1-12). 
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Figure 1-12: The different mechanism of DNA glycosylase action on modified bases. BER is initiated by either 
a monofunctional or bifunctional DNA glycosylase enzyme to remove the modified DNA base and then form 
AP site within the DNA. Monofunctional DNA glycosylases simply hydrolyse the glycosilic bond of the 
modified DNA base generating the AP site within the DNA. The following is incision of the DNA backbone 
5' to the AP site by APE1 enzyme. On the other hand, bifunctional DNA glycosylase enzymes possess an 
intrinsic AP lyase activity. If the excision is done by one of these bifunctional DNA glycosylase enzymes, then 
the following incision of the DNA backbone 3' to the AP site in the DNA strand is done by either β-elimination 
or βδ-elimination mechanisms. These two different mechanisms is facilitated by the intrinsic 3' AP lyase 
activity of these bifunctional DNA glycosylase enzymes. In the β-elimination mechanism, the bifunctional 
DNA glycosylase/AP lyase uses an internal lysine and cleaves the AP site by β-elimination, therefore, a 3' 
phospho α,β- unsaturated aldehyde (PUA) moiety is generated. After that, further processing by APE1 enzyme 
is required. While, the second mechanism includes bifunctional DNA glycosylases which catalyse βδ-
elimination at the AP site and then removes the deoxyribose residue to generate a 3' phosphate (P) moiety at 
the site of DNA break. The resulting of these different mechanisms is single strand break (SSB) where will 
contain either a 3' or 5' obstructive termini (Jeppesen et al., 2011, Meira et al., 2005). Figure is adapted from 
(Jeppesen et al., 2011). 
1.6.1.3 The Classification of BER 
The BER pathway can be classified into two sub-pathways. The first one is short-patch BER 
(SP-BER), also called single-nucleotide BER (SN-BER), where only one nucleotide is 
replaced. The second sub-pathway is long-patch BER (LP-BER) where about 2-13 
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nucleotides are replaced (Gorbunova et al., 2007). The choice of performing either SP-BER 
or LP-BER is a complex issue and still yet not completely understood. 
It has been hypothesised that the decision between performing one of the two sub-pathways 
of BER is modulated by poly (ADP-ribose) polymerase (PARP). The dRP lyase activity of 
Pol β cannot remove 5′-dRP groups generated by APE1 activity when 5′-dRP is oxidized or 
reduced and subsequently blocking downstream steps in SP-BER (Sukhanova et al., 2010). 
PARP can assist by switching from SP-BER to LP-BER by PARylation, which is synthesis 
of poly (ADP-ribose) (PAR), and attracting auxiliary proteins when direct repair by DNA 
polymerase β is blocked (Beneke and Bürkle, 2007).  
In addition, the decision between these two sub-pathways of BER has been shown previously 
to be affected by the ATP concentration. The SP-BER pathway reaction is expected to 
proceed immediately to ligation step when ATP concentration is high, while the LP-BER 
pathway is expected to take place at low concentration of ATP where ligation is less favoured 
(Petermann et al., 2003). Moreover, there are also other factors which can play a role in the 
choice between SP-BER and LP-BER. Examples for these factors are the type of DNA 
lesion, the type of DNA termini formed during the BER and the cell cycle stage (Fortini and 
Dogliotti, 2007). The next figure (Figure 1-13) shows both SP-BER and LP-BER sub-
pathways and also the enzymes and proteins involved in each sub-pathway. 
 
 
 
 
29 
 
 
Figure 1-13: The short-patch and long-patch base excision repair (BER) pathways. BER pathway is initiated 
by either a monofunctional or bifunctional DNA glycosylase to remove the modified base and then form AP 
site and subsequent formation of single strand break (SSB) as discussed above in Figure 1-12. This SSB formed 
will have either a 3' or 5' obstructive termini at the site of break. After that, the end processing of the BER is 
done by Pol β, APE1 or PNKP to produce the 3'-OH and 5'-P termini and then the following BER will diverge 
into two subpathways. The first one is short-patch BER (SP-BER) where repair synthesis of the single 
nucleotide gap is done by Pol β enzyme which helped by XRCC1, and then subsequent ligation by ligase IIIα 
(LIGIIIα) will finish the repair. The second subpathway is long-patch BER (LP-BER) where the repair 
synthesis of the 2-13 nucleotide gap is done by Pol β, and/or Pol δ/Ɛ which helped by PCNA. Finally, a resulting 
5' flap will remove by FEN1 and then the ligation can occur by ligase I (LIGI) which is the final step (Jeppesen 
et al., 2011). Figure is copied from (Kim and Wilson III, 2012). 
In strong contrast to the DNA glycosylase enzymes, most of the central BER pathway 
proteins such as Pol β, Ape1, FEN1, LIGIII and XRCC1 seem to be essential at the 
organismal level. This is because deletion of genes encoding each of these proteins causes 
embryonic lethality in mice which indicate a requirement of these proteins for animal 
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development (Sobol et al., 1996, Xanthoudakis et al., 1996, Ludwig et al., 1998, 
Kucherlapati et al., 2002, Tebbs et al., 1999, Puebla-Osorio et al., 2006, Gu et al., 1994). In 
addition, some cell lines lacking one of the central BER pathway proteins have been isolated 
successfully for different studies. Examples for these cell lines and their responses after 
exposure to the alkylating agents are discussed later in the following sections. 
However, this section will focus on the BER pathway which is initiated by AAG and will 
discuss AAG in details in the next section. This is because AAG is the only identified 
mammalian DNA glycosylase which can repair alkylation damage induced by MMS, both 
in humans and mice (Robertson et al., 2009). 
1.6.1.4 The BER Pathway Initiated by AAG 
As already mentioned, alkylated DNA bases are recognised and removed by AAG and this 
event initiates the BER pathway (Figure 1-14). Because this thesis focuses on the phenotypic 
outcomes of AAG-initiated BER, below, I will describe the BER proteins acting downstream 
to AAG in more detail. 
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Figure 1-14: The base excision repair (BER) and single strand break repair (SSBR) pathways. The BER can 
be initiated by a DNA glycosylase (AAG) to remove the damaged base (db) and then form an AP site within 
the DNA. After that, AAG is displaced from the AP site by APE1 enzyme which then incise the DNA backbone 
5' to the AP site. The end processing of the BER pathway is done by Pol β enzyme and repair synthesis of the 
single nucleotide gap is done by Pol β which repairs 5’-deoxyribose phosphate terminus (dRP) to produce the 
necessary 3’-hydroxyl (3'-OH) and 5’-phosphate (5'-P) termini. This is helped by the scaffold protein XRCC1, 
and then subsequent ligation by ligase III (L3) finishes the BER. SSBs arise directly from sugar damage and 
also indirectly during the process of BER (dotted arrow) are bound by poly(ADP-ribose) polymerase 1 
(PARP1). This binding will lead to PARP1 to be activated and automodified resulting in recruits the complex 
of XRCC1–L3 to the SSB. Then, PARP1 is replaced by the XRCC1–L3 complex and forms a molecular 
scaffold. PNK and APE1 will be recruited and damaged 5’- or 3’-termini (red circles) are then converted to 5'-
P and 3'-OH moieties. Pol β is then recruited to the site to fill-in the single nucleotide gap followed by ligation 
of the nick by L3. Gap filling with nascent DNA is indicated by a red line (Jeppesen et al., 2011, Caldecott, 
2003). Figure is modified from (Caldecott, 2003). 
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1.6.1.4.1 Alkyladenine DNA Glycosylase (AAG) 
The alkyladenine DNA glycosylase (AAG) is the only identified DNA glycosylase in 
mammals which can repair alkylation DNA damage in humans and mice (Meira et al., 2005). 
AAG is also known as 3-methyladenine DNA glycosylase, alkylpurine DNA glycosylase 
(ANPG) or methylpurine DNA glycosylase (MPG). This DNA glycosylase can protect 
against different types of DNA damages by catalysing the hydrolytic cleavage of the N-
glycosidic bond after flipping damaged nucleotides out of the double stranded DNA in order 
to release the damaged nucleobases (Patrick and Ellenberger, 2003). AAG excises a wide 
variety of DNA lesions and the previous table (Table 1-4) illustrates examples of these DNA 
lesions which are recognised by AAG and repaired by BER. 
Mammalian cells have only one DNA glycosylase (AAG) which catalyses the excision of 3-
meA from DNA (Figure 1-14). Besides 3-meA, AAG can excise other altered purine 
residues, such as 1, N6-ethenoadenine (εA) and hypoxanthine from DNA (Sedgwick et al., 
2007). Among these three lesions, 3-meA is considered as the preferred substrate for AAG 
and it is released more rapidly than either εA or hypoxanthine (Asaeda et al., 2000). 
However, some of these lesions have mispairing properties and therefore are mutagenic 
(Meira et al., 2005). In addition, some lesions block DNA synthesis, for instance 3-meA, 
and then pose a serious problem to the cell (Johnson et al., 2007, Engelward et al., 1998). 
Several studies have revealed that increased AAG activity via protein overexpression in 
different mammalian cells (e.g. breast cancer cells, Chinese hamster ovary cells, ovarian 
cancer cells, mouse embryonic fibroblasts and glioma cells) result in increased sensitivity of 
the cells to alkylating agent-induced cytotoxicity (Rinne et al., 2004, Ibeanu et al., 1992, 
Coquerelle et al., 1995, Fishel et al., 2007, Trivedi et al., 2008, Trivedi et al., 2005, Tang et 
al., 2011, Calléja et al., 1999). In addition, a recent study has investigated in vivo and also 
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ex vivo the consequences of alkylation treatment (MMS) using AAG overexpressing, wild-
type and Aag knock-out (Aag-/-) mice (Calvo et al., 2013). The results of this study revealed 
that AAG-dependent tissue damage was detected in wild-type mice but it was exacerbated 
in AAG overexpressing mice and it was completely suppressed in Aag-/- mice. This 
sensitivity to the MMS treatment was observed in the following cells: thymocytes, 
splenocytes, pancreatic β cells, cerebellar granule cells, bone marrow cells and retinal 
photoreceptors. The pattern of MMS toxicity and the relative sensitivities in vivo are as 
follows: AAG overexpression > wild-type > Aag-/-. 
In addition, cell extracts from Aag null tissues do not possess the activity to excise 3-meA, 
Hx, εA and oxanine DNA lesions (Hitchcock et al., 2004, Engelward et al., 1997). 
Furthermore, Aag-/- mouse bone marrow cells were more resistant to the cytotoxic effects of 
the model alkylating agent MMS than wild type cells (Roth and Samson, 2002). These 
unexpected findings of the resistance to MMS in Aag-/- mouse bone marrow cells are 
consistent with those of Meira and colleagues (2009) who found that Aag-/- retinas are 
completely resistant to alkylation-induced retinal degeneration. 
In contrast to this resistance to alkylating agents observed in Aag null cells for the cell types 
mentioned above, a previous study using Aag null embryonic stem (ES) cells has shown Aag 
null ES cells to be more sensitive to MMS than wild-type cells (Engelward et al., 1996). In 
addition, Aag-/- MEF cells were found to be more sensitive to the toxic effects of the 
alkylating agents MMS (Elder et al., 1998) and also MeOSO2(CH2)2-lexitropsin (Me-Lex), 
which specifically induces 3-meA lesions within the DNA, than wild-type MEF cells 
(Engelward et al., 1997). However, a subsequent study reported no increase in sensitivity 
after MMS treatment in Aag-/- MEF cells versus wild-type MEF cells (Sobol et al., 2003), 
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suggesting that the response to AAG substrates generated by MMS or alkylation exposure 
is complex and may depend on cell type-specific contexts. 
1.6.1.4.2 AP Endonuclease 1 
AP endonuclease 1 (APE1) enzyme is the major AP endonuclease in mammals. This enzyme 
is required in BER to process the BER intermediates (AP sites and SSBs) in order to facilitate 
the completion of the BER pathway by Pol β and also DNA ligase IIIα enzymes (Pascucci 
et al., 2002, Klungland et al., 1999). It has been suggested that APE1 is responsible for 
processing more than 95% of the total cellular AP sites incision activity generated in 
mammalian cells (Wilson and Barsky, 2001, Demple and Harrison, 1994). The activity of 
APE1 at AP sites in the BER initiated by AAG results in cleavage of the phosphodiester 
bond on the 5'-side of the AP site and then generation of a SSB. In addition, this reaction 
leads to the formation of a SSB containing a 3'-OH and a 5'-dRP group flanking the DNA 
break (Mol et al., 2000, Beernink et al., 2001).  
1.6.1.4.3 DNA Polymerase β 
DNA polymerase β (Pol β) enzyme is an essential BER protein. It is subsequent to the abasic 
site processing by APE1 enzyme in BER initiated by AAG, or also processing of a 3'-P 
terminus by PNK. Pol β carry out a DNA extension reaction resulting in the replacement of 
the damaged nucleotide (Wiederhold et al., 2004, Pascucci et al., 2002, Klungland et al., 
1999). According to Idriss et al. (2002), Pol β is composed of a 31 kDa polymerase domain 
which has DNA polymerase activity and catalyses the nucleotidyl transferase reaction, and 
also an 8 kDa N-terminal domain which has 5'-dRP lyase activity and then removes the 5'-
dRP formed after incision by APE1.  
It has been shown that deficiency of pol β in human breast cancer cells with elevated 
expression of AAG leads to an increase in sensitivity to alkylation damage (Trivedi et al., 
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2008). In addition, previous studies have published that pol β null mouse embryonic 
fibroblast (MEF) cells are hypersensitive to the monofunctional alkylating agents such as 
MMS, MNU, MNNG and EMS (Sobol et al., 1996, Horton et al., 2003, Horton and Wilson, 
2007, Ochs et al., 1999, Sobol et al., 2003). This hypersensitivity of pol β null MEFs to the 
monofunctional alkylating agent MMS supports the importance of the dRP lyase activity of 
pol β for the efficient repair of toxic alkylation DNA damages and toxic BER intermediates 
(Sobol et al., 1996, Sobol et al., 2000, Horton et al., 2003). 
1.6.1.4.4 Polynucleotide Kinase (PNK) 
Polynucleotide kinase (PNK), also called polynucleotide kinase/phosphatase (PNKP), 
possesses 5'-DNA kinase which catalyses phosphorylation of 5'-DNA termini. A study in 
molecular characterisation of PNK enzyme has shown that PNK has a 3'-DNA phosphatase 
activity as well responsible for the dephosphorylation of 3'-DNA termini. This evidence 
suggests that there is a role for PNK in DNA repair (Jilani et al., 1999, Karimi-Busheri et 
al., 1999). In addition to the role of PNK in BER, it also plays a role in repair SSB (Chappell 
et al., 2002, Whitehouse et al., 2001). 
A previous in vitro study was performed to determine the PNK repair activity on a SSB using 
the human recombinant enzymes PNK, Pol β, LIG IIIα and a double-stranded 
oligonucleotide which contained a single nucleotide gap flanked by a 3'-P and a 5'-OH 
(Whitehouse et al., 2001). This study revealed that completion of SSB repair was observed 
when all the enzymes (PNK, Pol β and LIG IIIα) were present. However, the absence of 
PNK abolished 3'-phosphatase activity and repair was not completed (Whitehouse et al., 
2001). Moreover, human cells that have PNK depleted, where PNK gene expression has 
been suppressed by at least 80–90%, show elevated sensitivity to MMS (Rasouli-Nia et al., 
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2004). So, these results suggest that the activity of PNK (both the 5'-DNA kinase and 3'-
DNA phosphatase) are required for the processing of SSB termini. 
1.6.1.4.5 Poly(ADP-Ribose) Polymerase (PARP) 
Poly(ADP-ribose) polymerases (PARPs) are present in mammals and constitute a large 
family of at least 18 proteins with poly(ADP-ribosyl)ation (PARylation) activity, which is 
synthesis of poly(ADP-ribose) (PAR) polymer (Amé et al., 2004). PARylation of nuclear 
proteins is a post-translational modification induced upon PARP binding to DNA single 
strand breaks which establishes a molecular link between chromatin modification and DNA 
damage, therefore, contributes to the survival of injured proliferating cells (Amé et al., 
2004). PARP-1 and PARP-2 are members of PARP family where PARP-1 has been shown 
to be responsible for almost 90% of the total cellular PARylation activity after DNA damage 
(Rouleau et al., 2010, Horvath et al., 2011, Masson et al., 1998, Schreiber et al., 2002). 
The activity of PARP-1 is stimulated rapidly upon detection of DNA strand breaks and 
binding to the damaged DNA by using NAD+ as substrate. It PARylates multiple proteins 
including itself (Amé et al., 2004, Horton et al., 2008). PARP-1 loses affinity for DNA as a 
consequence of self PARylation and it is released from its binding site allowing the access 
of other DNA repair proteins (D'Amours et al., 1999, Lindahl et al., 1995). 
PARP-1 might also function to sequester other DNA repair proteins to the site of the SSB 
after binding and activation. One example of this is the preferred interaction of XRCC1 with 
the activated form of PARP-1 which arises when PARP-1 has bound to SSB (Taylor et al., 
2002, Masson et al., 1998). In this way, the interaction of XRCC1 with PARP-1 might serve 
to recruit XRCC1 protein complexes to the site of SSB. This suggests that formation of repair 
foci might be mediated by PAR (Okano et al., 2003, El‐Khamisy et al., 2003). Moreover, 
XRCC1 is considered as a substrate for PARP-1-mediated PARylation. Therefore, this is 
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confirming the functional interaction between PARP1 and XRCC1 (Masson et al., 1998, 
Horton et al., 2008). In addition, LIG IIIα associates with PARylated PARP-1 can provide 
another possible mechanism for recruitment of the complex of XRCC1-LIG IIIα to the site 
of SSB (Leppard et al., 2003). 
PARP is not necessary for mice development and tissue differentiation because Parp-1 
knockout mice are viable and fertile (Dantzer et al., 1999). In addition, PARP-1- deficient 
cells have been shown in several studies to be hypersensitive to alkylating agents. PARP-1-
deficient MEF cells are hypersensitive to the treatment with MMS and MNU, as well as to 
hydrogen peroxide (H2O2) (Horton and Wilson, 2007, Dantzer et al., 2000, Trucco et al., 
1998, Horton et al., 2005, El‐Khamisy et al., 2003). This indicates PARP-1 is important in 
DNA repair and cellular resistance to DNA damaging agents. 
1.6.1.4.6 X-ray Repair Cross-Complementing 1 (XRCC1) 
X-ray repair cross-complementing 1 (XRCC1) interacts physically with several proteins of 
BER and activates many of these proteins (Hegde et al., 2008). XRCC1 serves as a SSB 
sensor protein and it is functioning as a scaffold protein for recruiting proteins involved in 
BER and SSBR. XRCC1 interacts with BER proteins including APE1 and PNK as well as 
Polβ and LIG IIIα enzymes (Whitehouse et al., 2001, Vidal et al., 2001). This interaction of 
XRCC1 with BER proteins (Polβ and LIG IIIα) suggests that XRCC1 is primarily involved 
in single nucleotide BER (Kubota et al., 1996, Caldecott et al., 1994).  
Studies have shown that mutation of the XRCC1 gene leads to hypersensitivity of the DNA 
to alkylating agents and also a moderate sensitivity to ionizing radiation as a result of a defect 
in the DNA SSBs repair (Thompson et al., 1982, Thompson et al., 1990, Tomkinson and 
Mackey, 1998). Furthermore, MEF cells with deficiency of XRCC1 are hypersensitive to 
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MMS (Horton and Wilson, 2007, Tebbs et al., 1999). This great hypersensitivity of cells 
lacking the XRCC1 indicates to a requirement of XRCC1 for efficient BER. 
1.6.1.4.7 DNA Ligase IIIα (LIG IIIα) 
The ligation event in the repair of BER is catalysed primarily by DNA ligase IIIα (LIG IIIα) 
(Cappelli et al., 1997, Winters et al., 1999). It interacts with XRCC1 to form a stable complex 
in somatic cells (Nash et al., 1997, Caldecott et al., 1995, Caldecott et al., 1994). In addition, 
XRCC1 is important for the stability of LIG IIIα because the level of LIG III is reduced in 
XRCC1-deficient cells compared to the normal cells (Cappelli et al., 1997, Caldecott et al., 
1995, Tomkinson and Mackey, 1998). Therefore, these results of the interaction between 
LIG IIIα and XRCC1 confirm that the DNA LIG IIIα enzyme is involved and plays an 
important role in BER and/or SSB repair (Tomkinson and Mackey, 1998).  
However, it is important to consider that the BER pathway consists of a series of steps that 
lead to the generation of potentially toxic repair intermediate products. Examples for these 
toxic intermediates are AP sites and SSBs. Also, these BER intermediates are more 
mutagenic and toxic to the cell than some of the initial base damage, for example 7-meG 
(Luke et al., 2010). So, any imbalance in the BER process may lead these toxic DNA 
intermediates to accumulate and potentially resulting in cell death (Trivedi et al., 2008). 
1.6.2 Imbalance of Base Excision Repair (BER) 
BER is a process which requires balanced expression of the proteins involved in order to 
avoid accumulation of toxic repair intermediates (Tang et al., 2010). BER imbalance may 
occur as a result of increased activity of the DNA glycosylase, or a decrease in any 
downstream BER stage (Fu et al., 2012, Calvo et al., 2013). The following BER proteins 
AAG, APE1, Pol β and XRCC1 which are described in (Figure 1-15) are essential for the 
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repair of DNA damaged by alkylating agents (Trivedi et al., 2008, Almeida and Sobol, 
2007). It has been suggested that deficiency of, or an inhibition in, one or more of these 
essential BER proteins will lead to repair-processing induced cell death (Trivedi et al., 2008). 
Furthermore, overexpression of AAG in cells results in the accumulation of toxic BER 
intermediates. The model postulated to explain these results is that overexpression of AAG 
enzyme creates a BER imbalance due to saturation of downstream BER enzymes and then 
accumulation of toxic BER intermediates (Rinne et al., 2004, Coquerelle et al., 1995, Rinne 
et al., 2005). The next figure (Figure 1-15) shows the outcomes of accumulation of the toxic 
BER intermediates in the BER pathway that is initiated by AAG. 
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Figure 1-15: The outcomes of accumulation of the toxic BER intermediates after initiation BER by AAG. Imbalance in the BER pathway can result in the accumulation of the 
toxic BER intermediates which eventually can lead to cell death. Accumulation of AP sites results in DNA replication block which eventually can lead to cell death. While, 
accumulation of SSBs lead to hyperactivation of PARP1 resulting in bioenergetic failure and cell death as PARP1 PARylates, which means adding polymers of ADP-ribose to 
various proteins, including itself, which require NAD+ as an energy source to catalyse the process (Rouleau et al., 2010, Beneke and Bürkle, 2007, Amé et al., 2004). 
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1.6.2.1 Accumulation of AP Sites 
AP sites are cytotoxic and mutagenic if not repaired. The accumulation of this toxic BER 
intermediate can block both transcription and also DNA replication (Cuniasse et al., 1990, 
Boiteux and Guillet, 2004, Yu et al., 2003). Persistent blockage of transcription can lead to 
transcriptional stress which constitutes an efficient trigger for cell death (Hoeijmakers, 
2001). Also, blocking DNA replication will eventually lead to cell death (Hoeijmakers, 
2001, Friedberg, 2003). Furthermore, cleavage of AP sites by APE1 results in the generation 
of SSB which is also a toxic intermediate if not repaired (Boiteux and Guillet, 2004). For 
these reasons, AP sites are a threat to cellular viability and also genomic integrity (Dianov 
et al., 2003).  
1.6.2.2 Accumulation of Single Strand Breaks (SSBs) 
Accumulation of SSBs within DNA is very cytotoxic to the cell. They can pose a serious 
threat to the stability of genes and cell survival if not repaired rapidly or appropriately 
(Caldecott, 2008). The impacts of these SSBs on cell fate are shown in the figure below 
(Figure 1-16). 
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Figure 1-16: The impacts of single strand breaks (SSBs) on cell fate. SSBs can arise as normal intermediate of 
BER and when the SSBs are not rapidly or appropriately repaired, then they can impact on cell fate by collapse 
DNA replication forks, block transcription or promote excessive activation of PARP1. Red circles denote the 
termini of damaged DNA (Caldecott, 2008). Figure is modified from (Caldecott, 2008). 
Accumulation of SSBs within DNA can induce cell death through excessive activation of 
PARP-1 which is the SSB sensor protein (Heeres and Hergenrother, 2007). It has been 
hypothesised that prolonged activation of PARP1 after accumulation of SSBs due to BER 
imbalance leads to depletion of cellular NAD+ and ATP (Chiarugi, 2002, Caldecott, 2008) 
which eventually lead to energetic failure and consequently cell death. PARP 
hyperactivation and NAD+ depletion would lead to caspase-independent apoptosis. In this 
case, apoptosis-inducing factor (AIF) is released from the mitochondria and translocates into 
the nucleus to induce chromatin condensation and DNA fragmentation (Yu et al., 2002, 
Daugas et al., 2000, Yu et al., 2006). 
In addition, cell death induced by SSBs in non-proliferating cells may involve stalling of 
RNA polymerases during transcription. This is due to the fact that SSBs can block RNA 
polymerase progression in vitro (Bendixen et al., 1990, Kathe et al., 2004). On the other 
43 
 
hand, the collapse or blockage of DNA replication forks in proliferating cells is the most 
likely consequence of unrepaired SSBs. This possibly can lead to the generation of double 
strand breaks (DSBs) within the DNA, which are DNA strand breaks where the breakage of 
the DNA occurs in both strands (Kouzminova and Kuzminov, 2006, Kuzminov, 2001). This 
type of DNA strand break is considered as one of the most cytotoxic forms of DNA damage 
and it can lead to cell death if not repaired (Chapman et al., 2012). 
DSBs can arise in the DNA following exposure of cells to exogenous agents, such as some 
classes of chemotherapeutic drugs or ionizing radiation (IR). Also, DSBs can occur 
spontaneously from endogenous DNA damaging sources when DNA replication forks 
encounter unrepaired AP sites or SSBs, leading to fork collapse (Pfeiffer et al., 2000). 
Exposure to these endogenous and exogenous agents which induce DSBs formation will 
trigger the activation of DSBs signalling and repair mechanisms. The histone variant H2AX 
is part of the DSBs response where after the detection of a DSB it is targeted for 
phosphorylation in the vicinity of a DSB by ataxia telangiectasia mutated (ATM) , a member 
of the phosphatidylinositol-3 kinase-related kinases (PIKKs). This phosphorylated form of 
H2AX is known as γ-H2AX (Kuo and Yang, 2008). In addition, it plays a role in the 
recruitment of multiple DNA signalling and repair proteins into repair sites (Rothkamm and 
Horn, 2009). 
1.7 Aim of the Study 
There are several studies performed previously in an effort to establish the relationship 
between cytotoxic effects of imbalance in BER pathway, PARP hyperactivation, 
bioenergetic failure and cell death in cells after treatment with alkylating agents (Yu et al., 
2002, Tang et al., 2010, Tang et al., 2011). On the basis of these studies it has been 
hypothesised that accumulation of toxic intermediate SSBs after BER initiation induce cell 
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death through hyperactivation of PARP-1 that lead to excessive depletion of cellular NAD+ 
and ATP. So, AAG-initiated BER on alkylation base damage is responsible for alkylation-
induced cell death.  
However, the differences in the experimental designs between these studies make it very 
difficult for the researcher to extrapolate certain results obtained from these different studies 
for quantitative and temporal characterisation of the events at each stage of the BER pathway 
when cells were treated with the alkylating agents. To date, there is no study trying to clarify 
the direct relationship between the BER imbalance, PARP hyperactivation, failure of the 
bioenergetics system and cell death after alkylation treatment. Therefore, the understanding 
of the events resulting from the BER imbalance to the eventual cell death after treatment 
with alkylating agents remains undefined and actually it is based on putting the knowledge 
from different studies together. So, this study seeks to quantitatively characterise the stages 
of the BER events initiated by AAG as the final outcome of the alkylation treatment and also 
show the temporal relationship between the stages of the BER events. 
1.8 Objectives 
In order to reach the aim of this study, the following objectives have been applied which also 
shown in the next figure (Figure 1-17): 
 Objective 1: To quantify AP sites which is the first step of the BER. 
 Objective 2: To measure the levels of DNA strand breaks.  
 Objective 3: To quantify the levels of PAR synthesis after PARP activation.  
 Objective 4: To investigate the cellular bioenergetic system.  
 Objective 5: To quantify cell death which is the last stage of imbalance BER. 
 Objective 6: To study the cell cycle progression. 
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Figure 1-17: The objectives of the study. Figure is modified from (Calvo et al., 2013). 
To achieve the overall aim and objectives of the current study, both wild-type and Aag-/- 
primary mouse embryonic fibroblast (MEF) cells were used. This is because using these two 
genotypes of MEF cells affords us the ability to interrogate two different cellular systems. 
The first one is the one where the ability to initiate the BER is intact by using wild-type MEF 
cells while Aag-/- MEF cells cannot initiate the BER. This will enable the current study to 
establish the correlation between AAG activity, imbalance of BER and cell death. 
In addition, an alkylating agent (MMS) was used in this study to treat the both genotypes of 
MEF cells. This is because MMS has specificity in alkylating base nitrogen in which 
generate DNA lesions specifically recognised by AAG. The dose used of MMS to treat the 
MEF cells in this study was 2.5 mM which is the LC50 (lethal concentration 50) for these 
cells based on earlier studies performed in Meira’s lab (data not shown). This LC50 for MMS 
represents a dose in which sufficient DNA damage is induced, leading to an intermediate 
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reduction in cell viability which then can allow this study to characterise the response to 
alkylation DNA damage. 
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Chapter 2: Materials and Methods 
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2.1 Materials 
2.1.1 Reagents 
2.1.1.1 Cell Culture 
Dulbecco’s modified Eagle medium (DMEM), gelatin from porcine skin, L-glutamine (200 
mM) solution, penicillin (10,000 units/mL)-streptomycin (10 mg/mL) solution, trypan blue 
(0.4%) solution, trypsin-EDTA (10×) solution were supplied by Sigma-Aldrich (St. Louis, 
MO, USA). Small (culture area 25 cm2), medium (culture area 80 cm2), large cell culture 
flasks (culture area 175 cm2) and fetal bovine serum (FBS) were obtained from PAA 
(Pasching, Austria). Cell culture dishes (90×20 mm) was purchased from SPL Life Sciences 
(Pocheon, South Korea). Mr. Frosty Freezing Container was purchased from Thermo 
Scientific (Loughborough, UK). Cell culture black 96-well plates was obtained from BD 
Biosciences (San Jose, CA, USA). 
2.1.1.2 Chemicals 
MMS (purity > 98%) was supplied by Fluka-Sigma-Aldrich (St. Louis, MO, USA). Boric 
acid was purchased from British Drug Houses (BDH) Chemical Ltd (Poole, UK). Absolute 
ethanol, absolute methanol, industrial methylated spirit (IMS), agarose powder, Tris Base, 
sodium hydroxide, acetic acid glacial and paraformaldehyde powder were supplied by Fisher 
Scientific (Loughborough, UK). Phosphate-buffered saline (PBS) tablets was obtained from 
Oxoid (Cambridge, UK). UltraPure Low Melting Point Agarose (LMPA) was purchased 
from Invitrogen (Frederick, MD, USA). Triton X-100, Radioimmunoprecipitation assay 
(RIPA) buffer, hydrogen peroxide (H2O2), Ethylenediaminetetraacetic acid disodium salt 
dehydrate (EDTA disodium salt), isopropanol solution, dimethyl sulfoxide (DMSO), 2-
mercaptoethanol and Tween 20 were obtained from Sigma-Aldrich (St. Louis, MO, USA). 
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2.1.1.3 General Labware 
Centrifuge tube (50 mL) and serological pipettes (50 mL, 25 mL, 10 mL and 5 mL) were 
supplied by Sarstedt (Nümbrecht, Germany). Universal polystyrene 30 mL containers was 
obtained from Sterilin (UK). Pipette sterile filter tips (Tip One) (1000 µL, 200 µL, 20 µL 
and 10 µL) were purchased from Starlab (Milton Keynes, UK). Solution reservoir 50 mL 
polystyrene (sterile) was obtained from VWR International (Radnor, PA, USA). Fastrak 
sterile filter tips (1000 µL, 200 µL, 20 µL and 10 µL) were obtained from Alpha Laboratories 
(Eastleigh, UK). Microscope slides was purchased from Fisher Scientific (Loughborough, 
UK). BD falcon round-bottom tube (12×75 mm) (5 mL) for FACS analysis was purchased 
from BD Biosciences (San Jose, CA, USA). PCR tubes and microcentrifuge tubes (2 mL, 
1.5 mL and 0.6 mL) were supplied by Axygen BioScience, Inc. (Union City, CA, USA). 
2.1.1.4 Molecular Biology 
Proteinase K solution (20 mg/mL) (AM2546) was obtained from Ambion (Life 
Technologies) (Austin, TX, USA). Nuclease-Free Water, 100bp DNA Ladder and GoTaq® 
G2 Hot Start Green Master Mix (2X) were supplied by Promega (Madison, WI, USA). 
Ribonuclease A from bovine pancreas (R4642) was obtained from Sigma-Aldrich (St. Louis, 
MO, USA). AAG P1, AAG P2 and AAG P4 primers (sequences are shown in Table 2.13, 
below) were supplied by Integrated DNA Technologies (IDT) (Coralville, IA, USA). 
2.1.1.5 Antibodies 
Anti-pADPr antibody [10H] (catalogue number ab14459) and anti-lamin B1 antibody 
(catalogue number ab133741) were purchased from Abcam (Cambridge, UK). Goat anti-
rabbit IRDye 680RD, goat anti-mouse IRDye 680RD, goat anti-rabbit IRDye 800CW and 
goat anti-mouse IRDye 800CW were supplied by LI-COR (Lincoln, NE, USA). Phospho-
Histone H2AX (Ser139) (20E3) Rabbit monoclonal antibody (catalogue number 9718S) was 
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obtained from Cell Signaling (Danvers, MA, USA). Polyclonal Rabbit Anti-Poly (ADP-
Ribose) [PAR] antibody (catalogue number 551813) was obtained from BD Biosciences 
(San Jose, CA, USA). 
2.1.1.6 Inhibitors 
Protease inhibitor cocktail (P8340), erythro-9-(2-Hydroxy-3-nonyl)-adenine (EHNA) 
hydrochloride salt, deferoxamine mesylate salt and FK866 hydrochloride hydrate of ≥ 98% 
purity were supplied by Sigma-Aldrich (St. Louis, MO, USA). 
2.1.1.7 Staining 
Cell-Tag 700 stain was purchased from LI-COR (Lincoln, NE, USA). Propidium iodide 
solution (1 mg/mL in water) was obtained from Sigma-Aldrich (St. Louis, MO, USA). 
SYBR Green I dye was supplied by Invitrogen (Frederick, MD, USA). SafeView Nucleic 
Acid Stain (catalogue number NBS-SV1) was purchased from NBS Biologicalas 
(Huntingdon, Cambridgeshire, UK). 
2.1.1.8 Comet Assay 
Comet assay lysis solution and comet slides (2 wells/slide) were obtained from Trevigen 
(Gaithersburg, MD, USA). 
2.1.1.9 Western Blot 
Mini-PROTEAN TGX Precast Gels (7.5% and 4-20%), 4X Laemmli sample buffer and 
Trans-Blot Turbo Midi PVDF Transfer Packs (catalogue number 170-4157) were supplied 
by Bio-Rad (Hercules, California, USA). Odyssey blocking buffer (PBS) and western blot 
incubation boxes were obtained from LI-COR (Lincoln, NE, USA). PageRuler Prestained 
NIR Protein Ladder (catalogue number 26635) was obtained from Thermo Scientific 
(Loughborough, UK). 
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2.1.1.10 Kits 
DNA damage quantification kit (DK02-12) was supplied by Dojindo (Kumamoto, Japan). 
NAD+/NADH cell-based assay kit (catalogue number 600480) was supplied by Cayman 
Chemical Company (Ann Arbor, MI, USA). ATP determination kit (catalogue number 
A22066) was purchased from Molecular Probes (Life Technologies). Pierce BCA Protein 
Assay kit (catalogue number 23225) was obtained from Thermo Scientific (Loughborough, 
UK). Genomic DNA isolation kit for cells and tissues (11814770001) was supplied by Roche 
Diagnostics (Mannheim, Germany).  
2.1.2 Preparation of Reagents and Buffers 
2.1.2.1 Phosphate Buffered Saline (PBS) (1X) 
One tablet of PBS is dissolved in 100 mL of reverse osmosis (RO) purified water. The 
solution is then sterilised by autoclavation before use. 
2.1.2.2 Gelatin Solution (0.1%): 
0.1% gelatin solution is used to coat cell culture dishes and flasks because it can improve 
cell attachment.  
Table 2-1: Preparation of 0.1% gelatin solution. 
Reagent Amount 
Gelatin 0.1 g 
RO H2O 100 mL 
The gelatin solution is then autoclaved and stored at room temperature (RT). Dishes and 
flasks are precoated with gelatin solution for 1 hour before culturing the cells. 
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2.1.2.3 EDTA 
Table 2-2: Preparation of 0.5 M EDTA (pH 8). 
Reagents Amount Final Concentration (mM) 
Disodium EDTA 186.1 g 500 
RO H2O 800 mL - 
EDTA is dissolved in RO water and pH of the resulting solution is adjusted to 8 with 
concentrated NaOH. The solution is vigorously stirred for complete dissolution (the 
disodium salt of EDTA will not dissolve until the pH of the solution is adjusted to 8). After 
that, RO H2O is added to bring the final volume to 1 L. The EDTA solution is then autoclaved 
and stored at RT. 
2.1.2.4 Tris Acetate-EDTA (TAE) Buffer (10X)  
Table 2-3: Preparation of 10X TAE Buffer. 
Reagents Amount 
Tris base 48.5 g 
Glacial acetic acid 11.4 mL 
0.5 M EDTA (pH 8) 20 mL 
RO H2O 800 mL 
Tris base is dissolved in RO H2O before the addition of acetic acid and EDTA. The final 
volume is then adjusted to 1 L with RO H2O. The solution is then stored at RT. Before use, 
10X TAE buffer is diluted to 1X TAE buffer in RO H2O. 
2.1.2.5 Agarose Gel (2%) 
Table 2-4: Preparation of 2% agarose gel. 
Reagent Amount 
Agarose 2 g 
1X TAE buffer 100 mL 
53 
 
Before use, the solution is boiled in microwave until the agarose completely melt. The 
molten 2% agarose was then left to cool at RT for about 3 minutes before use. 
2.1.2.6 EHNA Hydrochloride 
1 mL of DMSO was added to 25 mg of EHNA to prepare EHNA stock solution at 25 mg/mL. 
EHNA is aliquoted and stored at -20 °C. The working solution of EHNA to be used is 5 
g/mL.  
2.1.2.7 Deferoxamine Mesylate Salt 
8.4 mL of purified water was added to 84 mg of deferoxamine mesylate salt under sterile 
conditions to prepare 10 mg/mL deferoxamine mesylate solution. The solution is sterilized 
by filtration and aliquots of deferoxamine mesylate were stored at -20 °C. The working 
solution of deferoxamine mesylate is 0.66 g/mL.  
2.1.2.8 Tris-HCl 
Table 2-5: Preparation of 1 M Tris-HCl buffer (pH 8). 
Reagents Amount Final Concentration (mM) 
Tris Base 121.14 g 1000 
RO H2O 800 mL - 
Tris base is dissolved in RO H2O and pH has been adjusted to 8 with the appropriate volume 
of concentrated HCl. RO H2O is then added to bring the final volume to 1 L. The solution 
then autoclaved and stored at RT. 
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2.1.2.9 TE Buffer 
Table 2-6: Preparation of TE buffer. 
Reagents Volume (mL) Final Concentration (mM) 
1 M Tris-HCl (PH 8) 5 10 
0.5 M EDTA (PH 8) 1 1 
RO H2O 494 - 
Total 500 - 
TE buffer has been autoclaved and stored at RT.  
2.1.2.10 Paraformaldehyde (PFA) Fixative (4%) 
20 g of paraformaldehyde powder was added to 450 mL of distilled water at 60 °C. Five 
drops of 2N NaOH was then added to the solution and then the solution was removed from 
heating. After that, 50 mL of Milli-Q water containing (10x) PBS was added to the solution 
at room temperature to final volume of 500 mL and then the pH of the solution was adjusted 
to 7.2 with HCL. The solution was filtered and stored at -20 °C protected from light. 
2.1.2.11 Low Melting Point Agarose (0.5%) (LMPA) 
Table 2-7: Preparation of 0.5% low melting point agarose (LMPA). 
Reagent Amount 
LMPA 250 mg 
PBS 50 mL 
LMPA was dissolved in PBS by boiling in the microwave at least 3 times. Aliquots were 
then stored at 4 °C. Before use, LMPA was molten by heating in 90-100 °C water bath. The 
molten LMPA was then placed in a 37 °C water bath for at least 30 minutes before ready to 
use. 
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2.1.2.12 Alkaline Solution (pH > 13) 
Table 2-8: Preparation of alkaline solution (pH > 13). 
Reagent Amount 
NaOH Pellets 0.6 g 
200 mM EDTA 250 µL 
RO H2O 49.75 mL 
The reagents above were completely dissolved by stirring. The solution is allowed to cool to 
RT before use.  
2.1.2.13 TBE Electrophoresis Buffer (10X) 
Table 2-9: Preparation of 10X TBE electrophoresis buffer. 
Reagent Amount 
Tris Base 108 g 
Boric Acid 55 g 
EDTA (disodium salt) 9.3 g 
RO H2O 900 mL 
The compounds above were completely dissolved in RO H2O and final volume brought to 1 
L. The solution is then sterilised by autoclavation and stored at RT. Before use, 10X TBE is 
diluted to 1X TBE in RO H2O to prepare working buffer. 
2.1.2.14 PBS-Tween-20: 
Tween-20 has been added to autoclaved (1X) PBS until final concentration of 0.1%. The 
solution is mixed until completely dissolved and stored at RT. 
2.1.2.15 PBS-Triton X-100: 
Triton X-100 has been added to autoclaved (1X) PBS until final concentration of 0.1%. The 
solution is mixed until completely dissolved and stored at RT. 
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2.1.2.16 Western Blotting Running Buffer (10X) 
Table 2-10: Preparation of 10X Running Buffer  
Reagents Amount Final Concentration (mM) 
SDS 10.08 g 35 
Tris 30.3 g 250 
Glycine 144 g 1920 
RO H2O 1 L - 
Before use, 10X running buffer was diluted to 1X by adding 100 mL 10X running buffer to 
900 mL RO H2O. 
2.2 Equipment 
Table 2-11: List of the equipment used in the project. 
Equipment Manufacturer or Supplier 
HERACELL 150i CO2 incubator. 
Thermo Scientific 
(Loughborough, UK) 
Heraeus Biofuge Fresco refrigerated microcentrifuge. 
NanoDrop 2000 spectrophotometer. 
FACSCanto flow cytometer (model: 337175). 
BD Biosciences 
(San Jose, CA, USA) 
AccuSpin 400 centrifuge. 
Topmix FB15024 Vortex Mixer. 
pH meter (Hydrus 300). 
Fisher Scientific 
(Loughborough, UK) 
FLUOstar Omega - Multi-mode microplate reader. 
BMG Labtech 
(Offenburg, Germany) 
Grant Water Bath W14. 
Grant Instruments 
(Shepreth, UK 
Gallenkamp Economy Incubator with Fan Size 3. Gallenkamp 
Eppendorf Centrifuge 5810. 
Eppendorf Centrifuge 5424. 
Eppendorf Centrifuge 5415 D. 
Eppendorf Centrifuge 5415 R. 
Eppendorf Centrifuge 5804 R. 
New Brunswick Ultra-Low Temperature Lab Freezers. 
Eppendorf 
(Hamburg, Germany) 
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Table 2-11: List of the equipment used in the project. 
Equipment Manufacturer or Supplier 
Trans-Blot Turbo Transfer System. 
PowerPac HC power supply. 
Mini-PROTEAN Tetra System. 
Gel Doc EZ Imager.Roller mixer (SRT6). 
Shaking incubator. 
Stuart 
(Stone, UK) 
ODYSSEY CLx. 
LI-COR 
(Lincoln, NE, USA) 
EVOS FL Cell Imaging System. 
Life Technologies 
(Carlsbad, CA, USA) 
Rotatest shaker (model R100). 
Suspension mixer (model 802). 
Luckham 
Gene Genius Bio Imagine System. 
Syngene 
(Cambridge, UK) 
BioMAT Class II Safety Cabinet. 
Medical Air Technology (MAT) 
(Manchester, UK) 
Gelaire BSB 4 Class II Laminar Flow. 
Gelaire 
(Sydney, Australia) 
Scotsman AF 80 Self Contained Ice Flaker. 
Scotsman 
(Ipswich, Suffolk, UK) 
Accu-jet pro Pipette Controller. 
BrandTech Scientific 
(Essex, CT, USA) 
peqPOWER Power Supply. 
PEQLAB 
(Erlangen, Germany) 
Tetrad PTC-225 Peltier Thermal Cycler. 
MJ Research 
(Waltham, Massachusetts, USA) 
BioPette a variable volume pipette with tip ejector. 
Labnet 
(Edison, NJ, USA) 
Dri-Block (DB-20) heater. 
TECHNE 
(Stone, UK) 
Dry Bath Incubator (model: 111002). 
Boekel Scientific 
(Feasterville, PA, USA) 
Sartorius (CP622) Precision Balance. 
Sartorius 
(Goettingen, Germany) 
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Table 2-11: List of the equipment used in the project. 
Equipment Manufacturer or Supplier 
TMS Inverted Microscope. 
Eclipse TS100 Epi-fluorescence Inverted Microscope.  
RunOne Electrophoresis Cell. 
Embi Tec 
(San Diego, CA, USA) 
Millipore Milli-Q Biocel Water Purification System. 
EMD Millipore 
(Billerica, Massachusetts, USA)   
2.3 Software 
Table 2-12: List of the software used in the study. 
Software Developers 
GraphPad Prism (version 6.05). 
GraphPad Software, Inc. 
http://www.graphpad.com/ 
Image Studio (version 5.0). 
LI-COR Biosciences. 
http://www.licor.com/ 
ImageJ (version 1.47). 
Wayne Rasband. 
http://imagej.nih.gov/ij/ 
OpenComet (version 1.3). 
Benjamin M. Gyori and Gireedhar Venkatachalam. 
http://www.cometbio.org/ 
Reader Control (version 5.10). 
MARS Data Analysis (version 3.02). 
BMG Labtech Ltd. 
http://www.bmglabtech.com/ 
GeneSnap (version 7.12) 
Syngene. 
http://www.syngene.co.uk/ 
2.4 Study Design 
For the study detailed below, MEF cells were treated with 2.5 mM MMS and compared to 
untreated control cells. MMS treatment was done for one hour under serum free conditions, 
and after that time, MMS-containing serum-free media (SFM) was replaced with complete 
media containing 2% serum. For the MMS-treated group, cell harvesting was conducted at 
various time points after MMS treatment and 48 hour was the longest time point studied. For 
the untreated control group, cell harvesting from the culture medium was performed after 48 
hours from the replacement of SFM by complete culture medium containing 2% serum. 
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Figure 2-1 represents the study design while Figure 2-2 details the time points incorporated 
into this study. Moreover, Figure 2-3 displays a flow chart of this study. 
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Figure 2-1: Summary of the study design. Wild-type and Aag-/- MEF cells are grown in complete culture medium (supplemented with 15% FBS, 1% penicillin/streptomycin 
and 1% L-glutamine) at 37 °C and 5% CO2. MEF cells are counted, seeded and incubated overnight at 37 °C and 5% CO2 to allow cells to adhere to the culture vessel surface. 
One day later, MEF cells are treated with SFM containing or not (untreated control) 2.5 mM of MMS. Cells are then incubated at 37 °C under 5% CO2 level for one hour. After 
that, media is replaced with culture medium supplemented with 2% FBS, 1% penicillin/streptomycin and 1% L-glutamine. Then, MEF cells are re-incubated under the same 
conditions for different time points. 
Wild-type and Aag
-/-
 primary 
mouse embryonic fibroblast (MEF) 
cells 
Treating (or not) 
with MMS (2.5 mM) 
for 1 h in SFM 
Counting and seeding MEF 
cells and incubation 
overnight 
Removing MMS and adding 
2% serum culture medium and 
incubation 
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Figure 2-2: Diagrammatic representation of the time points incorporated into the study design to define the 
temporal events during AAG-dependent cell death. The time points indicate the repair time after MMS 
treatment. 
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Figure 2-3: A flow chart of the study design. 
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2.5 Methods 
2.5.1 Cell Culture 
2.5.1.1 Cell Lines and Culture Medium 
Wild-type and Aag knock-out (Aag-/-) primary mouse embryonic fibroblasts (MEFs) were 
isolated and generated from embryos of C57BL/6J mice which were a kind gift from 
Professor Leona Samson (MIT, Cambridge, MA, USA). The cell culture medium for both 
genotypes was Dulbecco’s Modified Eagle Medium (DMEM) (4.5 g/L glucose, with phenol 
red and without glutamine) supplemented with 15% FBS, 1% Penicillin-Streptomycin (10 
mg/mL) solution and 1% L-glutamine (200 mM) solution (complete medium). Cells were 
incubated in a humidified incubator at 37 ºC under 5% CO2. 
2.5.1.2 Isolation of Primary Mouse Embryonic Fibroblasts (MEFs) 
Timed-pregnant female mice were euthanised on postcoitum day E12.5-E13.5, where E0.5 
is the day of detection of a copulation plug. On E12.5-E13.5 day of gestation, the uterine 
horns were dissected out from the pregnant mouse and placed in a 50 mL falcon tube 
containing PBS. After that, each individual embryo was dissected from the uterus and both 
placenta and yolk sacs have been separated. Each embryo is then homogenised onto a 60 
mm dish pre-coated with 0.1% gelatin and containing complete media, using a 1 ml syringe 
by drawing embryonic tissue up and down until the disaggregated tissue moves freely in and 
out of the syringe. After tissue desagregation, dishes are incubated overnight in the 37 °C 
incubator at 5% CO2. One day later, the medium is aspirated and fresh complete medium 
added to the cells and dishes are incubated again under the same conditions until the cells 
become 70-80% confluent. 
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2.5.1.3 Passage of Cells 
Cells were grown in complete medium in either cell culture flasks or dishes until 
approximately 70-80% confluent. After that, the medium was removed by aspiration and 
then cells were washed with sterile PBS before addition of trypsin/EDTA (1x) solution. The 
flask was gently rocked to ensure even coverage of the cells with the trypsin/EDTA solution. 
After that, the cells were incubated at 37 ºC for approximately 2-3 minutes until the cells 
had detached, as assessed by microscopy. After that, complete medium (must be greater than 
a 1:1 ratio of complete medium to trypsin/EDTA solution) was added to the cells in order to 
ensure total inactivation of trypsin/EDTA.  
Cell suspension was then transferred to a universal tube and centrifuged at 300 × g for 5 
minutes. The supernatant was removed by aspiration and the pellet (cells) was re-suspend 
with complete medium and diluted 1:3 by dividing the cell suspension between 3 new flasks 
or dishes (of equal culture area) and then complete medium was added to each flask or dish 
to top up the flask or the dish (ex. the total volume was 15 mL for culture area 80 cm2 flask 
or 40 mL for culture area 175 cm2 flask). After that, the cells were incubated at 37ºC, 5% 
CO2 in humidified incubator. 
2.5.1.4 Preparation of frozen stocks 
Cells were grown in complete culture medium until 80-90% confluent. Cells were 
trypsinised as described above, counted and washed by centrifugation to remove trypsin. 
Cells were re-suspended in complete medium at a concentration of 2×106 cells/ml. After 
that, freezing medium (2x) containing 20% FBS, 20% dimethyl sulfoxide (DMSO), 60% 
regular complete medium (v/v) was added to the cell suspension to result a final cell 
suspension at 1×106 cells/mL. Aliquots of this cell suspension were placed in an alcohol bath 
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at -80 ºC for 24 hours in order to enable cooling at a rate of approximately 1-3 ºC/min before 
being transferred to liquid nitrogen storage. 
2.5.1.5 Plating of frozen stocks 
Cryovials containing frozen cells are thawed rapidly in a 37 °C water bath. The cell 
suspension was transferred to 5 mL growth medium (37 °C) and centrifuged at 300 × g for 
5 minutes at room temperature. Supernatant was removed and cell pellet re-suspended in 5 
mL of growth medium. The new cell suspension was transferred to a small cell culture flask 
(culture area 25 cm2) pre-coated with 0.1% gelatin, and incubated at 37 °C, 5% CO2. One 
day later, the old complete medium was removed and replaced with fresh complete medium 
and incubated again under the same conditions until reach the 80% confluency and then the 
cells are ready for passaging. 
2.5.1.6 Estimation of cell number using a haemocytometer 
Cell number was determined using a haemocytometer. For calculations of cell number, a 10 
μL sample was removed from a cell suspension and mixed with 10 μL Trypan Blue solution 
(1:1 ratio). Trypan Blue is excluded from live cells therefore cells which appear white/yellow 
on the grid are counted to calculate the cell concentration, whilst cells which appeared blue 
are counted to calculate the % cell viability. The Trypan Blue suspension (10 μL) was 
pipetted at the edge of the cover slip both side of each counting grid and allowed to fill the 
haemocytometer chamber by capillary action. The number of cells was counted in all 4 
corner regions of the grid, each corresponding to 1 mm2, utilising both sides of the 
haemocytometer, and a mean number of cells calculated. The concentration of cells in the 
original suspension was then calculated using the next equation (Freshney, 2005). 
 
66 
 
𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 𝑜𝑓 𝑐𝑒𝑙𝑙 𝑖𝑛 𝑜𝑟𝑖𝑔𝑖𝑛𝑎𝑙 𝑠𝑢𝑠𝑝𝑒𝑠𝑖𝑜𝑛 (/mL) = 
𝑀𝑒𝑎𝑛 𝑐𝑒𝑙𝑙 𝑐𝑜𝑢𝑛𝑡
𝑉𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑔𝑟𝑖𝑑 𝑠𝑒𝑐𝑡𝑖𝑜𝑛 (10−4 𝑚𝐿)
 × 𝐷𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟 𝑡𝑜 𝑜𝑟𝑖𝑔𝑖𝑛𝑎𝑙 𝑠𝑎𝑚𝑝𝑙𝑒 (2) 
The calculation of the estimated cell concentration in 1 mL in the original suspension is 
based on the mean cell count in a grid section of 1 mm2 with depth 0.1 mm from a 10 μL 
sample dilutes to a same volume with Trypan Blue (dilution factor of 2). 
2.5.2 Genotyping of Cell Lines 
After isolation of MEFs from embryos of pregnant mice, a genotyping protocol was 
performed in order to determine whether the wild type and/or the engineered mutation in the 
Aag gene was present in the samples. Total genomic DNA and a process called polymerase 
chain reaction (PCR) is used for genotyping.  
2.5.2.1 DNA Extraction 
The tissue or liver of each embryo was used to extract DNA in order to perform genotyping 
test by using PCR. At first, a mixture of 500 µL lysis buffer and 5 µL proteinase K (20 
mg/mL) was added to the cell pellet or tissue in 1.5 mL microcentrifuge tube and mixed very 
well by vortexing. After that, the solution is incubated for at least 2 hours at 55 °C in water 
bath with vortexing at defined intervals. Nucleic acid containing solution is separated from 
cellular debris by centrifugation at 20,000 × g for 5 minutes. The supernatant is transferred 
into a new 1.5 mL microcentrifuge tube and then 500 µL of isopropanol is added to the 
supernatant and mixed by inversion until the DNA precipitates. DNA is pelleted by 
centrifugation at 20,000 × g for 10 minutes, supernatant is discarded and the microcentrifuge 
tube has been left open to air dry for about 15 minutes. DNA pellet is resuspended in TE 
buffer overnight at RT before use. 
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2.5.2.2 PCR Test 
Three primers were used in multiplex PCR analysis of DNA for genotyping. These primers 
and their sequences are shown in the next table. 
Table 2-13: Primers used for AAG genotyping by PCR analysis. 
Primer Sequence (5'-3') 
AAG P1 ACC CCG CTT TAC AGA GAA 
AAG P2 GCC AAG ACA GAG ATG AGA CC 
AAG P4 TGG GGG TGG GAT TAG ATA 
At first, the primers are diluted from 100 µM to 10 µM by adding 10 µL to 90 µL of nuclease 
free water. After that, master mix for a 25 µL reaction volume is prepared for all samples as 
following: 
Table 2-14: Preparation of the master mix for the PCR. 
Substrates Volume (One Sample) 
Nuclease free water 8.5 µL 
2X Promega Master Mix (Go Tag Hot Start Green Master Mix) 12.5 µL 
10 µM AAG P1 1 µL 
10 µM AAG P2 1 µL 
10 µM AAG P4 1 µL 
Total Volume 24 µL 
After that, 24 µL of master mix is transferred to PCR tube (0.2 mL) and mixed with 1 µL of 
sample template. For negative control sample, only 1 µL of nuclease free water was added, 
while 1 µL from positive template was added for the positive control sample. After that, the 
samples were transferred to the PCR machine. The thermocycling conditions for PCR were 
the following: 
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Table 2-15: the thermocycling conditions for Genotyping by the PCR. 
Step Temperature Time Number of Cycle 
Initial Denaturation 95 °C 5 minutes 1 
Denaturation 95 °C 1 minute 
35 Cycles Annealing 60 °C 1 minute 
Extension 72 °C 1 minute 
Final Extension 72 °C 10 minutes 1 
Hold 4 °C Hold  
2.5.2.3 Making 2% Agarose Gel 
A 2% agarose gel was used to analyse the PCR sample. 10 µL of Safe View Nucleic acid 
was added to molten 2% agarose gel and mixture poured into an appropriate gel casting tray 
and allowed to polymerise. Half of each PCR product (12.5 µL) was applied into each gel 
well; 5 µL of DNA ladder was also added to one of the wells. Gel was run at 50V and DNA 
fragments visualised by Genegenius, using UV light.  
2.5.3 AP Site Quantification 
2.5.3.1 Experimental Design 
In this assay, a total of 14 repair time points were used to capture the change in AP site 
number with time after MMS treatment. Repair time points investigated in the study include 
time during when MEFs were exposed to MMS and also after MMS treatment. These repair 
time points included in this assay were: -0.75, -0.5, 0, 0.5, 1, 1.5, 2, 3, 4, 6, 12, 24 and 48 
hours, which represented the repair incubation time after removal of 2.5 mM MMS. Each 
repair time point was prepared in a triplicate set for both MMS-treated group and also 
untreated control group. 
At the start of the experiment, the MEF cells were counted by using a haemocytometer as 
described before. Then, 1.5×106 MEF cells were seeded in 10 cm2 tissue culture dishes 
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containing complete culture medium. The dishes were incubated overnight at temperature of 
37 ˚C under 5% CO2 level to allow the cells to adhere the surface of the dishes. 
2.5.3.2 Procedure 
One day later, culture medium was aspirated from the 10 cm2 tissue culture dishes seeded 
with 1.5×106 MEF cells and 10 mL of SFM containing 2.5 mM of MMS was added to the 
cells and incubated under the same conditions. After 15, 30 and 60 minutes incubation with 
MMS, MEF cells were harvested, while for those MEF cells not harvested after one hour 
incubation with MMS, the treatment were removed and 10 mL of 2% serum culture medium 
was added to the cells and then these MEFs were incubated under the same conditions as 
previously mentioned. After that, cell harvesting from the tissue culture dishes were made 
at designated time of 0.5, 1, 1.5, 2, 3, 4, 6, 12, 24 and 48 hours after the removal of MMS 
and the addition of 2% serum culture medium. 
In addition, untreated control samples were set up in parallel along with the treated samples. 
The complete culture medium containing 15% serum in the untreated control samples was 
removed and 10 mL of SFM was added to the cells. Then, the cells were incubated for one 
hour under the same conditions as the MMS-treated group. After that, the SFM was removed 
from the dishes and 10 mL of 2% serum culture medium was added to the cells and 
incubated. Harvesting of MEF cells from the untreated control group was performed after 
48 hours incubation with 2% serum culture medium. 
2.5.3.3 Cell Harvesting 
At designated time point, the dishes were removed from the incubator and the culture 
medium was aspirated in order to retain only the adherent cells in the dishes and get rid of 
both the floating cells and also the cellular debris. The cells were rinsed with 10 mL of ice-
cold PBS, followed by the addition of 2 mL of 1× strength trypsin to the cells and incubated 
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at 37 °C for approximately 2-3 minutes in order to detach the cells from the culture dishes.  
At end of the incubation, 3 mL of complete culture medium containing serum was added to 
the cells in order to inactivate the trypsin and then the cell suspension was completely 
transferred from the dish into a new universal tube to spin down at 300 × g for 5 minutes. 
After that, the supernatant was removed following centrifugation and then the cellular pellet 
was resuspended and washed two times with ice-cold PBS (5 mL) containing inhibitors (5 
µg/mL of adenine deaminase and 66 µg/mL of deferoxamine). After that, the supernatant 
was discarded after the second wash and then cellular pellet was stored at -20 °C until time 
of genomic DNA extraction where freezing can help the cells to partially lyse which can 
then facilitate the subsequent steps during genomic DNA extraction. 
2.5.3.4 Genomic DNA Extraction 
The reagents used to extract the genomic DNA from the samples in order to perform AP site 
quantification assay were obtained from Roche genomic DNA isolation kit for cells and 
tissues (Roche Diagnostics, Mannheim, Germany). The original protocol provided by the 
manufacturer was slightly modified in order to avoid generation of AP sites within the DNA 
because of heating (Lindahl and Nyberg, 1972). The cell pellet stored at -20 °C was thawed 
on ice, followed by resuspended in 450 µL of cellular lysis buffer solution containing 
inhibitors (5 µg/mL of adenine deaminase and 66 µg/mL of deferoxamine). The cellular 
suspension was transferred to a new 1.5 mL microcentrifuge tube and then 0.6 µL of 
proteinase K solution (20 mg/mL) was added and mixed, followed by incubation at 4 °C for 
16 hours ± 30 minutes with shaking. 
After that, the mixture was removed from 4 °C and incubated at 37 °C for 30 minutes with 
gentle shaking. Then, RNase A solution (15 µL) was added to the mixture, followed by 
incubation for 30 minutes at 37 °C. After that, 180 µL of protein precipitation solution was 
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added to the mixture and incubated on ice for 5 minutes and then the mixture was centrifuged 
at 16,000 × g for 40 minutes. After that, the supernatant was transferred to a new micro-
centrifuge tube and the pellet was discarded. After that, isopropanol (0.7-1 volume) was 
added to the collected supernatant and the mixture was centrifuged at 1400 × g for 10 
minutes. After centrifugation, the supernatant was removed and the pellet was resuspended 
in cold 70% ethanol (1 mL) and then spin down at 1400 × g for 5 minutes. After that, the 
supernatant was removed and the DNA pellet was then allowed to completely air dry from 
the ethanol at RT. The genomic DNA was then resuspended in 25 µL of TE buffer and stored 
at 4 °C until time of the quantification of AP sites. 
2.5.3.5 Principle of AP Site Assay 
Reagents used for the AP site quantification were supplied by Dojindo™ DNA damage 
quantification kit. Aldehyde Reactive Probe (ARP) reagent specifically reacts with an 
aldehyde group in the open ring form of the AP site. After that, AP site is tagged with a 
biotin residue. The biotin-tagged AP sites (biotinylated AP sites) in the DNA can then be 
quantified using avidin-biotin assay which is an ELISA-like assay, followed by a 
colorimetric detection of horseradish peroxidase conjugated to the avidin as an indicator 
enzyme. 
2.5.3.6 AP site Quantification 
Before conducting the AP site quantification assay, the concentration of genomic DNA in 
TE buffer was determined by using NanoDrop (Thermo Scientific) and then the final 
concentration of 100 ng/µL was adjusted accordingly, using TE buffer. The ratio of 
OD260nm/OD280nm of purified genomic DNA used in the subsequent AP sites quantification 
assay was higher than 1.8 in order to ensure that the genomic DNA solution consists of 
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highly purified genomic DNA. This is because samples contaminated with protein may result 
in a false positive error (Glasel, 1995). 
10 µL of ARP solution was mixed with 10 µL of the purified genomic DNA solution (100 
ng/µl), followed by incubation at 37 °C for one hour. After that, TE buffer (380 µL) was 
added to the mixture in the 1.5 mL Eppendorf tube and then the whole mixture was 
transferred to the TE-equilibrated filtration tubes provided by the kit for centrifugation at 
2500 × g for 15 minutes. After centrifugation, the filtrate solution in the filtration tube was 
removed and then TE buffer (400 µL) was transferred to the same filtration tube in order to 
resuspend the genomic DNA trapped on the filter. The filtration tube was centrifuged again 
at 2500 × g for 15 minutes and the filtrate was discarded after centrifuging. After that, two 
aliquots of 200 µL of TE buffer were added to the filtration tube in order to resuspend the 
ARP-labeled DNA on the filter. The ARP-labeled DNA solution was transferred completely 
to a fresh 1.5 mL tube and stored at 4 °C overnight. 
After that, the ARP-labeled genomic DNA (90 µL) was added and diluted with TE buffer 
(310 µL) in a new 1.5 mL microcentrifuge tube to yield diluted ARP-labeled genomic DNA 
solution. Then, 60 µL of the diluted ARP-labeled genomic DNA solution as well as standard 
ARP-DNA solution were transferred to the wells of a new 96-well plate where triplicate 
wells were used per sample and standard solution. After that, 100 µL of the DNA binding 
solution was added to the wells and mixed with 60 µL of the diluted ARP-labeled genomic 
DNA solution or standard ARP-DNA solution. After that, the 96-well microplate was stored 
at RT overnight in order to allow efficient DNA binding to the 96-well plate.  
One day later, the DNA binding solution was removed from the wells of the 96-well plate 
and then the wells were rinsed five times with washing buffer (250 µL). After that, 150 µL 
of diluted HRP-streptavidin solution was added to each well and then the 96-well plate was 
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incubated at 37 °C for one hour. Subsequently, the solution in the wells was removed and 
the wells were then rinsed five times by adding 250 µL of washing buffer solution. After the 
last washing, 100 µL of substrate solution was added into each well of the 96-well plate and 
then the 96-well plate was incubated for one hour at 37 °C. After this incubation, the 
colorimetric detection was made at optical density of 650 nm within one hour after 
incubation by using FLUOstar Omega - Multi-mode microplate reader. Finally, a calibration 
curve was prepared using the data obtained by standard ARP-DNA solutions and the number 
of AP sites in the genomic DNA samples was determined by using the calibration curve. 
2.5.3.7 DNA Normalisation 
In order to normalise AP site number by the amount of genomic DNA in each sample, SYBR 
Green I dye was used to quantify the amount of genomic DNA in the diluted ARP-labeled 
genomic DNA solution. 20 µL of the diluted ARP-labeled genomic DNA solution was 
transferred to the well of a black 96-well microplate and mixed with 80 µL of (1×) SYBR 
Green I dye solution. Triplicate wells were performed for each sample in a black 96-well 
plate. The absorbance of SYBR Green I dye was measured at optical excitation of 485 nm 
using FLUOstar Omega - Multi-mode microplate reader. Finally, a calibration curve was 
prepared using known DNA concentration standards and the amount of the DNA in the 
samples was quantified by using the calibration curve.  
2.5.4 DNA Single Strand Break quantification (Comet Assay)  
2.5.4.1 Experimental Design  
To quantify DNA single strand breaks (SSBs) in MEFs after treatment with MMS or with 
the positive control hydrogen peroxide (H2O2), both wild-type and Aag
-/- MEFs were seeded 
in a 6-well plate at a density of 2.5×105 cells/well as previously described. In this assay, a 
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total of 10 time points were used to quantify DNA SSBs in MEFs in response to MMS 
treatment.  
Each time point was done in duplicate wells, with controls including duplicates for both 
genotype cells in the absence of MMS treatment and also duplicate wells for positive control 
using H2O2 at concentration 1 mM. The time points included in this assay were: -0.5, 0, 0.5, 
1, 2, 4, 6, 12, 24 and 48 hours, which represented the repair incubation time following 
removal of 2.5 mM MMS. 
2.5.4.2 Procedure 
Cells were treated with 2.5 mM MMS prepared freshly in SFM for 1 hour as previously 
described. Treatment with MMS was applied firstly to 48 hour repair time point, and the 
subsequent repair time points were treated accordingly with MMS in order to allow all repair 
time points to end simultaneously. Untreated control wells were treated as the 48 hour repair 
time point with only SFM while for positive control wells were treated as -0.5 h time point 
with 1 mM of H2O2 prepared in SFM for 30 minutes only at 37°C under 5% CO2. 
2.5.4.3 Principle of the Assay 
DNA SSBs can be quantified using single cell gel electrophoresis (SCGE) assay, which is 
also referred to as the comet assay. The comet assay has several advantages: it is rapid, 
simple, sensitive, and inexpensive. In this assay, cells embedded in a thin agarose gel on 
microscope slides are lysed in order to remove all cellular proteins and subsequently the 
DNA is allowed to unwind under alkaline conditions. TBE electrophoresis (or neutral 
electrophoresis) following alkali unwinding will detect SSBs, DSBs, and may detect a few 
AP sites. Finally, DNA is stained with a fluorescent dye and visualised under microscope. 
During electrophoresis, broken damaged DNA (denatured DNA fragments) will migrate out 
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of the cell nucleus. The intensity of the comet tail relative to the head reflects the number of 
DNA breaks. 
2.5.4.4 Quantification of DNA SSBs 
While the cell samples are being prepared, the lysis solution is pre-chilled at 4°C for at least 
30 minutes before use. Also, the LMA is melted in a water bath of boiling water for 5 minutes 
and then placed in a 37°C water bath for at least 30 minutes. Molten LM is aliquoted into 
pre-warmed microcentrifuge tubes and placed at 37°C. 
Upon completion of treatment, culture medium was carefully aspirated, cells washed and 
trypsinised as already described. The resulting cell pellet was re-suspended in 100 µL PBS 
and then 50 μL of the cell suspension was combined with 500 μL of molten LMA (at 37°C) 
at a ratio of 1:10 (v/v). Out of this cell LMA mixture, 50 μL are immediately pipetted onto 
comet slide. The comet slides are then placed flat at 4°C in the dark for 10 minutes and 
subsequently immersed into pre-chilled lysis solution and left overnight at 4°C. After lysis, 
comet slides are immersed into freshly prepared alkaline solution (pH > 13) and incubated 
for at least 60 minutes at RT in the dark. Slides are then washed twice in 1X TBE buffer for 
5 minutes each time and transferred to a horizontal electrophoresis apparatus. After that, the 
comet slides are placed flat onto a gel tray and then aligned equidistant from the electrodes 
of the electrophoresis. Then, TBE buffer (1X) was added until level just covers the comet 
slides. After that, the power supply was set to 19 V (1 V per cm by measured electrode to 
electrode) and the voltage was applied for 10 minutes. After the electrophoresis, the comet 
slides were dipped in 70% ethanol for 5 minutes and then air dried. Finally, the comet slide 
was stored at RT until ready for staining. 50 μL of diluted SYBR Green I was added onto 
each circle of dried agarose and the comet slide was viewed by using epifluorescence 
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microscopy where SYBR Green I’s maximum excitation is 494 nm and maximum emission 
is 521 nm. 
2.5.5 Quantifing DNA Double Strand Breaks (DSBs) (γ-H2AX) 
2.5.5.1 Experimental Design  
To quantify DNA DSBs in MEFs after treatment with MMS or with the positive control 
hydrogen peroxide (H2O2), both wild-type and Aag
-/- of MEF cells were examined in the 
same black 96-well plate in each experiment. Wild-type and Aag-/- MEFs were counted and 
then seeded in a black 96-well plate at a density of 1×104 cells/well with 100 µL of complete 
culture medium, as previously described. In this assay, a total of 10 time points were 
examined to quantify DNA DSBs in MEFs in response to 2.5 mM MMS treatment.  
Each repair time point was done in quadruplicate wells in a black 96-well plate, with controls 
including duplicate wells for primary antibody-free used as control for background 
correction, quadruplicate wells for MEF cells without MMS treatment (untreated control) 
and duplicate wells for positive control using H2O2 at concentration 1 mM in the absence of 
MMS treatment for MEF cells. The repair time points used in the study were: -0.5, 0, 0.5, 1, 
2, 4, 6, 12, 24 and 48 hours, which represented the repair incubation time following removal 
of 2.5 mM MMS from the MEF cells. 
2.5.5.2 Procedure  
Cells were treated with 2.5 mM MMS prepared freshly in SFM for 1 hour, as described 
above. Treatment with MMS was applied firstly to the 48 hour repair time point, and then 
the subsequent repair time points were treated accordingly with MMS in order to allow all 
repair time points to end at the same time. In addition, two groups of untreated control and 
background wells were set up along with the active treatment where these wells were treated 
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as the 48 h time point with SFM only. For the positive control wells, cells were treated with 
1 mM of H2O2 for 30 minutes only at 37°C under 5% CO2. 
2.5.5.3 Principle of the Assay 
Quantification of DNA DSBs is based on H2AX phosphorylation detection. Phosphorylation 
of H2AX is reported as a unique feature induced in response to DNA DSBs originated from 
diverge origins including DNA damaging agents. The phosphorylated H2AX can be 
quantified using a new sensitive assay called In-Cell Western (ICW). Primary antibody 
against anti-phospho-H2AX was used in this assay. LI-COR Odyssey CLx is used to scan 
the plate with detection in both the 700 and 800 channels. 
2.5.5.4 Quantification of DNA DSBs 
Upon completion of treatment, culture medium is aspirated and cells immediately fixed for 
20 minutes at RT with 4% PFA. After cell fixation, fixative was removed and wells rinsed 
with 1X PBS. After that, cells were permeabilised with 0.1% Triton X-100 in 1X PBS for 5 
minutes at RT with gentle shaking on an orbital shaker by using a generous amount of buffer 
(200 μL/well) and this step was repeated 3 more times. Next, wells were blocked by adding 
150 μL of Odyssey Blocking Buffer (OBB) to each well for one hour and half at RT with 
gentle shaking on an orbital shaker, followed by overnight incubation with 50 µL of diluted 
rabbit monoclonal anti γ-H2AX antibody/well at 4 °C with no shaking. Antibody dilution 
was made in OBB at final concentration 1:200. Background wells were incubated with 50 
µL of OBB only without primary antibody. After overnight incubation with primary 
antibody, the plate was washed five times with 1X PBS + 0.1% Tween 20 for 5 minutes at 
RT with gentle shaking on an orbital shaker, using a generous amount of buffer (200 
μL/well). After the last wash, secondary detection was performed using an infrared 
fluorescent dye conjugated to goat antibody (goat anti-rabbit IRDye 800CW) diluted in OBB 
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at final concentration 1:1000. 50 μL of secondary antibody solution was added into each 
well and then incubated for 1 hour at RT, with gentle shaking on an orbital shaker and 
protection from light. For cell number normalization, CellTag 700 stain diluted in OBB at 
final concentration 1:1000 was used in conjugation with the secondary antibody. After this 
incubation, the plate was washed five times with 1X PBS + 0.1% Tween 20 for 5 minutes at 
RT with gentle shaking on an orbital shaker, using a generous amount of buffer (200 
μL/well) and protected from light. After last wash, cell stain and γ-H2AX were visualised 
simultaneously with the 700 nm channel (red colour) and the 800 nm channel (green colour), 
respectively, using the Odyssey CLx infrared imaging scanner. Raw absorbance data of each 
well in the black 96-well plate was corrected for the average of background wells; the 
relative fluorescence units (RFUs) from the scanned wells of the black 96-well plate allowed 
a quantitative analysis. For determination of genotoxicity, RFUs for γ-H2AX per cell (as 
determined by dividing γ-H2AX in 800 nm channel by cell number in 700 nm channel) were 
divided by the respective untreated control, in order to determine the change in the levels of 
γ-H2AX relative to the untreated control which expressed as % control. 
2.5.6 Quantification of PARylation (Western Blot) 
2.5.6.1 Experimental Design  
1.5×106 MEF cells were seeded onto 10 cm2 tissue culture dishes as previously described in 
the experimental design of AP site quantification. A total of 8 repair time points were used 
in the study in order to capture the change in PARylation with time after treatment with 2.5 
mM MMS. Repair time points investigated in the study include time during when MEFs 
were exposed to MMS and also after MMS treatment. The repair time points used in the 
study were: -0.5, 0, 0.5, 1, 2, 4, 6 and 12 hours, which represented the repair incubation time 
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after removal of 2.5 mM MMS and duplicate wells were used for each repair time point for 
both untreated control group and MMS-treated group. 
2.5.6.2 Procedure  
MEF cells were treated with MMS as described above and harvested at 30 and 60 minutes 
after adding MMS treatment. For those MEFs not harvested by one hour after the incubation 
with MMS, the treatment solution was removed and 2% serum culture medium was added 
to the cells and then these MEF cells were incubated under the same conditions as previously 
mentioned. After that, cells were harvested at 0.5, 1, 2, 4, 6 and 12 hours after removing 
MMS and addition of 2% serum culture medium. 
In addition, untreated control samples were set up in parallel along with the treated samples. 
The complete culture medium containing 15% serum in the untreated control samples was 
removed, followed by the addition of SFM (10 mL). Then, the MEF cells were incubated for 
one hour under the same conditions as the MMS-treated group, followed by removal of SFM 
and replacement with 2% serum culture medium. Harvesting of MEF cells from the 
untreated control samples was done at 12 hours after the removal of SFM and the addition 
of 2% serum culture medium. 
2.5.6.3 Cell Harvesting 
Cells were trypsined and harvested as described above. Following trypsinisation, cell pellet 
was washed in ice-cold PBS and cells centrifuged for 5 minutes at 300 × g. After this wash, 
the supernatant was removed and cell pellet was stored at -20 °C. 
2.5.6.4 Principle of the Assay 
Western blot technique can be used to quantify the PARylation levels in samples. In western 
blot technique, gel electrophoresis is used to separate native proteins based on molecular 
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weight. Then, these proteins are transferred onto a membrane, where they are incubated with 
antibodies (primary antibody) which are specific to the target protein. LI-COR Odyssey CLx 
is used to scan the membrane with detection in both the 700 and 800 channels. 
2.5.6.5 Preparation of Lysates 
Upon completing cell harvesting, samples were transferred from -20°C to ice and then cold 
lysis buffer (RIPA buffer) supplemented with protease inhibitor cocktail was added to the 
cell pellet and mixed very well. Cell suspension was then transferred into a pre-cooled 
microfuge tube and maintained constant agitation for 30 minutes at 4°C in ice. The samples 
were then centrifuged in a microcentrifuge at 4°C for 30 minutes at speed of 13,000 rpm. 
The supernatant containing the cell lysate was transferred to a fresh tube kept on ice, and the 
pellet was discarded. After that, the protein amount in each cell lysate was determined by 
performing BCA assay and the cell lysates were stored at -80 °C for later use. 
2.5.6.6 Preparation of Samples for Loading into Gels 
Once the amount of protein per µL is known, all samples are made up to a known quantity. 
Loading buffer is prepared freshly by adding 100 μL of 2-mercaptoethanol per 900 μL of 
(4X) Laemmli buffer (final concentration of 355 mM). After that, 1 part of loading buffer 
was mixed with 3 parts of the sample which has been made up to a standard total volume 
with Milli-Q water. After that, the mixture was boiled at 95-100 °C for 5 minutes to denature 
the protein prior to loading. 
2.5.6.7 Protein Separation by Gel Electrophoresis 
20 µg of protein/sample, along with 5 µL of molecular weight marker (protein ladder), were 
loaded into the wells of a mini format SDS-PAGE gel. Gel is run at 150 V in 1X running 
buffer. 
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2.5.6.8 Transferring the Protein from the Gel to the Membrane 
After electrophoretic separation of the proteins, the gel is removed from gel cassette and 
placed carefully on top of the ion reservoir stack with the membrane (anode stack) in the 
centre of the cassette base of the BIO-RAD transfer draw. After that, the gel is rolled flat 
using a blot roller to remove air bubbles between the gel and the membrane. Then, the second 
ion reservoir stack (cathode stack) is gently placed on the gel and roll to flatten using the 
blot roller to remove any air bubbles in the assembled transfer pack. The cassette lid is placed 
on the base and the draw is closed and the Trans-Blot Turbo Transfer System equipment is 
set to run as a standard gel for 30 minutes. 
2.5.6.9 Antibody Incubation and Quantification of PARylation 
After transferring the protein from the gel to the membrane, the membrane was transferred 
to western blot incubation box and 7 mL of odyssey blocking buffer (OBB) was added to 
the membrane and blocked for 1 hour at RT with gentle shaking. After blocking, the 
membrane was washed 3 times of 5-10 minutes/each with 1X PBS containing 0.1% Tween 
20 with gentle shaking. Then, primary antibodies (mouse monoclonal anti-PAR and rabbit 
monoclonal anti-lamin B1) diluted in 7 mL OBB containing 0.2% Tween 20 was added to 
the membrane as final concentration of 1:500 for anti-PAR and 1:1000 for anti-lamin B1. 
The membrane then was incubated overnight at 4 °C with gentle shaking.  
After incubation overnight, the membrane was washed 3 times for 5-10 minutes with 1X 
PBS containing 0.1% Tween 20. Then, secondary antibodies (goat anti-mouse IRDye 
800CW and goat anti-rabbit IRDye 680RD) diluted in 7 mL OBB containing 0.2% Tween 
20 was added to the membrane as final concentration of 1:7000 for both antibodies. After 
that, the membrane was incubated for 1 hour at RT with gentle shaking and with protection 
from light during the incubation. After the 1 hour incubation, the membrane was washed 3 
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times for 5-10 minutes with 1X PBS containing 0.1% Tween 20 followed by washing 2 times 
with 1X PBS for about 10 minutes to remove residual Tween 20. Finally, the membrane was 
scanning using LI-COR with detection of target protein (anti-PAR) in the green channel 
(800) and anti-lamin B1 in the red channel (700) using AutoScan function to improve the 
dynamic range of the image. 
2.5.7 Quantification of PARylation (In-Cell Western) 
2.5.7.1 Experimental Design and Procedure 
Wild-type MEFs were seeded in a black 96-well plate at a density of 5×103 cells/well. The 
experimental design and procedure for quantification of PARylation is the same as described 
previously for γ-H2AX quantification. 
2.5.7.2 Principle of the Assay 
PARylation can be quantified using a new sensitive assay called In-Cell Western (ICW). 
Primary antibody against anti-PAR was used in this assay. LI-COR Odyssey CLx is used to 
scan the plate with detection in both the 700 and 800 channels. 
2.5.7.3 Quantification of PARylation 
Quantification of PARylation was done as previously described for γ-H2AX quantification 
but using the rabbit polyclonal anti-PAR antibody as the primary antibody. 
2.5.8 Quantifying cellular NAD+ Levels  
2.5.8.1 Experimental Design  
Wild-type and Aag-/- primary MEFs were seeded at a density of 1×104 cells/well into a 96-
well plate with 100 μL of 15% serum culture medium and then the cells were incubated 
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overnight at 37 °C under 5% CO2 in order to adhere to the wells. A total of 7 repair time 
points were used in the study in order to measure the cellular NAD+ levels with time in 
response to MMS treatment. In brief, repair time points investigated in the study include 
time during when MEFs were exposed to MMS and also after MMS treatment.  
In a 96-well plate, each repair time point was done in quadruplicate wells for both genotypes 
of MEF cells. Controls were also included in the experimental design with duplicate cell-
free wells used as control for background absorbance correction, duplicate wells used as 
untreated control containing MEF cells without MMS treatment and duplicate wells for 
negative controls using FK-866 inhibitor at a concentration of 100 nM to inhibit 
nicotinamide phosphoribosyltransferase (NAMPT) in the absence of MMS treatment. The 
repair time points used in the study were: -0.5, 0, 0.5, 1, 6, 24 and 48 hours, which 
represented the repair incubation time after removal of 2.5 mM MMS treatment. 
2.5.8.2 Procedure  
In brief, 2.5 mM MMS was prepared freshly in SFM and then 100 μL of 2.5 mM MMS was 
added to the respective wells as described above. Treatment with MMS was applied firstly 
to the 48 hour repair time point, and the subsequent repair time points were treated 
accordingly with MMS in order to allow all repair time points to end simultaneously. 
Controls were treated as the 48 hour repair time point with only SFM for the untreated 
control or with 100 nm FK-866 for the negative control but without MMS. For FK-866 wells, 
SFM with 100 nM FK-866 was replaced after 1 hour incubation with 100 μL 2% serum 
culture medium containing 100 nm FK-866 and returned to the incubator at the same 
conditions as mentioned previously. 
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2.5.8.3 Principle of the Assay  
Reagents and NAD+ standards used to quantify the cellular NAD+ levels in the samples were 
supplied by the Cayman Chemical NAD+/NADH Cell-Based Assay Kit (600480) and 
prepared exactly as prescribed by the manufacturer. In the assay, alcohol dehydrogenase 
catalyses the oxidation of alcohol to acetoaldehyde, in which the formed NADH reduces a 
tetrazolium salt substrate to a highly-coloured formazan which absorbs strongly at 450nm. 
The amount of formazan produced is proportional to the amount of NAD+ in the cell lysate 
and can be used as an indicator of the cellular NAD+ concentration. 
2.5.8.4 Quantification of NAD+ Levels  
The final reaction solution was prepared as 9.5 mL assay buffer according to the 
manufacturer's instructions with 200 μL of a tetrazolium salt substrate, 100 μL of ethanol 
solution, 100 μL of alcohol dehydrogenase solution and 100 μL of NAD+ diaphorase 
solution. Upon completion of MMS treatment, the microplate was spin down at 500 × g for 
5 minutes, followed by removal of the culture medium by aspiration. After that, cells in each 
well were permeabilised with 100 μL of digitonin lysis buffer and then the cells were 
incubated at RT for 30 minutes with gentle shaking on an orbital shaker. After that, the 96-
well microplate was spin down at 1,000 × g for 10 minutes at 4 °C. After centrifugation, 75 
μL of the supernatant (cell lysates) from each well of the 96-well microplate was transferred 
to corresponding wells of a new clear bottom 96-well microplate and also 75 μL of each 
NAD+ standard was transferred into appropriate wells in duplicate. After that, 75 μL of the 
final reaction solution was added to each well and the clear 96-well microplate was then 
incubated at RT with gentle shaking on an orbital shaker for 3 hours. The final absorbance 
was measured at a wavelength of 450 nm. 
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2.5.8.5 Protein Normalising  
To normalise the intracellular NAD+ levels by the amount of protein in the samples, the 
amount of protein in the cell lysates solution was quantified using PierceTM BCA Protein 
Assay Kit provided by Thermo Scientific Company. In brief, 25 µL of the cell lysates 
solution of each sample was transferred to a 96-well plate. 200 µL of working reagent (WR) 
solution (prepared according to the kit manual) was added to each well of the 96-well 
microplate. After that, the 96-well plate was transferred to a plate shaker for mixing for 30 
seconds. After mixing, the 96-well plate was covered and incubated at 37 °C for 2 hours. 
The absorbance was measured at 562nm using FLUOstar Omega - Multi-mode microplate 
reader. Finally, a calibration curve was prepared using known diluted albumin (BSA) 
standards provided by the kit and the amount of the protein in the samples was quantified by 
using the calibration curve. 
2.5.9 Quantification of ATP Levels  
2.5.9.1 Experimental Design 
A total of 8 repair time points were used in the study to measure the cellular ATP levels with 
time in response to 2.5 mM MMS treatment. MEF cells were seeded in a 96-well microplate 
at a density of 1×104 cells/well in 100 µL of 15% serum culture medium as previously 
described. The repair time points measured were: 0, 0.5, 1, 2, 3, 6, 24 and 48 hours, which 
represented the repair incubation time after removal of 2.5 mM MMS. Each time point was 
done at least in quadruplicate, including untreated control and also the nicotinamide 
phosphoribosyltransferase (NAMPT) inhibitor FK-866 at concentration 100 nM in the 
absence of MMS treatment. 
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Mg2+ 
luciferase 
2.5.9.2 Procedure  
MEF cells were treated with MMS (2.5 mM) as previously described. In addition, the control 
wells were prepared and treated as the 48 hour time point with SFM only or with 100 nm 
FK-866 but without MMS as described in quantification of NAD+ levels. 
2.5.9.3 Principle of the Assay  
Reagents and ATP standards were provided by the Molecular Probes’ ATP Determination 
Kit and prepared exactly as per their kit protocol. The assay is based on luciferase’s absolute 
requirement for ATP in producing light from the following reaction: 
Luciferin + ATP + O2                            oxyluciferin + AMP + pyrophosphate + CO2 + light  
Light is generated in the chemical reaction by converting the chemical energy of luciferin 
oxidation through an electron transition, leading to form oxyluciferin where firefly luciferase 
catalyses luciferin oxidation reaction in the presence of ATP. The luminescent signal is 
measuring by a luminometer. 
2.5.9.4 Quantification of ATP Levels  
The final reaction solution provided by the ATP Determination Kit was prepared as 8.9 mL 
dH2O with 0.5 mL 20X Reaction Buffer, 0.1 mL 0.1 M DTT, 0.5 mL of 10 mM D-luciferin 
and 2.5 μL of firefly luciferase 5 mg/mL stock solution. Upon completion of MMS 
treatment, the 96-well plate was spin down at 500 × g for 5 minutes at RT, followed by the 
removal of culture medium by aspiration. After that, MEF cells in each well were 
permeabilised with 100 μL of digitonin lysis buffer and the 96-well microplate was 
incubated at RT for 30 minutes with gentle shaking on an orbital shaker. After incubation, 
the 96-well microplate was spin down at 1,000 × g for 10 minutes at 4 °C and then 100 μL 
of the supernatant (cell lysates) from each well of the 96-well microplate was transferred to 
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corresponding wells of a new 96-well microplate. 10 μL was transferred from the cell lysates 
to corresponding wells of a new white 96-well microplate and also 10 μL of each ATP 
standard was transferred into appropriate wells in the same white 96-well plate in duplicate. 
After that, 90 μL of the final reaction solution was added to each well, so the final volume 
was 100 μL in each well. The final bioluminescence was measured using FLUOstar Omega 
- Multi-mode microplate reader. 
2.5.9.5 Protein Normalisation  
To normalise the intracellular ATP levels by the amount of protein in the samples, the 
amount of protein in the cell lysates solution was quantified using PierceTM BCA Protein 
Assay Kit provided by Thermo Scientific Company, as previously described.  
2.5.10 Cell Viability Assay (Propidium Iodide Exclusion) 
2.5.10.1 Experimental Design  
For the detection of non-viable cells after treatment with MMS, both wild-type and Aag-/- 
cells were seeded in a 6-well plate at a density of 2.5×105 cells/well, as previously described.  
In this assay, a total of 8 time points were incorporated into the experimental design. Each 
time point was done in triplicate wells, with controls including duplicates for both genotypes 
in the absence of MMS treatment. The time points measured were: 0, 1, 2, 4, 6, 12, 24 and 
48 hours, which represented the repair incubation time after removal of treatment (2.5 mM 
MMS). 
2.5.10.2 Procedure  
Cells were treated with 2.5 mM MMS as previously described. Controls were treated as the 
48 h time point with SFM. 
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2.5.10.3 Principle of the Assay 
One method to assess cell viability is through the use of dye exclusion. Live cell has an intact 
membrane which can exclude a variety of dyes that easily penetrate the damaged, permeable 
membrane of non-viable cell. PI is a membrane impermeant dye which is generally excluded 
from viable cell, so it is used to detect dead cells in a cell suspension. A flow cytometer is 
required in this assay for quantitative analysis of PI labelled cells. 
2.5.10.4 Cell Harvesting and PI Labelling for Flow Cytometry 
The culture medium was collected and transferred to a 12×75 mm flow cytometry test tube. 
After that, the well was rinsed with 0.5 mL PBS and pooled with the reserved culture medium 
to retain both adherent and floating cells. Then, 0.5 mL of trypsin-EDTA (1×) solution was 
transferred to the well of the 6-well plate and incubated for approximately 2-3 minutes at 37 
°C under 5% CO2 level in order to detach the adherent cells from the bottom of the well. 
After that, 0.5 mL of complete culture medium was added to the well after incubation to 
inactivate the trypsin-EDTA and then the cellular suspension was pooled with the reserved 
culture medium again. Then, the mixture in the flow cytometry test tube was centrifuged at 
300 × g for 5 minutes, followed by removed of the supernatant and then the cell pellet was 
resuspended in 3 mL PBS and centrifuged again at 300 × g for 5 minutes for washing. PBS 
wash was repeated twice and at the end of the second wash, the supernatant was removed 
and the cell pellet was re-suspended in 500 µL PBS. After that, 1 µL of PI stock solution (1 
mg/mL) was added to the cell suspension to final concentration of 2 µg/mL to each sample. 
Then, the samples were incubated at RT for 15 minutes in the dark and then analysed by 
flow cytometry within one hour after PI labelling where 10,000 events have been collected 
per sample. 
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2.5.11 Cell Viability Assay (Cell Number) 
The determination of cell viability in this study was also performed by measuring cell 
number within the in-cell western assays. CellTag 700 Stain is used for the purpose of 
measuring cell number where it can accumulate in both the nucleus and cytoplasm of 
permeabilised cells. It is a near-infrared fluorescent, non-specific cell stain that provides 
accurate linear fluorescent signal reflects to the cell number. For determination of cell 
viability, cell number using CellTag 700 Stain recorded in the different experiments of in-
cell western after MMS treatment was compared to cell number in the untreated control cells. 
2.5.12 Cell Cycle Study 
2.5.12.1 Experimental Design  
Cell cycle status was determined by measuring DNA content using a flow cytometer after 
treatment with MMS. Both wild-type and Aag-/- cells were seeded in a 6-well plate at a 
density of 2×105 cells/well as previously described. In this assay, a total of 8 repair time 
points were used and each repair time point was done in triplicate wells, including controls 
for both genotype cells in the absence of MMS treatment. The time points measured were 0, 
2, 4, 6, 12, 24 and 48 hours, which represented the repair incubation time after removal of 
2.5 mM MMS. 
2.5.12.2 Procedure  
Cells were treated with 2.5 mM MMS as previously described. Controls were treated as the 
48 h time point with SFM. 
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2.5.12.3 Cell Harvesting and Fixation 
Cell harvesting procedure was done as previously described in Propidium iodide exclusion 
assay. After the wash with PBS, the supernatant was discarded and the cells pellet was fixed 
by adding dropwise 3 mL of ice-cold 70% ethanol while vortexing. After that, the samples 
were incubated at 4 °C in order to allow complete fix the cells for at least overnight but no 
more than a week. 
2.5.12.4 Principle of the Assay 
Propidium iodide (PI) is a fluorescent dye which binds to nucleic acids. RNaseA 
(ribonuclease A) is used to digest cellular RNA because PI binds DNA as well as RNA, and 
therefore decrease background RNA staining from the experiment. Ethanol is used to fix and 
permeabilise cells because PI is membrane impermeant. A flow cytometer is required for 
quantitative analysis. 
2.5.12.5 PI Labelling for Flow Cytometry 
After incubation at 4 °C for fixation, the mixture was centrifuged at 1000 × g for 5 minutes, 
followed by removal of the supernatant and the cell pellet was washed with 3 mL PBS and 
centrifuged again for 5 minutes at 1000 × g. A higher than 300 × g centrifugal force was 
applied in this study to better retain the fixed cells and avoid the loss of the smaller apoptotic 
cells during washing steps with PBS. The centrifugation of the cells at 1000 × g was expected 
to not lyse the cells which were fixed as this approach had been employed previously in 
many studies (Tentner et al., 2012). The washing step with 3 mL PBS buffer was repeated 
twice, followed by removal of the supernatant and the cell pellet was resuspended in 50 µL 
RNaseA of a (100 µg/mL) stock to ensure only DNA and not RNA is stained with PI. After 
that, the cells incubated at RT for 15 minutes and then 400 µL of PI (diluted in PBS to final 
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concentration of 50 µg/mL) was added to each sample. Then, the samples were analysed by 
flow cytometry where 10,000 events have been collected per sample.  
2.6 Statistical Analysis 
All   data   are   expressed as mean plus or minus standard error of the mean (SEM). 
Comparisons between each genotype of MEF cells with their respective control were 
statistically analysed by one-way ANOVA followed by Dunnett's multiple comparisons test. 
While, comparisons between the two genotypes were statistically analysed by two-way 
ANOVA followed by Sidak's multiple comparisons test, and considered signiﬁcantly 
different when p < 0.05. GraphPad Prism version 6.01 software was used to analyse the 
results in this study. 
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Chapter 3: BER Intermediates are Formed Similarly in Wild-
type and Aag-/- MEF Cells 
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3.1 Introduction 
DNA is subject to continuous attack by endogenous and environmental chemical and 
physical agents leading to the generation of DNA damage. Alkylating agents exemplify a 
ubiquitous family of chemically reactive compounds that transfer alkyl carbon groups to 
DNA and other cellular macromolecules, resulting in damaging functional and structural 
alterations to these molecules. Methyl methanesulfonate (MMS) is an alkylating agent which 
is widely used in research studies. MMS methylates DNA bases leading predominantly to 
the generation of 7-meG and 3-meA lesions within the DNA. These MMS-induced alkylated 
bases are primarily repaired by the base excision repair pathway (BER) initiated by enzymes 
called DNA glycosylases. These enzymes (for example AAG) recognise and remove a single 
damaged base to create an AP site (Fu et al., 2012). 
AP site is produced when a base is lost from DNA by cleavage of the N-glycosyl bond, 
leaving the sugar-phosphate chain intact (Friedberg et al., 2006). AP site is considered as 
one of the most frequent spontaneous lesions in the DNA where it is formed by spontaneous 
depurination and depyrimidination reactions (Freitas and de Magalhaes, 2011). Furthermore, 
AP sites can also be produced as an intermediate step of the BER pathway by DNA 
glycosylases (Boiteux and Guillet, 2004).  
Importantly, AP site is a potentially mutagenic and cytotoxic lesion to the cell which can 
block and prevent normal DNA transcription and replication (Boiteux and Guillet, 2004, 
Dianov et al., 2003). Incomplete or inefficient BER may leave unrepaired AP sites in the 
DNA (Freitas and de Magalhaes, 2011) leading to the accumulation of AP sites results in 
blocking to the DNA replication and transcription which eventually can lead to cell death 
(Boiteux and Guillet, 2004, Hoeijmakers, 2001). So, AP sites are a threat to cellular viability 
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and genomic integrity (Dianov et al., 2003). Furthermore, cleavage of AP sites by APE1 
results in the generation of SSBs (Boiteux and Guillet, 2004). 
SSBs are DNA strand breaks where one strand of the DNA double helix carries a breakage 
or interruption in the sugar-phosphate backbone. In addition to the formation of SSBs 
indirectly as an intermediate during the BER process, they also can form directly from 
disintegration of the deoxyribose sugar (Caldecott, 2014). Unrepaired SSBs can significantly 
impact cell fate in different ways (Caldecott, 2008). 
A potential impact of SSB formation is cell death induction through hyperactivation of the 
SSB sensor protein PARP1. Prolonged PARP1 activation leads to depletion of cellular 
NAD+ and ATP levels (Heeres and Hergenrother, 2007, Moroni, 2008), energetic failure and 
consequently cell death. In addition, in non-proliferating cells SSBs can induce cell death 
due to RNA polymerase progression stalling (Bendixen et al., 1990, Kathe et al., 2004). In 
contrast, in proliferative cells the blockage or collapse of DNA replication forks during the 
S phase of the cell cycle is the most likely culprit due to the formation of DSBs (Kuzminov, 
2001). 
DSBs are DNA strand breaks where the breakage of the DNA occurs in both strands. This 
type of DNA strand break is considered as one of the most cytotoxic forms of DNA damage 
and it can lead to cell death if not repaired (Chapman et al., 2012). DSBs can arise in the 
DNA following exposure of cells to exogenous agents, such as some classes of 
chemotherapeutic drugs or ionizing radiation (IR). Also, DSBs can occur spontaneously 
from endogenous DNA damaging sources when DNA replication forks encounter unrepaired 
AP sites or SSBs, leading to fork collapse (Pfeiffer et al., 2000). 
Exposure to these endogenous and exogenous agents which induce DSBs formation will 
trigger the activation of DSBs signalling and repair mechanisms. The histone variant H2AX 
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is part of the DSBs response where after the detection of a DSB it is targeted for 
phosphorylation in the vicinity of a DSB. This phosphorylated form of H2AX is known as 
γ-H2AX (Kuo and Yang, 2008). In addition, it plays a role in the recruitment of multiple 
DNA signalling and repair proteins into repair sites. This is visible under a microscope as 
nuclear aggregates which is known as foci. So, because γ-H2AX is signalling in the presence 
of DSBs, it is widely used as a biomarker for DSBs (Rothkamm and Horn, 2009). 
In addition for evidencing DNA strand breaks in the cells by γ-H2AX detection, the comet 
assay is yet another method for DNA strand break evaluation in the cells. The comet assay 
is also referred to as the single cell gel electrophoresis assay (SCGE). It is a rapid, 
uncomplicated and sensitive technique for detecting, analysing and quantifying DNA 
fragmentation associated with DNA damage at the level of individual cells (Hašplová et al., 
2012, Kumaravel et al., 2009).  
The comet assay was first developed by two Swedish scientists Ostling and Johanson in 1984 
for detecting DNA DSBs (neutral method). Later, it was modified by Singh et al. in 1988 for 
detecting DNA strand breaks under alkaline conditions (pH > 13) at the level of the single 
cell. At this high pH, not only DSBs will be detected but also SSBs and alkali-labile sites 
which offered significantly increased sensitivity for detecting genotoxicity because most of 
these genotoxic agents induce more SSBs and/or alkali-labile sites than DSBs. So, this type 
of comet assay which is based on alkaline conditions became the most popular method used 
of comet assay for quantification of the DNA strand breaks (Liao et al., 2009). 
3.2 Aim 
To temporally quantify the formation of BER intermediates in AAG proficient and deficient 
MEF cells after alkylation treatment.  
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3.3 Objectives 
 Temporal quantification of the AP site numbers in the samples after MMS treatment. 
 Temporal measurements of the DNA strand break levels in the samples after MMS 
treatment. 
 Temporal measurements of γ-H2AX signals in the samples after MMS treatment. 
3.4 Methods 
 Cell lines: wild-type and Aag-/- MEF cells. 
 Treatments: 2.5 mM MMS for 1 hour and 1 mM H2O2 for 30 minutes. 
 Spectrophotometry: used to quantify AP site numbers in the samples. 
 Fluorometry: used to quantify the DNA amount in the samples by using SYBRGreen 
staining in order to normalise the number of AP site to the DNA amount in each sample. 
 Comet assay: used to evaluate DNA strand breaks in individual cells. 
 In-cell western: used to quantify the level of γ-H2AX in alkylation treated cells. 
3.5 Results 
In this study, I characterised the molecular steps preceding AAG-dependent alkylation-
induced cell death in wild-type and Aag-/- MEF cells. A mechanism involving AAG-initiated 
BER pathway leading to the formation of the toxic BER intermediates (AP sites and SSBs) 
was invoked. At first, I assessed the activity of AAG on alkylated DNA damage by 
measuring the formation of AP sites. Also, I used the comet assay to quantify DNA strand 
breaks in wild-type and Aag-/- MEF cells harvested after treatment with MMS. Moreover, 
in-cell western technique has been used to detect the level of H2AX phosphorylation (γ-
H2AX) in MEF cells which reflects the amount of DNA strand breaks in the cells.  
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3.5.1 Abasic Sites Quantification 
AAG is the only known DNA glycosylase which can recognise and remove alkylated DNA 
bases during the BER process, and therefore the number of AP site lesions in DNA can be 
used as a direct measure of AAG activity (Robertson et al., 2009). Moreover, it is expected 
that the level of AAG activity will correlate positively with the level of AP sites in DNA for 
cells exposed to the same dose of the alkylating agent MMS.  
DNA modification that result in the formation of an aldehyde group (the open ring form of 
the AP site) is detected by specific reaction of Aldehyde Reactive Probe (ARP) with the 
aldehyde group where AP site is tagged with biotin residue. This reaction makes it possible 
to quantify AP sites using avidin-biotin assay, followed by a colorimetric detection of 
peroxidase conjugated to the avidin. 
Figure 3-1 (upper panel) shows the result for AP site quantification in wild-type MEF cells. 
Within this genotype, the number of AP sites increases gradually after MMS addition and 
reaches a peak 30 minutes after MMS wash-out; this peak is then followed by a decrease in 
AP site number with time. However, there is no statistical significant increase in the number 
of AP sites when comparing between the treated and the untreated control for each time-
point by using one-way ANOVA test. 
On the other hand, MMS treatment has also led to AP site-induction in Aag-/- MEF cells 
(Figure 3-1, bottom panel) despite a lack of AAG activity within this cell type. Surprisingly, 
the AP site-induction levels were statistically significant at 0, 1, 3 and 4 hours after MMS 
treatment, when comparing treated and untreated control cells using one-way ANOVA 
followed by Dunnett's multiple comparisons test. 
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Figure 3-1: Comparison of change in AP site numbers with time in treated wild-type MEF cells (upper panel) 
and treated Aag-/- MEF cells (bottom panel). Time before 0 hour (-0.75 and -0.50) indicates time during 
treatment period when MEF cells are exposed to MMS (2.5 mM). Time from 0 to 48 hours represents the time 
after MMS wash-out. Data shown are mean values ± standard error of the mean (SEM) of three independent 
experiments and each time point was done in triplicate. One-way ANOVA test was performed (Dunnett's 
multiple comparisons test) for statistical analysis and significance was assumed if p < 0.05. 
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However, it is noteworthy that the AP site number in the untreated control for Aag-/- MEF 
cells was smaller (2.1 ± 1.2 AP sites/100 kbps) than the number of AP sites found in the 
untreated control of wild-type MEF cells (4.2 ± 1.4 AP sites/100 kbps). So, this difference 
in the basal level of AP sites may have contributed to the statistical significances found in 
some time points in Aag-/- MEF cells as shown in Figure 3-1 (bottom panel). 
In order to establish whether time and/or genotype significantly affect AP site induction, 
two-way ANOVA analysis was used. As expected from the results of wild-type and Aag-/- 
MEF cells, the findings indicated no a statistical significance between these two genotypes 
as shown in Figure 3-2. 
Figure 3-2: Comparison of AP site induction with time between wild-type and Aag-/- MEF cells after MMS 
treatment. Time before 0 hour (-0.75 and -0.50) indicates time during treatment period when MEF cells are 
exposed to MMS (2.5 mM). Time from 0 to 48 hours represents the time after MMS wash-out. The values 
shown are means ± standard error of the mean (SEM) (n = 3). Statistical analysis done with two-way ANOVA 
followed by Sidak's multiple comparisons test. Red arrow indicates the time when 2.5 mM MMS was added 
to the cells, while the green arrow indicates the time when MMS was removed from cells.  
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3.5.2 DNA Strand Break Quantification 
DNA strand breaks can be assessed in the samples through different techniques. In this study, 
comet assay and phosphorylation of γ-H2AX have been used to quantify strand breaks in the 
samples. 
3.5.2.1 Comet Assay 
The first technique used in this study to quantify the DNA strand breaks in the samples is 
the comet assay. In this technique, damaged fragments of DNA has the ability to migrate 
towards the anode during electrophoresis, while undamaged DNA will migrate slower and 
remain within the nuclei confines when a current is applied. The term “comet” assay was 
given because the image obtained from the analysed sample in this assay has a similar 
appearance to a “comet” with a distinct circular head corresponding to the intact DNA and 
a tail which consisting of fragmented or damaged of the DNA.  
In this study, hydrogen peroxide (H2O2) was used as a positive control due to its ability to 
induce oxidative DNA damage. Wild-type and Aag-/- MEF cells were treated with H2O2 (1 
mM) in serum free media for 30 minutes at 37°C/5% CO2 and the level of DNA strand breaks 
was measured using the comet assay. The next figure (Figure 3-3) shows representative 
photomicrographs of the comet data for each time point after MMS treatment within wild-
type and Aag-/- cell populations. 
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Figure 3-3: Photomicrographs of comet assay data with time after MMS treatment (2.5 mM) in 
wild-type and Aag-/- MEFs. Time before 0 hour (-0.50) indicates time during treatment period when 
MEF cells are exposed to MMS. Time from 0 to 48 hours represents the time after MMS wash-out. 
Positive control samples were treated with H2O2 (1 mM) for 30 minutes at 37°C/5% CO2. 
Time 
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Figure 3-3: Photomicrographs of comet assay data with time after MMS treatment (2.5 mM) in 
wild-type and Aag-/- MEFs. Time before 0 hour (-0.50) indicates time during treatment period when 
MEF cells are exposed to MMS. Time from 0 to 48 hours represents the time after MMS wash-out. 
Positive control samples were treated with H2O2 (1 mM) for 30 minutes at 37°C/5% CO2. 
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Figure 3-3: Photomicrographs of comet assay data with time after MMS treatment (2.5 mM) in 
wild-type and Aag-/- MEFs. Time before 0 hour (-0.50) indicates time during treatment period when 
MEF cells are exposed to MMS. Time from 0 to 48 hours represents the time after MMS wash-out. 
Positive control samples were treated with H2O2 (1 mM) for 30 minutes at 37°C/5% CO2. 
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There are three common parameters to present the data obtained by the comet assay in order 
to quantify the level of total DNA strand breaks in the samples. These parameters are shown 
in the next table (Table 3-1) with the definition for each parameter. 
Table 3-1: Parameters used to present the comet assay data. 
Parameter Definition Calculation 
Tail  
DNA % 
Ratio between the total intensity of 
the tail and the total intensity of the 
comet. 
𝑇𝑎𝑖𝑙 𝑖𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦
𝐶𝑜𝑚𝑒𝑡 𝑖𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦 
× 100 
Tail 
Moment 
Product of the tail length and tail 
DNA %. 
𝑇𝑎𝑖𝑙 𝑙𝑒𝑛𝑔𝑡ℎ × 𝑇𝑎𝑖𝑙 𝐷𝑁𝐴 % 
Olive Tail 
Moment 
Product of the tail DNA % and the 
distance between the centres of the 
mass of head and tail. 
(𝑇𝑎𝑖𝑙 𝑚𝑒𝑎𝑛 − 𝑇𝑎𝑖𝑙 ℎ𝑒𝑎𝑑) × 𝑇𝑎𝑖𝑙 𝐷𝑁𝐴 % 
(Vilhar, 2004, Mozaffarieh et al., 2008, Liao et al., 2009, Kumaravel et al., 2009). 
Figures (3-4) and (3-5) present the results of tail DNA % and tail moment obtained from the 
comet assay of wild-type MEFs. While, figures (3-6) and (3-7) provide the results for Aag-/- 
MEFs. Moreover, the results of the third parameter of the comet assay (olive tail moment) 
can be seen in the Appendices. It is important to point out that the average shown for each 
comet assay parameter data in this study stems from at least 100 cells per time point per 
experiment. 
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Figure 3-4: Histographs illustrating the tail DNA % in wild-type MEFs. The top graph shows the tail DNA % 
with time after treatment with MMS (2.5 mM) in SFM comparing to their respective untreated control. The 
bottom graph shows the tail DNA % after treatment with H2O2 (1 mM) for 30 minutes at 37°C/5% CO2 as a 
positive control. Each time point was done in duplicate and the data shown are mean values ± SEM of three 
independent experiments. One-way ANOVA test was performed (Dunnett's multiple comparisons test) and 
significance was assumed if p < 0.05. 
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Figure 3-5: Histographs illustrating the tail moment in wild-type MEFs. The top graph shows the tail moment 
with time after treatment with MMS (2.5 mM) in SFM comparing to their respective untreated control. The 
bottom graph shows the tail moment after treatment with H2O2 (1 mM) for 30 minutes at 37°C/5% CO2 as a 
positive control. The data shown are mean values ± SEM of three independent experiments and each time point 
was done in duplicate. One-way ANOVA test was performed (Dunnett's multiple comparisons test) and 
significance was assumed if p < 0.05. 
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Figure 3-6: Histographs illustrating the tail DNA % in Aag-/- MEFs. The top graph shows the tail DNA % with 
time after treatment with MMS (2.5 mM) in SFM comparing to their respective untreated control. The bottom 
graph shows the tail DNA % after treatment with H2O2 (1 mM) for 30 minutes at 37°C/5% CO2 as a positive 
control. The data shown are mean values ± SEM of three independent experiments and each time point was 
done in duplicate. One-way ANOVA test was performed (Dunnett's multiple comparisons test) and 
significance was assumed if p < 0.05. 
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Figure 3-7: Histographs illustrating the tail moment in Aag-/- MEFs. The top graph shows the tail moment with 
time after treatment with MMS (2.5 mM) in SFM comparing to their respective untreated control. The bottom 
graph shows the tail moment after treatment with H2O2 (1 mM) for 30 minutes at 37°C/5% CO2 as a positive 
control. The data shown are mean values ± SEM of three independent experiments and each time point was 
done in duplicate. One-way ANOVA test was performed (Dunnett's multiple comparisons test) and 
significance was assumed if p < 0.05. 
C
o
n
tr
o
l
-  
0
.5
0 0
0
.5
0 1 2 4 6
1
2
2
4
4
8
0 .0
2 .5
5 .0
7 .5
1 0 .0
1 2 .5
1 5 .0
1 7 .5
2 0 .0
T im e  (H r )
T
a
il
 M
o
m
e
n
t
M
e
a
n

 S
E
M

   
 
 
C
o
n
tr
o
l
H
2
O
2
0 .0
2 .5
5 .0
7 .5
1 0 .0
1 2 .5
1 5 .0
1 7 .5
2 0 .0
T
a
il
 M
o
m
e
n
t
M
e
a
n

 S
E
M

109 
 
The results show that both wild-type and Aag-/- MEFs displayed significantly increased 
levels of DNA strand breaks after treatment with either H2O2 or MMS. The strand break 
induction was found to be statistically significant in some time points for both genotypes by 
one-way ANOVA followed by Dunnett's multiple comparisons test. 
It is apparent from these experimental results that H2O2 and MMS induced the formation of 
DNA strand breaks very fast as breaks can be detected 30 minutes post-treatment in both 
wild-type and Aag-/- MEF cells. In addition, both wild-type and Aag-/- MEF cells 
demonstrated significantly delayed DNA strand break repair rates as breaks can be measured 
in the cells as late as 48 hours post MMS wash-out. 
Next, I compared DNA strand break induction in the two cell types by two-way ANOVA. 
These results are shown in the Figure 3-8 and Figure 3-9 for tail DNA % and tail moment, 
respectively. Olive tail moment results are displayed in the Appendices. In addition, Figure 
3-10 shows the representative scatter plots of the raw data of 100 individual comet tail 
moments per sample from one of the experiments presented in Figure 3-9. This is useful in 
order to show the variation level in DNA strand breaks within single populations of both 
wild-type and Aag-/- MEF cells. 
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Figure 3-8: Histogram graph illustrating the temporal increase in tail DNA % after MMS treatment measured 
by comet assay in wild-type and Aag-/- MEFs. (Top) Time represents the number of hours when the MEFs were 
incubated in culture medium containing 2% serum after one hour treatment with MMS. The bottom graph 
shows the tail DNA % after treatment with H2O2 (1 mM) for 30 minutes at 37°C/5% CO2 as a positive control. 
While there is a trend for increased tail DNA % levels in some time points in wild-type versus Aag-/- MEFs, no 
statistically significant difference was observed by two-way ANOVA. 
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Figure 3-9: Histogram graph illustrating the temporal increase in tail moment after MMS treatment measured 
by comet assay in wild-type and Aag-/- MEFs. (Top) Time represents the number of hours when the MEFs were 
incubated in culture medium containing 2% serum after one hour treatment with MMS. The bottom graph 
shows the tail DNA % after treatment with H2O2 (1 mM) for 30 minutes at 37°C/5% CO2 as a positive control. 
While there is a trend for increased tail moment levels in some time points in wild-type versus Aag-/- MEFs, 
no statistically significant difference was observed by two-way ANOVA. 
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Figure 3-10: Representative scatter plots of comet tail moments, from one of the experiments included 
in Figure 3-9, for non-treated control or treated wild-type and Aag-/- MEF cells with 1 mM H2O2 
(positive control) or 2.5 mM MMS at different time points. Each dot represents the comet tail moment 
of an individual cell, and 100 individual cells were scored per sample (cells numbered from 0 to 100). 
Time before 0 hour (-0.50) indicates time during treatment period when MEF cells are exposed to 
MMS. Time from 0 to 48 hours represents the time after MMS wash-out. Positive control samples were 
treated with H2O2 (1 mM) for 30 minutes at 37°C/5% CO2. 
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Figure 3-10: Representative scatter plots of comet tail moments, from one of the experiments included 
in Figure 3-9, for non-treated control or treated wild-type and Aag-/- MEF cells with 1 mM H2O2 
(positive control) or 2.5 mM MMS at different time points. Each dot represents the comet tail moment 
of an individual cell, and 100 individual cells were scored per sample (cells numbered from 0 to 100). 
Time before 0 hour (-0.50) indicates time during treatment period when MEF cells are exposed to 
MMS. Time from 0 to 48 hours represents the time after MMS wash-out. Positive control samples were 
treated with H2O2 (1 mM) for 30 minutes at 37°C/5% CO2. 
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Figure 3-10: Representative scatter plots of comet tail moments, from one of the experiments included 
in Figure 3-9, for non-treated control or treated wild-type and Aag-/- MEF cells with 1 mM H2O2 
(positive control) or 2.5 mM MMS at different time points. Each dot represents the comet tail moment 
of an individual cell, and 100 individual cells were scored per sample (cells numbered from 0 to 100). 
Time before 0 hour (-0.50) indicates time during treatment period when MEF cells are exposed to 
MMS. Time from 0 to 48 hours represents the time after MMS wash-out. Positive control samples were 
treated with H2O2 (1 mM) for 30 minutes at 37°C/5% CO2. 
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The results from the comparison between both wild-type and Aag-/- MEF cells show that 
H2O2 and MMS induced similar levels of DNA strand breaks in both wild-type and Aag
-/- 
MEF cells, although Aag-/- MEFs lack AAG activity. In addition, MEF cells of both 
genotypes exhibited similar repair rates but with more delay found in wild-type MEFs at 
some later time points. What is interesting in these data is that we did not observe a reduction 
in DNA strand break induction following H2O2 and MMS treatment in Aag
-/- MEFs. In 
addition to the evidence of accumulation of DNA strand breaks from the mean comet tail 
moments from multiple averaged experiments in both wild-type and Aag-/- MEF cells, also 
scatter plots of the raw data of individual comet tail moments from individual experiments 
confirm these findings (Figure 3-10). 
3.5.2.2 Phosphorylation of H2AX 
The alkaline comet assay detects both SSBs and DSBs and therefore I wanted to verify the 
strand break induction in cells using an independent technique. The second technique used 
in this study to measure the level of DNA strand breaks in the samples was in-cell western. 
This technique is a rapid and a quantitative immunofluorescence assay. It uses spectrally-
distinct which allow quantify two targets at 700 nm and 800 nm channels. Proteins in fixed 
cultured cells is detected in this assay by using target-specific primary antibodies and 
infrared fluorescent secondary antibodies. Primary antibody against anti-phospho-H2AX 
was used in this assay which allowed for the quantification of the levels of phosphorylated 
H2AX histone, a known marker for DSBs. In addition, I wanted to verify whether AAG 
activity would in any way modulate the level of H2AX activation in MEF cells. 
In the results of γ-H2AX, the % control induction of γ-H2AX per cell in the samples was 
calculated after the quantification of γ-H2AX signal and the cell number signal. A 
representative picture of an in-cell western 96-well plate is shown in Figure 3-11 with cell 
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number in red channel (cell-tag 700 staining) and γ-H2AX in green channel. In addition, the 
results for the γ-H2AX quantification in wild-type and Aag-/- MEFs are presented in Figure 
3-12 and Figure 3-13, respectively, where MMS treated cells of wild-type and Aag-/- MEFs 
were compared with their respective untreated control.  
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Red Channel (700 nm) Cell-Tag 700 Staining 
 
 
 
 
                 
Green Channel (800 nm) Anti-γ-H2AX Antibody 
 
Figure 3-11: Representative pictures of in-cell western experiment for quantification of γ-H2AX signals in 
MEFs after MMS treatment with time. (Top) Cell-tag 700 staining in red channel to quantify the cell number 
signal in the wells. (Bottom) Anti-γ-H2AX antibody in green channel to quantify the γ-H2AX signal in the 
wells. Column 1: background wells contain γ-H2AX unlabelled MEF cells, in the positive control wells MEFs 
were treated with H2O2 (1 mM) for 30 minutes at 37°C/5% CO2. Column 2: untreated cells (control). Column 
3-12: time points after treated the MEF cells with MMS (2.5 mM). 
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Figure 3-12: Histographs illustrating the quantification of γ-H2AX per cell in wild-type MEFs. (Top) graph 
shows the % control of γ-H2AX with time after treatment with MMS (2.5 mM) comparing to their respective 
untreated control. (Bottom) graph shows the % control of γ-H2AX after treatment with H2O2 (1 mM) for 30 
minutes at 37°C/5% CO2 as a positive control. The data shown are mean values ± SEM of four independent 
experiments and each time point was done in quadruplicate. One-way ANOVA test was performed (Dunnett's 
multiple comparisons test) and significance was assumed if p < 0.05. 
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Figure 3-13: Histographs illustrating the quantification of γ-H2AX per cell in Aag-/- MEFs. (Top) graph shows 
the % control of γ-H2AX with time after treatment with MMS (2.5 mM) comparing to their respective untreated 
control. (Bottom) graph shows the % control of γ-H2AX after treatment with H2O2 (1 mM) for 30 minutes at 
37°C/5% CO2 as a positive control. The data shown are mean values ± SEM of four independent experiments 
and each time point was done in quadruplicate. One-way ANOVA test was performed (Dunnett's multiple 
comparisons test) and significance was assumed if p < 0.05. 
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Taken together, the results for the H2AX phosphorylation analysis and the comet assay 
indicate that the profile of DNA break induction is very similar in wild-type and Aag-/- MEFs. 
The phosphorylation levels of H2AX as detected by in cell western in wild-type and Aag-/- 
MEF cells were almost equivalent. Both wild-type and Aag-/- MEF cells showed gradual γ-
H2AX induction following MMS treatment peaking at 2 h, 4 h and 6 h followed by a 
decrease with time where only a limited induction of γ-H2AX was detected in both 
genotypes after 12 h, 24 h and 48 h.  
In wild-type MEFs, treatment with MMS resulted in a 12-15 fold increase γ-H2AX per cell 
over control between the 2 h and 6 h time points. Also, a similar profile of γ-H2AX induction 
per cell was observed for Aag-/- MEFs with a corresponding 13-14 fold increase when 
compared to the untreated control between the 2 h and 6 h time points. Additionally, 
comparable to the MMS treatment, high induction of γ-H2AX was found in both genotypes 
of MEF cells after treatment with H2O2 for 30 minutes. 
Figure 3-13 illustrates the comparison of the phosphorylated histone H2AX levels between 
the both genotypes of MEF cells. The results reveal a clear trend with early time points for 
increased induction of γ-H2AX levels found in wild-type versus Aag-/- MEF cells. There was 
6-fold induction of γ-H2AX in wild-type cells observed after 1 hour from adding MMS, 
while only 3.8-fold induction in Aag-/- cells was observed at the same time. There were also 
7.9 and 5.5-fold inductions of γ-H2AX seen at 0.5 h time point in wild-type and Aag-/- MEF 
cells, respectively. However, using two-way ANOVA test, no statistically significant 
difference was observed for each time point between wild-type and Aag-/- MEFs (Figure 3-
14). 
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Figure 3-14: The comparison of temporal increase in γ-H2AX levels after MMS treatment measured by in-cell 
western between wild-type and Aag-/- MEFs. (Top) Time represents the number of hours when the MEFs were 
incubated in culture medium containing 2% serum after one hour treatment with MMS. (Bottom) graph shows 
the level of γ-H2AX after treatment with H2O2 (1 mM) for 30 minutes at 37°C/5% CO2 as a positive control. 
Statistical analysis was performed by two-way ANOVA. 
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3.6 Discussion 
Previous studies have found that Aag-/- mouse bone marrow cells and Aag-/- photoreceptor 
cells were more resistant to the cytotoxic effects of MMS than wild-type cells (Roth and 
Samson, 2002, Meira et al., 2009). A mechanism involving AAG-initiated BER pathway 
leading to the formation of the toxic BER intermediates (AP sites and SSBs) and cytotoxicity 
was invoked to explain the resistance observed in the Aag-/- cells. In order to verify whether 
BER intermediate formation alone can explain this phenomenon, in this study I aimed at 
elucidating the events preceding AAG-dependent cell death induced by alkylating agents 
using MEFs as a cell culture system.  
To better understand the kinetics of BER intermediate induction, I quantified the AP site 
number in genomic DNA extracted from wild-type and Aag-/- MEF cells treated with the 
model alkylating agent MMS. In addition, the DNA strand break levels were measured in 
both genotypes of MEF cells by using the comet assay. Moreover, the relationship between 
BER intermediate accumulation and DSB induction was investigated with the quantification 
of MMS-induced γ-H2AX levels in wild-type and Aag-/- MEFs.  
A total of 14 repair time points were incorporated into this study to capture the temporal 
change in BER intermediate formation. This design took into consideration that generation 
of toxic AP site intermediates induced by MMS can occur at different times for different 
type of mammalian cells. It has been demonstrated that levels of alkali-labile AP sites 
increased noticeably after MMS treatment within 4–6 hours for both WIL-2 lymphoblastoid 
cells and normal non-established dermal fibroblasts, whereas in HeLa cells such lesion was 
found to be maximal immediately after MMS exposure (Mirzayans et al., 1988). 
Our results indicate that the AP site number varied between the two genotypes of MEF cells 
at particular time points. The results of AP site quantification in wild-type MEF cells indicate 
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that the highest number of AP sites was detected 30 minutes post- MMS wash-out with an 
average of 16 AP sites detected per 100 kbps. This was followed by a decrease in AP site 
number with time. However, our findings differ from the previous research done by Sobol 
and colleagues (2002). They have found that MMS treatment (1 mM MMS for 1 hour) led 
to no increase in AP site number in MEF cells, unless the DNA was also heat treated, in 
which case a MMS-dependent increase in AP site number was found (Sobol et al., 2002). 
Sobol and co-workers used a slot-blot based technique for their measurements while the 
current study used a sensitive colorimetric assay. The differences in sensitivity between the 
two techniques could explain the discrepancy between our results and those reported by 
Sobol and co-workers (2002). AP sites were quantified in the previous study directly after 1 
hour exposure to MMS (equivalent to our 0 h time point) and also 4 hour after exposure 
(equivalent to our 4 h time point). In contrast, our findings indicate an immediate increase 
in AP sites after MMS treatment, although this increase is not statistically significant 
comparing AP site numbers in wild type treated vs. untreated controls.   
In contrast, the quantification of AP sites in Aag-/- MEF cells indicate increased formation of 
AP sites after MMS treatment similar to wild-type MEF cells in spite of the absence of AAG 
activity within this cell type. Indeed, for some time points, there is a statistically significant 
difference between MMS-treated AP-site induction in Aag-/- MEF cells when compared to 
the untreated control. 
These results of the AP site number show that the number of endogenous AP sites in wild-
type MEF cells is 4 per 100 kbps DNA whereas it is 2 AP sites per 100 kbps in Aag-/- MEF 
cells. Therefore, these data indicate that basal level of AP sites in both genotypes of MEF 
cells persist at 2-4 lesions per 100 kbps under normal physiological conditions. Then, the 
number of AP sites per cell for both genotypes of MEF cells in the steady state is 
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approximately between 60,000 and 120,000 (estimates are for two 3×109 base pairs genomes 
per cell) (Friedberg et al., 2006). This is in the range (2,000–200,000 AP sites/cell) reported 
previously in the literature (De Bont and van Larebeke, 2004). 
The basal level of AP site number found in wild-type and Aag-/- MEF cells is in agreement 
with previous reports. According to the manufacturer of the AP site quantification kit 
(Dojindo Laboratories, Kumamoto, Japan), it is expected between 2 to 4 AP sites per 100 
kbps can be formed during the DNA isolation process. Moreover, in vitro studies have shown 
that basal number of AP site in HeLa cells, calf thymus cells and human lung fibroblast 
(IMR-90) cells was approximately 1 per 100 kbps (Chastain et al., 2006, Atamna et al., 
2000). However, the reason why wild-type MEFs have higher basal levels of AP sites than 
Aag-/- MEFs seems likely that this increase at the basal level of AP sites originates from 
endogenous DNA damages by the activity of AAG that remove these endogenous DNA 
damages. 
An issue that was not addressed in this study was using methoxyamine (MX) as a negative 
control for AP sites. MX is an agent that can bind to the AP sites and then prevent these AP 
sites from cleavage by APE1 to form SSBs (Liu et al., 1999), which leads to accumulation 
of AP sites within the cells and subsequently interrupting the BER pathway. Aldehyde 
reactive probe (ARP) reagent has been used in this study to quantify AP sites generated by 
MMS where the ARP reacts specifically with an aldehyde group which is the open ring form 
of the AP sites in order to detect it. MX also binds to AP sites in order to block and inhibit 
BER repair but MX and ARP have similar reactivity toward the aldehyde group at AP sites. 
Consequently, MX will block AP sites and reduce ARP binding, so MX could be used as a 
negative control after MMS treatment for AP site quantification in this study (Liu et al., 
2002). 
125 
 
In addition to quantify AP site number, an important objective of this study was to measure 
the levels of DNA strand breaks in both genotypes of MEF cells after exposure to MMS. A 
previous study in A549 cells (human lung adenocarcinoma epithelial cells) done by Fisher 
and colleagues in 2007 using γ-ray calibration curves technique for calculating the total 
number of DNA strand breaks per cell revealed that the mean tail moment ~30 was 
equivalent to ~30,000 total DNA strand breaks per cell immediately after 100 µM H2O2 
treatment (Fisher et al., 2007). If we now turn to our results of the comet assay, it shows that 
the mean tail moment found in wild-type and Aag-/- MEFs after 30 minutes from adding the 
MMS treatment were ~7 and ~5 respectively which is equivalent to ~7,000 and ~5,000 total 
DNA strand breaks per cell, respectively. Moreover, the maximum mean tail moment for 
both wild-type and Aag-/- MEF cells was ~10 which is equivalent to ~10,000 total DNA 
strand breaks per cell found in both genotypes of MEFs in some time points (2 h and 12 h 
for wild-type, while 2 h, 4 h and 6 h for Aag-/- MEFs). In addition, after 48 h of repair time 
the mean tail moment found in wild-type MEFs was ~5 (equivalent to 5,000 total DNA 
strand breaks per cell), while in Aag-/- MEFs was ~3 (equivalent to 3,000 total DNA strand 
breaks per cell). These findings indicate that the DNA strand breaks are present and 
accumulate in both genotype of MEF cells even after 48 hours from removing the MMS 
treatment. 
Our comet assay results contrast with published results from Ensminger et al. (2014). Using 
a neutral comet assay approach, they show statistically significant increased tail factor in 
MMS treated wild-type MEFs versus similarly treated Aag-/- MEFs, 4 h and 8 h after 
treatment (Ensminger et al., 2014).  However, the previous study is different from our study 
in a number of respects. As already stated, the neutral comet assay was performed in the 
previous study to preferentially measure DSBs but the comet assay protocol used in our 
study is an alkaline approach more suitable to measure both DSBs and SSBs. Also, wild-
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type and Aag-/- MEFs in the previous study were treated with a lower dose of MMS (1 mM). 
So, these differences between the two studies may be the cause of this discrepancy and it 
may indeed be that DSB levels are different between the two genotypes and higher in wild 
type cells. However, it is important to notice that the phenotypic characterization reported 
by Ensminger and co-workers is not associated with reported survival data and therefore it 
is hard to gauge how the differences they observed in γ-H2AX foci formation and DNA 
strand breaks formation relate to cellular outcome. 
Furthermore, this study set out with the aim of evaluating the genotoxic potency of MMS 
treatment to induce DSBs in both wild-type and Aag-/- MEFs by detection of γ-H2AX in the 
MMS-treated samples. For this purpose in-cell western which is a new technique was used 
in this study. It has been reported that quantification of γ-H2AX by in-cell western technique 
is sensitive, easy and specific (Khoury et al., 2013). 
This study finds no induction of γ-H2AX detected in either wild-type or Aag-/- MEFs 30 
minutes post-MMS treatment. In contrast, a 13-15 fold-induction in γ-H2AX levels was 
detected 2 hours after MMS wash-out with the same level of induction remaining until the 6 
h time point in both wild-type and Aag-/- MEFs. If one compares these results with the comet 
assay data, one notices that the induction of breaks as detected by the comet assay happens 
much faster; with the comet assay, DNA strand break induction is detected 30 minutes after 
MMS addition to the culture media for both genotypes and this induction is sustained until 
the 6 h time point. Take together, the lack of γ-H2AX induction at the early time points 
(before the 2 h time point) compared to the high level of DNA strand breaks observed from 
comet assay under the same experimental conditions suggest that the vast majority of DNA 
strand breaks detected before 2 h time point following MMS treatment are SSBs while after 
2 h time point they are DSBs. 
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These results support recent research using A549 cells which reveals that DSBs are induced 
after MMS treatment and that this requires, in addition to S-phase progression, the formation 
of SSBs during BER (Ensminger et al., 2014). In addition, these results of γ-H2AX induction 
after treatment with MMS are in accordance with a previous study indicating that high levels 
of γ-H2AX are induced in HeLa cells after 2 hours of MMS treatment (Liu et al., 2003). 
Moreover, another study showed that very few γ-H2AX foci were detectable after treatment 
with 0.5 mM MMS for 15 minutes in wild-type MEF cells (Pascucci et al., 2005). Our results 
are in accordance with these published results and suggest that MMS-induced γ-H2AX 
formation is dose and time dependent. This was confirmed by previous research showing 
that γ-H2AX foci were increased with increasing MMS concentrations (Ensminger et al., 
2014). 
In contrast to our results, Ensminger et al. (2014) report a lack of γ-H2AX foci induction in 
S- or G2-phase after treatment with 2.5 mM MMS for 1 hour in Aag-/- MEF cells. This differs 
from the findings presented here which shows γ-H2AX induction levels in Aag-/- MEFs 
similar to wild-type MEFs after the same MMS dose. The possible reasons for this 
discrepancy between the two studies are that in the previous study they used 
immunohistochemistry technique to count the γ-H2AX foci in S-phase cells only while in 
our study in-cell western has been used to quantify the total signal level of γ-H2AX in all 
cells. Also, the results presented in the previous study were for cells treated with MMS for 
1 hour and to compare this time point to our results which shows that there was slight 
induction of γ-H2AX found after 1 hour of MMS treatment. However, it might be useful in 
the future to confirm our results of γ-H2AX by counting the foci by fluorescence 
immunocytochemistry. 
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Moreover, H2O2 was used in our study because it has been shown that more than 99.5% of 
DNA strand breaks produced after H2O2 treatment are SSBs (Bradley and Kohn, 1979). 
Nonetheless, H2O2 treatment efficiently induced H2AX phosphorylation in both wild-type 
and Aag-/- MEFs. There was a 10-11 fold-induction in γ-H2AX detected per cell in both 
wild-type and Aag-/- MEFs after treatment with 1 mM H2O2 for 30 minutes at 37 °C. These 
data are surprising because H2O2 has been reported to induce a very low ratio of SSBs:DSBs 
(1 DSB:3250 SSBs) after treatment with 100 µM H2O2 (Olive and Johnston, 1996, 
Takahashi and Ohnishi, 2005).  
One possible explanation for this might be that since we used a high dose of H2O2 (1 mM) a 
high number of SSBs were formed and placed randomly within the DNA strands, so DSBs 
can arise in the DNA in this case when two SSBs are formed close to each other on the 
opposite complementary strands of the DNA (Bradley and Kohn, 1979, Olive and Johnston, 
1996). Also, DSBs can be formed in the DNA when DNA lesions induced after treatment 
with H2O2 interfere with DNA transcription or replication (Sedelnikova et al., 2010). In 
addition, a recent study showed that oxidative stress resulting from H2O2 treatment can 
induce γ-H2AX formation which was mostly not mediated by ATM, and then it is not 
associated with DSB formation (Katsube et al., 2014). However, these results of SSBs and 
DSBs induced after H2O2 treatment in this study are in agreement with those obtained by 
Driessens and colleagues in 2009 who revealed that H2O2 induces both SSBs and DSBs in a 
rat thyroid cell line (PCCl3), human thyroid primary culture cells, pig thyroid slices and also 
in F208 cell line which is a non-transformed rat fibroblast cell line (Driessens et al., 2009). 
Furthermore, a previous study showed that a very high dose of H2O2 can produce increased 
formation of γ-H2AX in Chinese hamster lung fibroblast and Chinese hamster ovary (CHO) 
cells besides its ability to produce SSBs (Banáth and Olive, 2003, Dahm-Daphi, 2000). 
Indeed, the ratio of H2O2-induced DSBs versus SSBs seems to be dose dependent.  
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Previous studies have demonstrated γ-H2AX based assays to be more sensitive than comet 
assay in vitro and in vivo (Graillot et al., 2012a, Ismail et al., 2007, Trouiller et al., 2009, 
Watters et al., 2009, Leopardi et al., 2010, Audebert et al., 2010). However, there are some 
limitations for γ-H2AX to be used as a marker for DSBs. The major limitation is the 
formation of γ-H2AX that is not associated with DSBs in response to single stranded DNA 
(ssDNA) produced during DNA replication (Sharma et al., 2012). Also, recent evidence 
reveals that γ-H2AX might be linked to necrosis or apoptosis rather than to true DNA strand 
breaks (Imreh et al., 2011, Khoury et al., 2013). So, these results of γ-H2AX therefore need 
to be interpreted with careful consideration as evidence for the induction of DSBs because 
phosphorylation of H2AX can result from many cellular scenarios and may not solely 
correlate with DSBs formation. 
From this study, we can see that wild-type MEFs were slightly more sensitive to MMS than 
Aag-/- MEFs in the early time points for AP sites and γ-H2AX inductions, but these 
differences were not statistically significant. In addition, the current study found that the 
background level of AP sites and DNA damage (comet assay) and γ-H2AX (in-cell western) 
were similar in both wild-type and Aag-/- MEFs. This means that a limited induction of 
spontaneous AP sites, DNA strand breaks and γ-H2AX could be observed in both genotypes 
of MEFs and this confirm the genotoxic potential of MMS treatment to induce AP sites and 
DNA strand breaks in a similar fashion in both wild-type and Aag-/- MEFs. 
There are several possible interpretations for why the induction of AP sites and DNA strand 
breaks after MMS treatment is not abolished in Aag-/- MEF cells. Firstly, increases in the 
rates of depurination after MMS treatment can result in AAG-independent AP site 
generation and proceed to generate DNA strand breaks. Secondly, a redundant DNA 
glycosylase could participate in recognising alkylated DNA bases in Aag-/- MEF cells, with 
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resulting formation of AP sites and DNA strand breaks. Yet another possible explanation is 
that treatment with 2.5 mM MMS might lead to induce oxidative stress to the cells in an 
indirect manner (Rowe et al., 2008). This could be as a result of mitochondrial DNA damage 
which can lead to a decrease in electron transport and an increase in ROS production which 
can modify bases by oxidation (Spasskaya et al., 2014). These oxidised DNA bases are 
recognised by different DNA glycosylases which can initiate the BER pathway to remove 
these oxidised DNA bases in the absence of AAG, which lead to formation of AP sites and 
DNA strand breaks within the DNA. 
In addition, it is important to take account of the in vivo and in vitro tissue and cells O2 status. 
Normal O2 concentration of tissue for in vivo is ranging from 2% to 4% whereas in vitro 
experimentations are performed usually in 20% O2 concentration such as this current study 
(Friedberg et al., 2006). This standard 20% atmospheric O2 for in vitro studies could generate 
an oxidative stress to the cells. This was proved by the observation that primary MEF cells 
avoided cellular senescence when these cells are grown at 3% O2 instead of 20% O2 under 
normal cell culture conditions (Parrinello et al., 2003). So, the cell culture conditions of this 
study can also contribute to the induction of oxidative stress to MEF cells and production of 
ROS. This will result in oxidative DNA damages which can recognise by different DNA 
glycosylases as explained previously. 
To conclude, the number of AP sites and the formation of DNA strand breaks induced after 
MMS treatment in wild-type MEF cells was similar to the Aag−/− MEF cells. The genotype-
specific differences in AP sites and DNA strand break formation between both wild-type 
and Aag-/- MEFs were not statistically significant and this is true for each time point after 
treatment with MMS and H2O2. The present study does not provide evidence for a 
mechanism related to an AAG-dependent increase or accumulation of BER intermediates. 
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This study indicates that the absence of AAG activity on alkylated DNA bases did not protect 
against AP site and DNA strand break formation. 
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Chapter 4: AAG is Required for PARylation Leading to Rapid 
Bioenergetics Failure and Cell Death 
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4.1 Introduction 
PARylation of proteins is mediated by poly(ADP-ribose) polymerase enzymes (PARPs). 
These PARP enzymes use NAD+ as substrate to synthesise the PAR polymer. Out of the 
PARP family, PARP-1 has been shown to be responsible for almost 90% of the total cellular 
PARylation activity after DNA damage. PARP-1 is considered as a DNA damage molecular 
sensor, where the catalytic activity of PARP-1 is stimulated more than 500-fold on binding 
to DNA single strand breaks. PARP catalyses the synthesis of the PAR polymer upon 
detection of DNA strand breaks with chain lengths ranging from approximately 2-300 
residues (Rouleau et al., 2010, Horvath et al., 2011). 
PAR synthesis has a major role in recruitment of single-strand break repair (SSBR)/BER 
proteins to the damaged site. Also, PARP-1 activity after cells are exposed to DNA-
damaging agents can result in different consequences depending on the intensity of stimuli. 
PARP-1 activation in case of mild DNA damage results in DNA repair by recruitment of 
repair enzymes (Schreiber et al., 2006). In contrast, extensive DNA damage can lead to the 
hyperactivation of PARP-1 which results in the rapid depletion of cellular NAD+ and 
consequently ATP, leading to energy depletion and cell death (Rouleau et al., 2010). 
However, the molecular mechanism for the energy collapse after PARP hyperactivation 
which leads to cell death remained unclear. Studies have shown that PAR synthesis is 
consuming NAD+ leading to depletion of cellular NAD+ and ATP levels. This decrease in 
the cellular NAD+ and ATP levels was postulated to lead to cell death due to the resulting 
energy collapse (Pieper et al., 1999, Ha and Snyder, 1999). These findings have been 
challenged by other studies which show that cell death is induced by PAR polymer as 
signaling molecule which is independent of the loss of cellular energy stores (Andrabi et al., 
2006). Furthermore, depletion of cellular NAD+ levels have been shown in some studies to 
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start subsequently to the depletion of cellular ATP levels (Paschen et al., 2000) which is 
contrary to the hypothesis that the depletion in cellular ATP levels occurs due to the 
consumption of cellular NAD+. In addition, activation of PARP-1 in cells lacking PAR 
glycohydrolase (PARG), the PAR-degradative enzyme, has been shown in other studies to 
result in cell death through PAR-mediated activation of parthanatos which does not require 
NAD+ depletion (Zhou et al., 2011). Furthermore, recent work reveals that the bioenergetic 
failure after PARP activation is caused by inhibition of the enzyme hexokinase and therefore 
glycolysis; this inhibition is dependent on PAR synthesis but not on depletion of cellular 
NAD+ levels (Fouquerel et al., 2014, Andrabi et al., 2014). Thus, the mechanisms underlying 
the decrements in PARP activation and depletion of cellular NAD+ and ATP levels remain 
poorly known. 
There are two metabolic pathways for NAD+ synthesis in the cell which determine the 
cellular NAD+ levels. The first one is a de novo pathway where NAD+ is produced from the 
amino acid tryptophan (Trp) which is considered the de novo precursor of NAD+. The second 
metabolic pathway is the NAD+ salvage pathway (Pittelli et al., 2010). 
The NAD+ salvage pathway is performed in the cell by recycling preformed components in 
the NAD+ synthesis process such as nicotinamide (NAM) back to NAD+. This pathway is 
important for the maintenance of cellular NAD+ levels in the cells and then it is essential for 
cellular survival after DNA damage (Yang et al., 2007). Nicotinamide 
phosphoribosyltransferase (NAMPT) is the main enzyme in the NAD+ salvage pathway. It 
catalyses the formation of nicotinamide mononucleotide (NMN) from NAM which is the 
first step in the NAD+ salvage pathway (Pittelli et al., 2010, Nakahata et al., 2009). It has 
been shown that FK-866 inhibits specifically this NAD+ salvage pathway by direct targeting 
of NAMPT enzyme (Hasmann and Schemainda, 2003). However, the metabolites and the 
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enzymes catalysing the reactions in the NAD+ salvage pathway are shown in the next figure 
(Figure 4-1).  
 
Figure 4-1: Schematic of NAD+ salvage pathway. The first step is the formation of nicotinamide 
mononucleotide (NMN) from nicotinamide (NAM) and 5-phosphoribosyl-1-pyrophosphate (PRPP) which is 
operated by nicotinamide phosphoribosyltransferase (NAMPT) enzyme. The second step is the formation of 
NAD+ from nicotinamide mononucleotide (NMN) and ATP which is operated by nicotinamide 
mononucleotide adenylyltransferases (NMNAT) enzyme. NAD+ is consumed as a donor of ADP-ribose units 
during the synthesis of poly(ADP-ribose) (PAR) by Poly(ADP-ribose) polymerase (PARP), with the 
concomitant release of NAM. FK-866 inhibits the NAD+ salvage pathway where it is a specific inhibitor for 
NAMPT enzyme (Pittelli et al., 2010, Luo and Kraus, 2012). (PPi) inorganic pyrophosphate. 
4.2 Aims 
 To quantify the level of PARylation in AAG proficient and deficient MEF cells after 
alkylation treatment. 
 To investigate the bioenergetics system after alkylation treatment in AAG proficient and 
deficient MEF cells. 
 To examine the cytotoxicity of alkylation treatment in AAG proficient and deficient 
MEFs. 
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4.3 Objectives 
 Quantify the temporal level of PAR synthesis in the wild-type and Aag-/- MEF cells after 
MMS treatment. 
 Measure the temporal level of cellular NAD+ in the wild-type and Aag-/- MEF cells after 
MMS treatment. 
 Measure the cellular ATP level with time in the wild-type and Aag-/- MEF cells after 
MMS treatment. 
 Study the cell viability in the wild-type and Aag-/- MEF cells with time after MMS 
treatment. 
4.4 Methods 
 Cell lines: wild-type and Aag-/- MEF cells. 
 Treatments: 2.5 mM MMS for one hour and 100 nM FK-866 for 48 hours. 
 Western blot: used to measure the level of PARylation in whole cell extracts. 
 In-cell western: used to quantify the level of PARylation in the permeabilised cells. 
 Spectrophotometry: used to measure the cellular NAD+ levels in whole cell extracts. 
 Luminometry: used to measure the cellular ATP levels in whole cell extracts. 
 Flow cytometry: used to study the cell viability in the harvested cells by using PI 
exclusion dye. 
4.5 Results 
Previous studies have shown that increased PAR synthesis after hyperactivation of PARP-1 
leads to cell death through a massive depletion of cellular NAD+ which can also result in 
depletion of cellular ATP levels leading to cell death (Fan and Zong, 2014). In the present 
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study I examined the influence of MMS treatment on PARP-1 hyperactivation in wild-type 
and Aag-/- MEF cells. 
At first, I determined the temporal activation of PARP upon alkylation by measuring PAR 
synthesis. Also, cellular bioenergetics has been investigated by measuring the cellular levels 
of NAD+ and ATP in wild-type and Aag-/- MEF cells after treatment with MMS. In addition, 
MMS cytotoxicity has also been examined by measuring cell viability in both genotypes of 
MEF cells.  
4.5.1 Quantification of PARylation 
The levels of PARylation or PAR synthesis were examined in wild-type and Aag-/- MEFs in 
response to alkylating agent-induced DNA damage. Western blot technique was used to 
quantify the PARylation levels in samples. In this technique, gel electrophoresis is used to 
separate native proteins based on molecular weight. Then, these proteins are transferred onto 
a membrane, where they are incubated with antibodies which are specific to the target 
protein. LI-COR Odyssey CLx is used to scan the membrane with detection in both the 700 
nm and 800 nm channels which allow detect two different targets on the same blot. 
The results using SDS-PAGE of the whole cell extracts and immunoblotting in initial 
experiments show that an increased level of PARylation was detected starting at 0.50 hour 
time point only in extracts from wild-type MEFs (Figure 4-2, top) compared with Aag-/- 
MEFs (Figure 4-3, top). In addition to qualitatively monitoring PARylation by 
immunoblotting, quantification of the total cellular PAR levels in the immunoblots can 
represent a suitable quantitative evaluation of the PAR synthesis status after treatment with 
MMS. Separate quantification of each independent experiment is shown in (Figure 4-2, 
bottom) and (Figure 4-3, bottom) for both wild-type and Aag-/- MEF cells. 
138 
 
As shown in (Figure 4-2, bottom), a rise in PARylation found after 30 minutes from 
removing MMS in wild-type MEFs compared with untreated control cells, and continued 
until it reached a peak after 12 hour repair time. After one hour of MMS treatment, 
approximately a 2-fold increase in PARylation was observed while a maximum 5.5-fold 
increase was observed at 12 h time point. 
This temporal increase in PAR synthesis found in wild-type MEFs is in contrast with PAR 
level measurements in Aag-/- MEFs, where no significant PAR synthesis after MMS 
exposure was seen in Aag-/- MEFs and levels remained constant and similar to what is seen 
in the untreated control (Figure 4-3, bottom). These results indicate that PAR synthesis after 
MMS-induced DNA damage is AAG-dependent. 
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Figure 4-2: PAR synthesis following MMS treatment of wild-type MEFs. (Top) Immunoblot of PAR in 
untreated control and treated with 2.5 mM MMS, then incubated for the repair time specified. (Bottom) Time 
course of total PAR levels quantification of untreated control cells and cells treated with MMS in two 
independent experiments. Time before 0 hour (-0.50) indicates the number of hours when the wild-type MEFs 
were treated with MMS. Time from 0 to 12 hours represents the total hours when MEFs were incubated in 
culture medium containing 2% FBS after one hour treatment with MMS. The data shown are separate 
quantification of each independent experiment and each time point was done in duplicate. 
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Figure 4-3: PAR synthesis following MMS treatment of Aag-/- MEFs. (Top) Immunoblot of PAR in untreated 
control and treated with 2.5 mM MMS, then incubated for the repair time specified. (Bottom) Time course of 
total PAR levels quantification of untreated control cells and cells treated with MMS in two independent 
experiments. Time before 0 hour (-0.50) indicates the number of hours when the Aag-/- MEFs were treated with 
MMS. Time from 0 to 12 hours represents the total hours when Aag-/- MEFs were incubated in culture medium 
containing 2% FBS after one hour treatment with MMS. The data shown are separate quantification of each 
independent experiment and each time point was done in duplicate. 
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The result of elevated PARylation found in wild-type MEFs was verified and confirmed by 
using another technique which is in-cell western and also different antibody (Figure 4-4). 
The results obtained from in-cell western were similar to the results obtained from western 
blot. Both techniques show elevated PAR synthesis with time continued until reached a peak 
after 12 hour repair time. 
Similar to the results obtained by the western blot technique, 2-fold increase in PARylation 
was observed after one hour from removing MMS whereas a maximum 5-fold increase was 
observed at 12 h time point. Also, the results were statistically significant at 12 hour time 
point (p = 0.0090) when comparing these cells of wild-type MEFs to their respective 
untreated control by using one-way ANOVA test followed by Dunnett's multiple 
comparisons test. 
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Figure 4-4: Histographs illustrating the quantification of PARylation per cell in wild-type MEFs by in-cell 
western technique. Graph shows the % control of PARylation with time after treatment with MMS (2.5 mM) 
comparing to their respective untreated control. Time represents the number of hours when the wild-type MEFs 
were incubated in culture medium containing 2% serum after one hour treatment with MMS. Statistical 
significance was found at 12 hour time points. The data shown are mean values ± SEM of three independent 
experiments and each time point was done in quadruplicate. One-way ANOVA test was performed (Dunnett's 
multiple comparisons test) and significance was assumed if p < 0.05. 
4.5.2 Bioenergetic System investigation 
DNA damage-induced cell death has been linked to the hyperactivation of PARP which leads 
to NAD+ depletion, loss of ATP, and eventual cell death. To determine if the excess 
PARylation formed in the wild-type MEFs resulted in rapid failure in the bioenergetics 
system of these cells, I investigated the cellular levels of NAD+ and ATP in wild-type and 
Aag-/- MEF cells at times up to 48 h after MMS treatment. In addition, the inhibitor FK-866 
has been used in this study as a positive control where it has been shown to potently inhibit 
the NAMPT enzyme within the NAD+ salvage pathway and then decrease the cellular NAD+ 
levels in the cells which is independent of PARP activation (Yang et al., 2007, Pittelli et al., 
2010).  
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4.5.2.1 Cellular NAD+ Levels 
The levels of cellular NAD+ in cultured cells were measured using a colorimetric method. 
In this assay, alcohol dehydrogenase enzyme catalyses the formation of acetaldehyde from 
ethanol, in which NAD+ found in cell samples is reduced to NADH. This reaction is followed 
by the oxidation of newly formed NADH to NAD+ resulting in the reduction of a tetrazolium 
salt substrate to formazan which is catalysed by diaphorase enzyme. The formation of 
formazan can be used as an indicator of the total cellular NAD+ concentration in the samples 
because the amount of formazan formed is proportional to the amount of total NAD+ in the 
cell lysate. 
The results of cellular NAD+ levels after MMS treatment show that NAD+ levels were 
diminished at 6 hour of the value seen in the control to 27% in wild-type MEFs and 31% in 
Aag-/- MEFs. The kinetics of the reduction in cellular NAD+ levels were followed by 
increased between 6 hour and 24 hour to 54% and 61% in both wild-type and Aag-/- MEFs, 
respectively. After that, the levels of cellular NAD+ underwent further depletion between 24 
hour and 48 hour, reaching a final levels of approximately 40% of the control levels in wild-
type and approximately 30% in Aag-/- MEF cells.  
Interestingly, the results of cellular NAD+ levels show that wild-type MEFs cells suffered a 
dramatic decrease in cellular NAD+ levels starting as early as 30 minutes after MMS 
treatment (Figure 4-5, upper panel), reaching approximately 50% of the control levels at 1 
hour time point. While, in notable contrast to wild-type MEFs, the Aag-/- MEFs show delayed 
NAD+ depletion, in contrast reaching approximately 90% of the control levels at 1 hour time 
point (Figure 4-6, upper panel). In addition, the depletion of cellular NAD+ levels reached 
approximately 30% of the control levels in both genotypes at 6 hour. These results indicate 
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that the cellular NAD+ levels in MEF cells was more rapidly reduced by the presence of 
AAG enzyme in MEF cells. 
In addition, the results of the cellular NAD+ levels were statistically significant in some time 
points in both genotypes of MEF cells when one-way ANOVA test was performed followed 
by Dunnett's multiple comparisons test. In wild-type MEFs, 0 h, 0.5 h, 1 h, 6 h, 24 h and 48 
h time points while only 6 h, 24 h and 48 h time points in Aag-/- MEF cells were statistically 
significant when compared to their respective untreated control. 
Moreover, I treated wild-type and Aag-/- MEF cell lines with the FK-866 inhibitor at a 
concentration of 100 nM for 48 hours. The results of disruption of NAD+ salvage pathways 
in MEFs show that as expected both wild-type and Aag-/- MEF cells treated with NAMPT 
inhibitor using FK-866 underwent dramatic decrease in cellular NAD+ levels after 48 hours 
of incubation time (Figures 4-5 and 4-6, lower panel). The decrease in cellular NAD+ levels 
after treatment with FK-866 inhibitor was equivalent to those induced by MMS treatment 
after 48 hour in wild-type MEFs (40%). While in Aag-/- MEFs the decrease in cellular NAD+ 
levels after FK-866 treatment (9%) was greater than for MMS treatment at the 48 hour time 
point (27%). Statistically significant differences were found between wild-type and Aag-/- 
MEF cells treated with FK-866 comparing to their untreated control (p = 0.0020 and p < 
0.0001, respectively). 
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Figure 4-5: Measurement of NAD+ levels in wild-type MEFs. (Top) Temporal changes of cellular NAD+ levels 
after treatment with 2.5 mM MMS for 1 hour. Time before 0 hour (-0.50) indicates the number of hours when 
the MEFs were treated with MMS while time from 0-48 hours represents the total hours when wild-type MEFs 
were incubated in culture medium containing 2% FBS after one hour treatment with MMS. (Bottom) Total 
cellular NAD+ levels of untreated control cells and cells treated with 100 nM FK-866 for 48 hours in 2% FBS 
culture medium. The data shown are mean values ± SEM of at least three independent experiments and each 
time point was done in quadruplicate. One-way ANOVA test was performed (Dunnett's multiple comparisons 
test) and significance was assumed if p < 0.05. 
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Figure 4-6: Measurement of NAD+ levels in Aag-/- MEFs. (Top) Temporal changes of cellular NAD+ levels 
after treatment with 2.5 mM MMS for 1 hour. Time before 0 hour (-0.50) indicates the number of hours when 
the MEFs were treated with MMS while time from 0 to 48 hours represents the total hours when Aag-/- MEFs 
were incubated in culture medium containing 2% FBS after one hour treatment with MMS. (Bottom) Total 
cellular NAD+ levels of untreated control cells and cells treated with 100 nM FK-866 for 48 hours in 2% FBS 
culture medium. The data shown are mean values ± SEM of at least four independent experiments and each 
time point was done in quadruplicate. One-way ANOVA test was performed (Dunnett's multiple comparisons 
test) and significance was assumed if p < 0.05. 
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Moreover, two-way ANOVA analysis followed by Sidak’s multiple comparisons test was 
performed in order to compare the effect of the presence and absence of AAG in MEF cells 
on the cellular NAD+ levels after MMS treatment. The results show that as expected there 
were statistically significant differences between wild-type and Aag-/- MEF cells in the early 
time points at 0 hour, 0.5 hour and 1 hour (Figure 4-7, upper panel). 
The interesting finding is that cellular NAD+ levels recovered transiently in both wild-type 
and Aag-/- MEF cells from 27 and 31% of control at 6 hour time point to 54 and 61% of 
control at 24 hour time point, respectively. This recovery was followed by a drop in cellular 
NAD+ levels at 48 hour time point in both genotypes of MEF cells to 40% of control in wild-
type MEFs and 28% of control in Aag-/- MEFs. 
In addition, the FK-866 inhibitor was more efficient in reducing the levels of cellular NAD+ 
in Aag-/- MEF cells than wild-type MEF cells. After 48 hour of FK-866 exposure, the 
depletion of cellular NAD+ levels reached approximately 40% of the control levels in wild-
type, while only 10% of the control levels of the cellular NAD+ levels found in Aag-/- MEF 
cells after the same period of FK-866 exposure (Figure 4-7, lower panel). These differences 
in cellular NAD+ levels between both genotypes of MEF cells after treatment with FK-866 
were statistically significant (p = 0.0248). 
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Figure 4-7: The comparison of measurement of cellular NAD+ levels in wild-type and Aag-/- MEFs. (Top) 
Histogram graph illustrating the temporal changes for cellular NAD+ levels in wild-type and Aag-/- MEFs 
following a one hour treatment with the alkylating agent MMS. Repair time points represent the time at which 
MMS treatment was removed from MEF cells and replaced with culture medium containing 2% serum and the 
subsequent recovery incubation period. (Bottom) Total cellular NAD+ levels of untreated control cells and cells 
treated with 100 nM FK-866 for 48 hours in 2% serum media. Two-way ANOVA was performed followed by 
Sidak’s multiple comparisons test and significance was assumed if p < 0.05. 
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4.5.2.2 Cellular ATP Levels 
Cellular ATP levels in MEF cells were measured at times up to 48 hour after MMS exposure 
under the same conditions used for cellular NAD+ measurements. Bioluminescence assay is 
used in this study to determine cellular ATP levels in samples. This assay is based on the 
reaction of ATP with added luciferase and D-luciferin which results in the production of 
light. This emitted light from the reaction can be used as an indicator of the total cellular 
ATP concentration in the samples because emitted light is proportional to the concentration 
of ATP inside the cell. 
The time course analysis on the effects of 2.5 mM MMS on cellular ATP levels showed that 
wild-type MEFs underwent approximately 20% ATP depletion after 1 hour from removing 
the treatment (80% of the control levels) and cellular ATP level was further diminished at 3 
hour to 31% of the control levels, remained constant between 3 and 6 hours, and underwent 
further depletion between 6 and 48 hours, reaching approximately 10% of the control levels 
(Figure 4-8, upper panel). While, the cellular ATP levels after MMS treatment in Aag-/- MEF 
cells was increased at 1 hour (approximately 125% of the control levels) and underwent 
further depletion till 48 hour, reaching approximately 10% of the control levels (Figure 4-
19, upper panel). 
In addition, the results of cellular ATP levels were statistically significant in some time 
points in both genotypes of MEF cells when one-way ANOVA test was performed followed 
by Dunnett's multiple comparisons test. These statistical significances differences were 
observed at 2 h, 3 h, 6 h, 24 h and 48 h time points in wild-type while in Aag-/- MEF cells at 
6 h, 24 h and 48 h time points. 
Moreover, the effect of FK-866 (100 nM) on cellular ATP levels has been examined in both 
genotypes of MEF cells after 48 hours of exposure to the inhibitor. Surprisingly, the results 
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showed that MEF cells exposed to 100 nM FK-866 underwent approximately 17% of the 
ATP control levels in Aag-/- MEFs while there was no significant depletion observed in wild-
type MEFs comparing to their control levels (approximately 82% of the ATP control levels) 
after 48 hours exposure time as shown in Figures (4-8, lower panel) and (4-9, lower panel). 
There were no statistical significances in ATP levels after FK-866 treatment in the wild-type 
MEFs but the results were statistical significances in Aag-/- MEFs (p < 0.0001).  
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Figure 4-8: Measurement of ATP levels in wild-type MEFs. (Top) Temporal changes of cellular ATP levels 
after treatment with 2.5 mM MMS for 1 hour. Time before 0 hour (-0.50) indicates the number of hours when 
the MEFs were treated with MMS while time from 0-48 hours represents the total hours when wild-type MEFs 
were incubated in culture medium containing 2% FBS after one hour treatment with MMS. (Bottom) Total 
cellular ATP levels of untreated control cells and cells treated with 100 nM FK-866 for 48 hours in 2% serum 
culture medium. The data shown are mean values ± SEM of at least four independent experiments and each 
time point was done in quadruplicate. One-way ANOVA test was performed (Dunnett's multiple comparisons 
test) and significance was assumed if p < 0.05. 
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Figure 4-9: Measurement of cellular ATP levels in Aag-/- MEFs. (Top) Temporal changes of cellular ATP 
levels after treatment with 2.5 mM MMS for 1 hour. Time before 0 hour (-0.50) indicates the number of hours 
when the MEFs were treated with MMS while time from 0 to 48 hours represents the total hours when Aag-/- 
MEFs were incubated in culture medium containing 2% serum after one hour treatment with MMS. (Bottom) 
Total cellular ATP levels of untreated control cells and cells treated with 100 nM FK-866 for 48 hours in 2% 
serum culture medium. The data shown are mean values ± SEM of at least five independent experiments and 
each time point was done in quadruplicate. One-way ANOVA test was performed (Dunnett's multiple 
comparisons test) and significance was assumed if p < 0.05. 
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Moreover, two-way ANOVA analysis followed by Sidak’s multiple comparisons test was 
performed in order to compare the effect of the presence and absence of AAG in MEF cells 
on the cellular ATP levels after MMS treatment. The results show that as expected there 
were statistically significant differences between wild-type and Aag-/- MEF cells in the early 
time points at 1 hour (p = 0.0083), 2 hour (p = 0.0003) and 3 hour (p = 0.0009) (Figure 4-
10, upper panel). These findings indicate that ATP depletion was more pronounced in wild 
type MEF cells in the early 6 hours post-MMS treatment than Aag-/- MEF cells followed by 
a similar pattern of ATP depletion in the two genotypes of MEF cells between 6 and 48 
hours. 
In addition, FK-866 was more efficient in reducing the cellular ATP levels in Aag-/- MEF 
cells than wild-type MEF cells. After 48 hour of FK-866 exposure, the depletion of cellular 
ATP levels reached approximately 82% of the control levels in wild-type, while only 17% 
of the control levels was found in similarly treated Aag-/- MEF cells (Figure 4-10, lower 
panel). These differences in cellular ATP levels between both genotypes of MEF cells after 
treatment with FK-866 were statistically significant (p < 0.0001). In addition, these results 
indicate that the cellular ATP levels were not affected by NAMPT inhibition using 100 nM 
FK-866 in wild-type MEF cells but were strongly affected in Aag-/- MEF cells. 
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Figure 4-10: The comparison of measurement of cellular ATP levels in wild-type and Aag-/- MEFs. (Top) 
Histogram graph illustrating the temporal changes for cellular ATP levels in wild-type and Aag-/- MEFs 
following a one hour treatment with MMS. Repair time points represent the time at which MMS treatment was 
removed from MEF cells and replaced with culture medium containing 2% serum and the subsequent recovery 
incubation period. (Bottom) Total cellular ATP levels of untreated control cells and cells treated with 100 nM 
FK-866 for 48 hours in 2% serum media. Two-way ANOVA was performed followed by Sidak’s multiple 
comparisons test and significance was assumed if p < 0.05. 
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4.5.3 Cell Viability 
Imbalance in BER after severe DNA damage can eventually lead to cell death. Here, the 
cytotoxicity of MMS on wild-type and Aag-/- MEF cells was determined by using two 
cytotoxic assays, namely the cellular staining and quantification procedure used during in-
cell western technique to quantify the cell number and Propidium Iodide (PI) exclusion dye 
to quantify PI positive cells which reflects the non-viable cells. 
4.5.3.1 Cell Number 
In this study, I determined the cell viability by measuring cell number with in-cell western 
assay. To determine cell viability, the cell number was estimated by fluorescence signal 
quantification of the CellTag 700 stain, which accumulates in both the cytoplasm and the 
nucleus of the permeabilised cells, and provides linear fluorescent signal across a wide range 
of cell types and cell numbers. 
The results show that the MMS treatment conditions utilised in this study were cytotoxic in 
both genotypes of MEF cells, but it was more cytotoxic towards wild-type MEFs than to 
Aag-/- MEFs in the early time points (Figure 4-11). The cell viability of MEF cells at 2 hour 
post-MMS treatment was significantly below 80% for wild-type MEFs, whereas for Aag-/- 
MEFs the 80% cell viability threshold was reached at 6 hour post-MMS treatment. Also, 
both genotypes of MEF cells were significantly below 50% cell viability at 12 hour post-
MMS treatment (Figure 4-11). In contrast, a slight increase of cell viability was observed for 
both genotypes of MEF cells at 24 hour time point comparing to 12 hour time point. 
In addition, MMS was significantly toxic as measured by CellTag 700 stain for both 
genotypes of MEF cells. The results were statistically significant when the treated cells were 
compared to the untreated control cells using one-way ANOVA test followed by Dunnett's 
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multiple comparisons test. These statistically significant results were observed early in wild-
type MEFs at 2 h, 4 h, 6 h, 12 h, 24 h and 48 h time points but the statistical significances in 
Aag-/- MEF cells were observed late at 12 h, 24 h and 48 h time points only (Figure 4-11). 
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Figure 4-11: Temporal changes of percentage cell viability as measured by CellTag 700 staining in wild-type 
(top) and Aag-/- (bottom) MEF cells. Time represents the number of hours when the MEFs were incubated in 
culture medium containing 2% serum after one hour treatment with MMS. Wild-type and Aag-/- MEF cells 
were plated in a black 96-well plate, then fixed, permeabilised, stained with CellTag 700 stain. The data shown 
are mean values ± SEM of at least four independent experiments and each time point was done in quadruplicate. 
One-way ANOVA was performed followed by Dunnett’s multiple comparisons test and significance was 
assumed if p < 0.05. 
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Figure 4-12: Line graph illustrating the temporal changes of percentage cell viability as measured by CellTag 
700 staining in wild-type and Aag-/- MEF cells. Time represents the number of hours when the MEFs were 
incubated in culture medium containing 2% serum after one hour treatment with MMS. Wild-type and Aag-/- 
MEF cells were plated in a black 96-well plate, then fixed, permeabilised, stained with CellTag 700 stain. Two-
way ANOVA was performed followed by Sidak's multiple comparisons test and significance was assumed if 
p < 0.05. 
In addition, the above line graph (Figure 4-12) shows the comparison between the wild-type 
and Aag-/- MEF cells. Two-way ANOVA followed by Sidak's multiple comparisons test 
showed that both treatment and genotype are significant factors affecting MEF viability to 
alkylation at the 4 hour time point. These results of cell viability using in-cell western 
technique indicate that wild-type MEFs are more sensitive to MMS than Aag-/- MEF cells in 
the early time points after treatment. However, in order to confirm these results, another 
technique has been used in this study by using PI dye exclusion. 
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4.5.3.2 Propidium Iodide (PI) Exclusion Dye 
The use of dye exclusion is one of many methods to assess cell viability in cell population. 
A variety of dyes are excluded by viable cells which have intact membranes but they easily 
enter the non-viable cells which have damaged, permeable membranes. PI is a membrane 
impermeant dye which is excluded from viable cells. Flow cytometry was used in this study 
to quantify the number of PI positive cells which reflects the number of the non-viable cells. 
The results of PI exclusion dye show that the number of PI positive cells was increased 
gradually with time after MMS treatment in both genotypes of MEF cells (Figure 4-14). This 
increase in PI positive cells was observed starting at 4 hour post-MMS treatment and 
increased gradually with time reaching the highest at 48 hour time point where the number 
of PI positive cells was approximately 45% in both genotypes of MEF cells (Figure 4-14).  
In addition, MMS was significantly toxic as measured by PI exclusion dye to both genotypes 
of MEF cells. This toxicity was statistically significant for both genotypes of MEFs observed 
at the 12 hour time point after MMS treatment onwards (Figure 4-14). The next figure 
(Figure 4-13) shows the flow cytometric analysis which reveals the morphological changes 
of PI positive cells with time after MMS treatment in wild-type and Aag-/- MEF cells.  
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Figure 4-13: Comparative flow cytometric analysis of morphological histograms with time after 
MMS treatment (2.5 mM) in wild-type and Aag-/- MEFs. Time from 0 to 48 hours represents the 
time after MMS wash-out. MEF cells were harvested, stained with PI exclusion dye and analysed 
using flow cytometry. 
Time 
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Wild-type MEFs Aag-/- MEFs 
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Figure 4-13: Comparative flow cytometric analysis of morphological histograms with time after 
MMS treatment (2.5 mM) in wild-type and Aag-/- MEFs. Time from 0 to 48 hours represents the 
time after MMS wash-out. MEF cells were harvested, stained with PI exclusion dye and analysed 
using flow cytometry. 
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Figure 4-13: Comparative flow cytometric analysis of morphological histograms with time after 
MMS treatment (2.5 mM) in wild-type and Aag-/- MEFs. Time from 0 to 48 hours represents the 
time after MMS wash-out. MEF cells were harvested, stained with PI exclusion dye and analysed 
using flow cytometry. 
Time 
Point 
Wild-type MEFs Aag-/- MEFs 
48 
hour 
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Figure 4-14: Temporal changes of percentage PI positive cells as measured by PI exclusion dye in wild-type 
(top) and Aag-/- (bottom) MEF cells. Time represents the number of hours when the MEFs were incubated in 
culture medium containing 2% serum after one hour treatment with MMS. Wild-type and Aag-/- MEF cells 
were harvested, stained with PI dye and analysed using flow cytometry. The data shown are mean values ± 
SEM of three independent experiments and each time point was done in triplicate. One-way ANOVA was 
performed followed by Dunnett’s multiple comparisons test and significance was assumed if p < 0.05. 
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In addition, the difference between wild-type and Aag-/- MEF cells was not statistically 
significant using two-way ANOVA analysis (Figure 4-15). These results indicate that at the 
2.5 mM concentration of MMS, both genotypes of MEF cells have a similar range of 
cytotoxicity as revealed by using PI exclusion dye methodology. However, these results of 
PI exclusion dye contrasts with that of cell viability results obtained from in-cell western 
technique. 
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Figure 4-15: Histogram graph illustrating the temporal changes of percentage PI positive cells as measured by 
PI exclusion dye in wild-type and Aag-/- MEF cells. Time represents the number of hours when the MEFs were 
incubated in culture medium containing 2% serum after one hour treatment with MMS. Wild-type and Aag-/- 
MEF cells were harvested, stained with PI dye and analysed using flow cytometry. There were no statistically 
significant differences between wild-type and Aag-/- MEF cells. 
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4.6 Discussion 
Cell death induced by excessive DNA damage can be initiated by PAR synthesis after PARP 
hyperactivation, leading to depletion of cellular NAD+ and ATP levels. Cells display low 
basal level of PAR polymer under normal conditions but exposure to DNA-damaging agents 
such as alkylating agents can dramatically increase PAR levels in cells (Horvath et al., 2011). 
This increase of PAR polymer synthesis is taken as an indication of the DNA damage 
occurrence and severity. 
Here in this study, I show that the AAG enzyme, which initiates BER, represents a crucial 
link in the increased sensitivity to alkylating agents induced by PAR synthesis after PARP 
hyperactivation resulting from severe DNA damage. Loss of AAG expression in Aag-/- MEF 
cells may play a protective role in suppressing PAR synthesis after exposure to DNA-
damaging agents, thus allowing this genotype of MEF cells to be initially more resistant to 
the alkylating agent. Based on these results, BER initiation by AAG enzyme is required for 
the PARylation which leads to rapidly loss of cellular bioenergetics. 
Inhibition of NAD+ salvage pathway by incubation of MEF cells with 100 nM FK-866 for 
48 hour was investigated in this study. This 48 hour incubation time of 100 nM FK-866 
treatment (NAD+ biosynthesis inhibition) is not toxic for both genotypes of MEF cells when 
evaluated by a cell viability assay using PI exclusion dye (data not shown). FK-866 inhibitor 
at 100 nM prompted no significant changes of cellular ATP levels in wild-type MEFs after 
48 hours of exposure in contrast to cellular NAD+ levels.  
These findings are in agreement with those obtained by Pittelli and colleagues in 2010 who 
found that FK-866 at 100 nM prompted depletion of cellular NAD+ levels (40% of control 
levels) but no changes of cellular ATP levels up to 48 hour incubation time in HeLa cells. 
Also, recent research has shown that treatment with 10 µM FK-866 inhibitor for 5 hours led 
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to a decrease in cellular NAD+ levels in cortical neurons but it fails to decrease the cellular 
ATP levels (Andrabi et al., 2014). Moreover, another recent study has published that 
inhibition of NAMPT with FK-866 (10 nM) in a glioblastoma-derived cell line (LN428) 
overexpressing AAG for 24 hours resulted in a decrease in the cellular NAD+ levels by 
approximately 75%, while the cellular ATP levels remained unchanged (Fouquerel et al., 
2014). 
On the other hand, Aag-/- MEFs appeared to be more sensitive to the effect of FK-866 
inhibitor on both cellular NAD+ and ATP levels than wild-type MEFs. This finding was 
unexpected and further research should be undertaken to investigate this surprising finding. 
However, further studies would be worthwhile to investigate whether MMS sensitivity in 
MEF cells can be suppressed and the level of cellular NAD+ can be recovered by addition to 
the culture medium of exogenous NAD+ or NAD+ precursors such as nicotinamide 
mononucleotide (NMN). Another possible area of future research would be to investigate 
whether addition of PARP inhibitor in wild-type MEFs after MMS treatment could suppress 
MMS sensitivity by preventing the massive decrease in both NAD+ and ATP. 
The current study found that the depletion of cellular NAD+ levels was not accompanying 
with the depletion of cellular ATP levels in wild-type MEF cells. This is because the 
depletion of cellular NAD+ levels preceded the depletion of cellular ATP levels. A recent 
study done by Fouquerel and colleagues in 2014 reveal that PARylation after PARP-1 
hyperactivation can block glycolysis leading to ATP loss in a glioblastoma-derived cell line 
which is independent from NAD+ depletion. This block in glycolysis was found to be due to 
hexokinase inhibition. These findings of the previous research are in support with our results 
in this study where the depletion of cellular ATP levels was concomitant with the increase 
of PAR synthesis in wild-type MEF cells which started after 30 minutes from removing the 
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MMS treatment (0.50 hour time point), while the NAD+ depletion started after 30 minutes 
from adding the MMS treatment (-0.50 hour time point). Also, cellular ATP levels in wild-
type MEF cells were not affected by the depletion of the cellular NAD+ levels in the absence 
of PAR synthesis by using FK-866 inhibitor which can prove that the NAD+ depletion is 
independent from the ATP depletion in the wild-type MEFs. However, further research 
should be undertaken to investigate the cause of cell death and energy collapse in Aag-/- MEF 
cells although the PARylation was absent in these cells. 
Furthermore, one great advantage of using the in-cell western technique is that it allows 
determination of the cytotoxicity and genotoxicity of a drug simultaneously on adherent cells 
cultured in a 96-well plate format (Graillot et al., 2012b, Audebert et al., 2011, Audebert et 
al., 2010, Audebert et al., 2012, Graillot et al., 2012a, Jamin et al., 2013, Martin et al., 2013). 
However, there is one unanticipated finding from the cell viability results obtained from in-
cell western technique which is that the percentage of cell viability found at 24 hour and 48 
hour time points was not lower than the percentage of cell viability at 12 hour time point. 
This discrepancy could be attributed to the population doubling time of the MEF cells. Yusuf 
and his colleagues in 2013 examined the population doubling time of MEF cells and found 
that these MEF cells exhibited a short population doubling time of about 24 hour (Yusuf et 
al., 2013). So, the discrepancy found between 12 hour time point and later time points could 
be because that the viable cells were growing and doubling. Furthermore, because the 
seeding of MEF cells in the 96-well plate for the 12 hour, 24 hour and 48 hour time points 
done in different days, so this discrepancy which found between 12 hour and later time points 
could be due to well-to-well variations in cell number. 
In addition to study the cell viability using in-cell western technique, also PI exclusion dye 
technique was used in this study to examine the cytotoxicity of MMS in the MEF cells where 
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dead cells stained with PI exclusion dye were quantified by flow cytometry. Surprisingly, 
parallel cytotoxicity of the MMS treatment was observed in both wild-type and Aag-/- MEF 
cells using PI exclusion dye.  
These results of PI exclusion dye provided inconsistent results with cell number results using 
CellTag 700 staining and this may be due to the sensitivity of the PI exclusion dye assay. 
This PI exclusion dye test has a limitation where this assay can measure only the dead cells 
with damaged membranes and may not measure dying or apoptotic cells with intact 
membranes (Komissarova et al., 2005). This may explain why this study did not find an 
increase in percentage PI positive cells early before 4 hour post-MMS treatment. So, the 
evaluation of percentage PI positive cells using PI exclusion dye after MMS treatment may 
be underestimated due to the fact that early dead or apoptotic cells can still maintain their 
membrane integrity and not allow the PI stain to enter to the dead cells (Brink et al., 2006). 
Furthermore, quantification of cellular ATP levels is widely accepted and used in research 
studies as a valid marker for cell viability. This is because ATP is present in all metabolically 
active cells and ATP concentrations rapidly decrease when the cells become non-viable (Riss 
et al., 2004). The results of quantification of the cell viability based on quantification of the 
cellular ATP levels or on the cell number data after MMS treatment showed similar 
cytotoxicity trend in both wild-type and Aag-/- MEF cells. This observation is indicating and 
supporting that PI exclusion dye assay is not a suitable method for the evaluation of the cell 
viability in this study. 
Together, the massive consumption of cellular NAD+ levels after PARP hyperactivation and 
PAR synthesis can lead to loss of all energy production as cells try to regenerate NAD+ using 
ATP. All of these features are observed in this study only in wild-type MEF cells after MMS 
treatment when BER is initiated by AAG. These results indicate that the rapid depletion of 
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physiological NAD+ and ATP levels in wild-type MEFs as a result of PAR synthesis after 
MMS treatment precedes and promotes the onset of cell death in these cells comparing to 
Aag-/- MEF cells. Also, the evaluation of MMS-treated MEF cells in the present study 
revealed no PAR synthesis in BER-deficient cells, but this did not prevent these cells from 
depletion of cellular NAD+ and ATP levels and eventually cell death. So, PARP activation 
is expected to be the cause for cell death in wild-type MEFs after MMS treatment, while in 
Aag-/- MEFs the energy failure is expected to be the cause for cell death in the absence of 
PARP activation. 
To conclude, only wild-type MEFs undergo PARP hyperactivation resulted in PAR 
synthesis that leads to rapid depletion of total cellular NAD+ and ATP levels. Like wild-type 
MEFs, Aag-/- MEFs undergo NAD+ and ATP depletion after severe DNA damage but, unlike 
wild-type MEFs, exhibit delayed depletion of intracellular NAD+ and ATP levels. Also, the 
absence of AAG activity in MEF cells delays MMS-induced cell death conferring more 
resistance to DNA-damaging agents compared to wild-type MEF cells. 
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Chapter 5: The Effects of Alkylation Treatment on The Cell 
Cycle Profiles of Wild-Type and Aag-/- MEFs 
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5.1 Introduction 
The essential series of events in a cell that produces two identical daughter cells after division 
and replication is called the cell cycle. It can be divided into four phases in eukaryotes, 
namely, gap 1 (G1), synthesis (S), gap 2 (G2), and mitosis (M). Also, there is one more phase 
called gap 0 (G0) but it is outside the cell cycle. The G1, S and G2 phases in the cell cycle 
are known as interphase (Houtgraaf et al., 2006, Williams and Stoeber, 2012). The cell cycle 
is illustrated in the figure below (Figure 5-1). Moreover, Table 5-1 is showing the brief 
description for each phase in the cell cycle. 
 
Figure 5-1: Schematic representation of the cell cycle. Figure is copied from (Myers, 2012). 
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Table 5-1: The brief description of each phase in the cell cycle.  
Phase State 
G0 A resting state where the cell has left the cycle and is not actively dividing. 
G1 The cell increases in size and grows larger. 
S 
DNA replication occurs in this phase of the cell cycle where the cell synthesises a 
complete copy of the DNA in its nucleus. 
G2 
The cell continues to grow and begins to reorganise its contents in order to become 
ready to divide in mitosis. 
M 
The cell growth stops and the cell divides its copied nuclear DNA and cytoplasm to 
produce two new identical daughter cells. 
(Houtgraaf et al., 2006) 
The triggering of cell cycle arrest after DNA damage is a typical consequence of DNA 
damage response activation in cells. The advantage of this process is prevention of the 
replication of DNA lesions that are potentially mutagenic. Also, cell cycle arrest provides 
time for the DNA lesions to be completely repaired. Cell cycle arrest is mediated by a 
network of signalling pathways identified as cell cycle checkpoints. There are three main 
checkpoints, namely, G1/S, intra-S-phase and G2/M checkpoints which are responsible for 
monitoring the integrity of the genome in the DNA (Lukas et al., 2004, Houtgraaf et al., 
2006). The roles of each checkpoint are listed in Table 5-2. 
Table 5-2: The roles of each checkpoint in the cell cycle. 
Checkpoints Roles 
G1/S To prevent the initiation of cellular replication in the presence of DNA damage. 
Intra-S-phase 
To arrest DNA synthesis after DNA damage which occur during DNA 
replication in the S phase. 
G2/M To ensure damaged DNA is not segregated during mitosis. 
(Lukas et al., 2004, Houtgraaf et al., 2006). 
Increased sensitivity to a damaging agent in cells can result from defects in checkpoint 
controls. Following DNA damage, there are factors playing a role in the choice of checkpoint 
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and also the outcome of the DNA damage response. These factors are the cell location at the 
time of DNA damage in the cell cycle, nature and extent of the DNA damage and also the 
type of the cell (Kaufmann and Paules, 1996, Bartek and Lukas, 2001). 
5.2 Aims 
 To study the cell cycle progression in AAG proficient and deficient MEF cells after 
alkylation treatment. 
5.3 Objectives 
 Study the cell cycle in the wild-type and Aag-/- MEF cells with time after 2.5 mM MMS 
treatment. 
5.4 Methods 
 Cell lines: wild-type and Aag-/- MEF cells. 
 Treatments: 2.5 mM MMS for one hour. 
 Fixation: 70% ethanol. 
 Flow cytometry: used to analyse the cell cycle in the fixed MEF cells by using PI dye. 
5.5 Results 
Cell cycle analysis distinguish cells in different phases of the cell cycle. Cells are 
permeabilised with ethanol before analysis and treated with RNaseA in order to digest 
cellular RNA. After that, cells are stained with PI that binds to DNA and these stained cells 
has fluorescence intensity proportional to the amount of DNA. The stained cells is measured 
in the flow cytometer for quantitative analysis which are considered a measurement of the 
cellular DNA content. 
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Flow cytometry analysis was performed in this study to examine whether the differences in 
the bioenergetics system between wild-type and Aag-/- MEF cells after MMS treatment 
reflect changes in the cell cycle progression between these two genotypes of MEF cells. The 
next figure (Figure 5-2) shows the flow cytometric analysis which reveals the morphological 
changes of cell cycle with time after MMS treatment in wild-type and Aag-/- MEF cells.  
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Figure 5-2: Comparative flow cytometric analysis of morphological histograms with time for 
studying cell cycle after MMS treatment (2.5 mM) in wild-type and Aag-/- MEFs. Time represents 
the number of hours after 1 hour treatment with MMS. At the end of the incubation time, MEF 
cells were harvested, fixed, stained with PI dye and analysed using flow cytometry. 
Time Point Wild-type MEFs Aag-/- MEFs 
Untreated 
Control 
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hour 
  
2 
hour 
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Figure 5-2: Comparative flow cytometric analysis of morphological histograms with time for 
studying cell cycle after MMS treatment (2.5 mM) in wild-type and Aag-/- MEFs. Time represents 
the number of hours after 1 hour treatment with MMS. At the end of the incubation time, MEF 
cells were harvested, fixed, stained with PI dye and analysed using flow cytometry. 
Time Point Wild-type MEFs Aag-/- MEFs 
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Figure 5-2: Comparative flow cytometric analysis of morphological histograms with time for 
studying cell cycle after MMS treatment (2.5 mM) in wild-type and Aag-/- MEFs. Time represents 
the number of hours after 1 hour treatment with MMS. At the end of the incubation time, MEF 
cells were harvested, fixed, stained with PI dye and analysed using flow cytometry. 
Time Point Wild-type MEFs Aag-/- MEFs 
24 
hour 
  
48 
Hour 
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The results of the cell cycle study show that there was an increased arrest occurred in the S 
and G2/M phases of both wild-type and Aag-/- MEF cells after MMS treatment. These 
accumulations of both MEF cell lines in the S and G2/M phases occurred very early in wild-
type MEF cells and were noted after one hour of MMS treatment. There were 5% of the cells 
present in S phase, whereas 21% of the cells were present in G2/M phase in the untreated 
control cells. After one hour of MMS treatment, 12% of the cells were present in S phase, 
whereas 28% of the cells were present in G2/M phase (Figure 5-3).  
In contrast, the accumulation of Aag-/- MEF cells in the S phase occurred early after treatment 
with MMS, while there was a slight increase in the accumulation of cells in G2/M phase 
after one hour of MMS treatment but it was obvious at 12 hour post-treatment and later. 
There were 6% of Aag-/- MEF cells in S phase, whereas 17% was in G2/M phase in the 
untreated control cells. After one hour of MMS treatment, 10% and 20% of the cells were 
present in S and G2/M phases, respectively (Figure 5-4). 
Moreover, the accumulation of wild-type MEFs after MMS treatment in S and G2/M phases 
peaked at 24 hour time point where 20% and 39% of the cells were accumulated in S and 
G2/M phases of the cell cycle, respectively. In Aag-/- MEF cells, the accumulation of the 
cells in S phase peaked at 12 hour and 24 hour time points (14%), while the accumulation 
of the cells in G2/M phase peaked at 12 hour and 48 hour time points (24%). 
One-way ANOVA followed by Dunnett’s multiple comparisons test showed that there were 
statistical significances in the accumulation of wild-type MEFs in S phase after MMS 
treatment observed early after one hour from adding the treatment. While in the G2/M phase, 
there were statistical significances at 24 hour and 48 hour time points. On the other hand, 
there were no statistically significant in Aag-/- MEF cells in the S and G2/M phases although 
there were accumulation of the cells in these phases of the cell cycle after MMS treatment. 
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In addition, treatment of both MEF cell lines with 2.5 mM MMS resulted in an increased in 
the population of cells in the sub-G1 phase with time which reflects the number of dead cells. 
However, Figures (5-3) and (5-4) show the results of the cell population in all cell cycle 
phases for both genotypes of MEF cells after MMS treatment. 
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Figure 5-3: Temporal cell cycle analysis of wild-type MEF cells. Time represents the number of hours after 1 hour treatment with MMS. At the end of the incubation time, cells 
were harvested, fixed and stained with PI dye and the percentage of cells in each phase was determined using flow cytometry. The data shown are mean values ± SEM of at 
least three independent experiments and each time point was done in triplicate. One-way ANOVA was performed followed by Dunnett’s multiple comparisons test and 
significance was assumed if p < 0.05. 
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Figure 5-4: Temporal cell cycle analysis of Aag-/- MEF cells. Time represents the number of hours after 1 hour treatment with MMS. At the end of the incubation time, cells 
were harvested, fixed and stained with PI dye and the percentage of cells in each phase was determined using flow cytometry. The data shown are mean values ± SEM of at 
least three independent experiments and each time point was done in triplicate. One-way ANOVA was performed followed by Dunnett’s multiple comparisons test and 
significance was assumed if p < 0.05. 
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The Figures (5-5) and (5-6) below display a comparison between the percentages of cells in 
each phase of the cell cycle for wild type and Aag-/- MEF cells. The results show that, in an 
initial  unsynchronous population, MMS treatment led to a more pronounced accumulation 
of cells in the S and G2/M phases in wild-type if comparing to Aag-/- MEF cells for all time 
points after MMS treatment. This higher percentage of cells is statistically significant at 24 
hour post-treatment in G2/M phase (p = 0.0005) using two-way ANOVA followed by 
Sidak’s multiple comparisons test. Together, these results indicate that wild-type MEF cells 
may experience more delay in S and G2/M after MMS treatment than Aag-/- MEF cells. This 
could suggest that AAG-mediated DNA damage processing of alkylation base damage 
leading to the formation of intermediates results in a different DNA damage profile in each 
of the cell lines with perhaps the Aag-/- cells having a damage profile that is less capable of 
inducing cell cycle arrest than the DNA damage overall present in the wild-type cells. 
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Figure 5-5: Comparison of temporal cell cycle analysis of sub-G1 (top) and G0/G1 (bottom) phases between 
wild-type and Aag-/- MEF cells. Time represents the number of hours when the MEFs were incubated in culture 
medium containing 2% serum after one hour treatment with MMS. At the end of the incubation time, cells 
were harvested, fixed and stained with PI dye and the percentage of cells in each phase was determined using 
flow cytometry. The data shown are mean values ± SEM of at least three independent experiments and each 
time point was done in triplicate. Two-way ANOVA was performed followed by Sidak’s multiple comparisons 
test and significance was assumed if p < 0.05. 
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Figure 5-6: Comparison of temporal cell cycle analysis of S (top) and G2/M (bottom) phases between wild-
type and Aag-/- MEF cells. Time represents the number of hours when the MEFs were incubated in culture 
medium containing 2% serum after one hour treatment with MMS. At the end of the incubation time, cells 
were harvested, fixed and stained with PI dye and the percentage of cells in each phase was determined using 
flow cytometry. The data shown are mean values ± SEM of at least three independent experiments and each 
time point was done in triplicate. Two-way ANOVA was performed followed by Sidak’s multiple comparisons 
test and significance was assumed if p < 0.05. 
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5.6 Discussion 
Cells employ biochemical signalling pathways in order to temporarily arrest cell cycle 
progression after DNA damage and then allow more time for the cells to repair the DNA 
damage. This will prevent the toxicity of the DNA damage or the generation of mutagenic 
lesions when the DNA damage is repaired accurately. Otherwise, cell cycle checkpoints are 
activated when this damage is not repairable which may result in permanent cell cycle arrest 
or cell death induction (Horton et al., 2003). 
As wild-type and Aag-/- MEF cells have shown bioenergetic differences after MMS 
treatment, I next assessed whether these differences reflect changes on cell-cycle progression 
after DNA damage. In this study, both genotypes of MEF cells were exposed to 2.5 mM 
MMS for one hour and cell cycle distribution was assessed in different incubation time up 
to 48 hours after DNA damage.  
When the cell cycle progression was analysed using flow cytometry, accumulations of both 
genotypes of MEF cells display a delay in late S-G2 phase after MMS treatment, but this 
delay is more pronounced in the wild type cells. Also, this study did not detect accumulations 
of both genotypes of MEF cells in G0/G1 phase at any time point after MMS treatment. 
These observations indicating that the arrests in the cell cycle progression after MMS 
treatment occurs through S and G2/M phases in the MEF cells. 
These finding are in agreement with a previous study which found that the cell cycle arrest 
in wild-type MEF cells after MMS treatment occurred in S and G2/M phases (Horton et al., 
2003). Moreover, the cell cycle arrest in S and G2/M phases have been observed previously 
in human teratocarcinoma-derived (P3) cells and also embryonic stem cells following 
exposure to MMS (Morris et al., 1991, Engelward et al., 1998). 
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The delay of MEF cells in S phase could be then because replication forks encountering 
DNA strand breaks which reflects longer persistence or increased number of SSBs at 
replication forks and consequently a prolonged intra S phase checkpoint. In addition, the late 
arrest of both genotypes of MEF cells after MMS treatment in G2/M phase confirm that the 
MEFs which at the time of MMS treatment were in G0/G1 and S phases continued to 
progress to G2/M phase. This may suggest that the DNA after S phase exit is still damaged. 
This finding is in support with the observation that, in replicative cells, genotoxic stress 
during duplication can transiently delay the S-phase progression in the cell cycle to allow 
for repair time. Then, if the damages are still in the cells and not repaired during this delay 
in the S phase, the cells then can exit the S phase and arrest when they are reaching the G2/M 
checkpoint (Brem et al., 2008). However, this late accumulation of MEF cells in G2/M phase 
can be attributed to the persisting presence of unrepaired DSBs in these cells as DSBs can 
occur during replication in S phase and need to be repaired before mitosis (Branzei and 
Foiani, 2008). 
In addition, this study has shown that there were 72% and 74% of wild-type and Aag-/- MEF 
cells, respectively, found in G0/G1 phase in the untreated control. While, at 48 hour time 
point after treatment with MMS, only 24% of wild-type MEFs and 44% of MEFs with 
lacking of AAG are found in G0/G1 phase. This is indicating that at this time point these 
MEF cells do not resume progression through the cell cycle. 
Other experiments have been done in this study with 15% serum culture medium in order to 
investigate whether incubation of both genotypes of MEF cells in 2% serum culture medium 
after one hour of MMS treatment can have an effect on the cell cycle progression. The 
different serum conditions did not lead to significant changes in the cell cycle response to 
MMS treatment, whether MEF cells were incubated in 15% serum culture medium or in 2% 
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serum culture medium, the profiles were very similar. After MMS treatment, the cells 
progression through the cell cycle with 15% serum culture medium display an almost 
identical cell cycle distribution to that seen with 2% serum culture medium. However, the 
results of the cell cycle progression of the 15% serum culture medium can be seen in the 
Appendices.  
To conclude, the absence of AAG-mediated DNA alkylation damage processing alters cell 
cycle progression after alkylation treatment. There is reduced arrest in S and G2/M phases 
of the cell cycle in Aag-/- cells if compared to the wild-type MEFs after MMS treatment.  
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Chapter 6: Final Discussion and Conclusion 
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6.1 Final Discussion 
AAG activity is fundamental to the initiation of BER process which then can lead to the 
generation of toxic BER intermediates. Modulation of AAG activity is a possible approach 
to examine to what extent BER initiated by AAG contributes to the toxic effects of different 
types of the alkylating agents in mammalian cells. Aag-/- MEF cells were used in this study 
along with wild-type MEF cells to provide answers about the relationship between AAG 
activity, BER imbalance, bioenergetic failure and cell death. 
Referring to the aim of this study, I quantitatively characterised the BER events initiated by 
AAG as shown in the next figure (Figure 6-1). Also, I studied the temporal relationship 
between these BER events. It is hoped that by elucidating this relationship from initiation of 
BER pathway to cell death, a better understanding can be achieved that could contribute to 
the development of better therapeutic options to sensitise cancer cells to alkylating agent 
treatment. 
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Figure 6-1: The objectives of the study. This study set out with the aim of characterisation the temporal 
molecular steps of BER initiated by AAG to remove the alkylated DNA bases after MMS treatment in wild-
type and Aag-/- MEF cells. The first objective was to quantify AP sites which is the first step of the BER. The 
second objective was to measure the levels of DNA strand breaks. The third objective was to quantify the levels 
of PAR synthesis after PARP activation. The fourth objective was to investigate the cellular bioenergetic 
system by measuring the cellular NAD+ and ATP levels. The fifth objective was to quantify cell death which 
is the last stage of imbalance BER. Figure is modified from (Calvo et al., 2013). 
The interesting findings referring to the aim of the present study were that MMS treatment 
is equally toxic to wild-type MEFs and Aag-/- MEFs, despite a protection from NAD+ and 
ATP depletion seen in Aag-/- MEFs in early time points. AAG initiated BER to remove the 
alkylated DNA bases formed by MMS in wild-type MEFs may generate toxic BER 
intermediates (AP sites and DNA strand breaks) more rapidly than in Aag-/- MEFs, but these 
toxic intermediates are formed in both genotypes. Indeed, the number of AP sites formed in 
the early time points after MMS treatment in the wild-type MEF cells is higher than in the 
Aag-/- MEF cells. In Aag−/− MEF cells, AP sites number peaked at a later stage than in wild-
type MEF cells, confirming that AAG activity on alkylated DNA bases is rapidly generating 
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BER intermediates. These BER intermediate formation is translated into a differential PARP 
activation picture, depending on whether AAG is present or not. The lack of PARP activation 
seen in Aag-/- cells agrees with the initial protection from NAD+ and ATP depletion seen in 
this genotype, however the end result for the two cell types is similar bioenergetic failure 
and cell death.  
AAG has been identified as the major mammalian DNA glycosylase acting on alkylated 
bases from DNA during BER (Robertson et al., 2009). So, AAG is required for the removal 
of both 7-meG and 3-meA DNA lesions generated by MMS treatment. Therefore, in contrast 
to wild-type MEFs, treatment of Aag-/- MEFs with MMS was expected to have different 
consequences: in the absence of AAG, both MMS-induced 7-meG and 3-meA were expected 
to remain within the DNA structure in Aag-/- MEF cells (Engelward et al., 1996, Engelward 
et al., 1998). 
The DNA lesions 7-meG and 3-meA are different in their biological significance. The 
primary 7-meG is neither cytotoxic nor mutagenic but it can form AP site, either as an 
intermediate during BER, or by spontaneous depurination (Rinne et al., 2005). Meanwhile, 
3-meA is a cytotoxic DNA lesion because it can block DNA polymerase, leading to the 
subsequent collapse of the DNA replication fork and generation of DSB in the DNA and 
consequently to the onset of a downstream cascade of signalling events resulting in initiation 
of the process of cell death (Johnson et al., 2007, Engelward et al., 1998). Therefore, it was 
expected that the accumulation of both DNA lesions 7-meG and 3-meA within the DNA in 
Aag-/- MEF cells would be the reason for the sensitivity resulting from MMS treatment (Fu 
et al., 2012).  
However, our study does not support this idea. This is because our findings show a similar 
profile for formation of BER intermediates such as AP sites and DNA strand breaks in both 
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wild-type and Aag-/- MEF cells after MMS treatment. This very similar profile suggests that 
7-meG lesion, the predominant lesion (70 – 80 %) formed by MMS treatment, if not removed 
by AAG is generating AP sites through spontaneous depurination or is being acted upon by 
a redundant glycosylase. However, the half-life of 7-meG lesion was determined to be 
approximately 147 hours which is a very long time to account for the levels of AP site 
formation we observed after MMS treatment in Aag-/- MEF cells (Smith and Engelward, 
2000). Furthermore, 3-meA lesion is also ruled out in this study as a possible cause of the 
observed alkylation sensitivity in Aag-/- MEF cells, although it has the potential to block 
DNA replication causing replication fork collapse, generating DSB and eventually cell 
death. The reasons for that are because the results of the γ-H2AX quantification in this study 
did not indicate any excessive generation of DSBs within the DNA of Aag-/- MEFs 
comparing to wild-type MEFs where the levels of activation of γ-H2AX were almost 
equivalent in both genotypes of MEF cells. Also, the results of cell cycle progression in this 
study did not show a similar arrest profile in Aag-/- MEF cells comparing to wild-type MEF 
cells, with wild type cells displaying a larger accumulation of cells in the late S-G2 phase. 
So even though Aag-/- cells should accumulate more unrepaired 3-meA, they do show less 
arrest at the late S-G2 phase than wild type cells although it is more likely that the toxicity 
of 3-meA lesion in cells is during the S-phase of the cell cycle when the cell is replicating 
(Engelward et al., 1998). Furthermore, it has been shown that the half-life of 3-meA lesion 
was found to be approximately 24 hours which is also long time to account for the observed 
pattern of AP site formation in Aag-/- MEF cells (Smith and Engelward, 2000).  
So, both 7-meG and 3-meA lesions are probably not remaining unrepaired in the DNA; if 
nor acted upon by AAG, these lesions are being removed due to spontaneous depurination. 
It is reasonable to speculate that AP site generation pattern in Aag-/- MEF cells after MMS 
treatment is due to another DNA repair pathway in addition to BER which can then repair 
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the alkylated DNA bases formed by MMS, or there is a redundant DNA glycosylase in 
absence of AAG which can then compensate for this activity leading at the end to generate 
AP sites and DNA strand breaks. These suggestions corroborate the ideas of Smith and 
Engelward (2000), who suggested that there is another DNA repair pathway which can 
remove 7-meG and 3-meA lesions from the DNA because the two DNA lesions were 
actively removed from DNA in Aag-/- MEF cells faster than the rate of spontaneous 
depurination for both lesions. Therefore, as not only 3-meA lesion would cause replication 
fork collapse but AP sites are also cytotoxic and can cause replication fork collapse, so the 
fact that we see similar AP sites and similar DNA strand breaks formation in this study in 
both genotypes of MEF cells is actually reasonable. 
Moreover, the study done by Smith and Engelward (2000) has found that the repair of 3-
meA DNA lesion in Aag-/- cells was much slower than in wild-type cells, while the removal 
of 7-meG lesion was equal and efficient in both wild-type and Aag-/- cells. This study 
suggested that AAG enzyme is the major DNA glycosylase for removing and repairing 3-
meA lesion, while another DNA glycosylase acts on 7-meG lesion. Based on these findings 
and in case of lacking of AAG activity in Aag-/- MEF cells in our study will lead to 
accumulation of alkylated DNA bases such as 3-meA lesion, it would be interesting to 
investigate the BER intermediate profile in both genotypes of MEF cells treated with Me-
Lex which is an alkylating agent that generates almost exclusively 3-meA lesion (> 90%) 
comparing to MMS (Horton et al., 2003). Indeed, Engelward et al. (1996) revealed that Aag-
/- embryonic stem cells treated with the alkylating agent Me-Lex were more sensitive than 
wild-type embryonic stem cells. 
The results of the cell cycle progression in this study show that both genotypes of MEF cells 
display a delay in late S-G2 phase after MMS treatment, but this delay is more pronounced 
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in the wild type cells. This delay could be then because replication forks encountering DNA 
strand breaks which reflects longer persistence or increased number of SSBs at replication 
forks and consequently a prolonged intra S phase checkpoint. In addition, late accumulation 
of MEF cells in G2/M phase was noted in this study which can attribute to the persisting 
presence of unrepaired DSBs in these cells as DSBs can occur during replication in S phase 
and need to be repaired before mitosis (Branzei and Foiani, 2008).  
In addition, our study shows that AAG represents a crucial link in the increased sensitivity 
to alkylating agents induced by PAR synthesis after PARP activation resulting from DNA 
damage. The rapid depletion of physiological NAD+ and ATP levels in wild-type MEFs as 
a result of PAR synthesis after MMS treatment precedes and promotes the onset of cell death 
in these cells. While, loss of AAG expression in Aag-/- MEF cells plays a protective role in 
suppressing PAR synthesis after exposure to DNA-damaging agents because the evaluation 
of MMS-treated MEF cells in the present study revealed no PAR synthesis in AAG-deficient 
cells. This allowed this genotype of MEF cells to be initially protected from MMS-induced 
NAD+ and ATP depletion, although this did not prevent both genotypes from subsequent 
equivalent depletion of cellular NAD+ and ATP levels and eventually cell death.  
A recent study reveals that PARylation resulting from PARP-1 activation blocks the 
glycolytic enzyme hexokinase leading to ATP loss which is independent from NAD+ 
depletion, in a glioblastoma-derived cell line (Fouquerel et al., 2014). Also, results from 
another study show that bioenergetic failure induced by PARP activation in mouse cortical 
neurons is caused by inhibition of glycolysis through inhibition of hexokinase which is PAR-
dependent (Andrabi et al., 2014). These findings are in agreement with our results in which 
the depletion of cellular NAD+ levels preceded the depletion of cellular ATP levels in wild-
type MEF cells. Also, the depletion of cellular ATP levels in the current study was 
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concomitant with the increase of PAR synthesis in wild-type MEF cells. Moreover, cellular 
ATP levels in wild-type MEF cells were not affected by the depletion of the cellular NAD+ 
levels in the absence of PAR synthesis by using FK-866 inhibitor which can prove that the 
NAD+ depletion is independent from the ATP depletion in the wild-type MEFs. Based on 
these findings, AAG-mediated BER initiation is required for PARylation and rabid 
bioenergetic failure. In addition to the glycolysis blocking, phosphorylation of H2AX 
histone also required ATP which can then contribute to the loss of ATP levels after alkylation 
treatment (Lans et al., 2012). Moreover, MMS generates DNA damage in the mitochondrial 
DNA where if accumulated and not properly repaired can lead to instability and then 
mitochondrial dysfunction which accompanied by a drop in ATP levels (Piršel and Bohr, 
1993, van Loon and Samson, 2013, Prakash and Doublié, 2015, Moiseeva et al., 2009, 
Muftuoglu et al., 2014).  
Mitochondrial DNA is exposed to damaging agents such as alkylating agents and it suffers 
damage more than nuclear DNA. In a study conducted by Bandy and Davison (1990), it was 
shown that alkylating agents can modify mitochondrial DNA at least 10-fold more than is 
nuclear DNA. There are some reasons explaining why mitochondrial DNA is more 
susceptible to alkylating agents such as MMS than nuclear DNA. The high lipid content and 
also a negative charge on the inner surface of the mitochondrial inner membrane generated 
by mitochondrial membrane potential make mitochondria particularly susceptible to 
lipophilic chemical such as alkylating agents. Mitochondria import lipophilic cations from 
the cytosol and this results in tremendous accumulation and concentration (up to 1000-fold) 
of lipophilic cation in mitochondria, specifically in mitochondrial membranes (Druzhyna et 
al., 2008). Alkylating agents such as MMS are lipophilic substances with positive charges 
and therefore tend to accumulate and concentrate within the mitochondria which will affect 
the mitochondrial function. Mitochondrial DNA is attached to the mitochondrial inner 
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membrane and then it is sensitive to membrane disturbances and a main target for 
electrophilic compounds such as MMS and generate alkylation damages on mitochondrial 
DNA with a 10-fold higher ratio with respect to nuclear DNA (Bandy and Davison, 1990). 
In addition, mitochondrial DNA lacks of protective histones where this can be another factor 
contributing to vulnerability of mitochondrial DNA to damages (Marín-García, 2012).   
On the other hand, the bioenergetic failure in Aag-/- MEFs is expected to be the cause for cell 
death in the absence of PARylation-mediated cell death process. In fact, the ATP level was 
increased directly after adding MMS treatment which can confirm that glycolysis is efficient 
and not blocked in these cells, consistent with the absence of PARylation. The possible 
reasons for the depletion of cellular NAD+ and ATP levels in this genotype of MEF cells 
could be because the consumption of ATP during the phosphorylation of H2AX which could 
lead to concomitant depletion of NAD+. This suggestion seems to be consistent with the 
results of this study which found that the MMS-induced loss of NAD+ and ATP in Aag-/- 
MEFs began one hour after MMS exposure, concomitant with the peak of H2AX 
phosphorylation. Also, the mitochondrial dysfunction as a result of accumulated unrepaired 
mitochondrial DNA damages can also contribute to a drop in ATP levels (van Loon and 
Samson, 2013, Prakash and Doublié, 2015, Moiseeva et al., 2009, Muftuoglu et al., 2014). 
However, further research should be undertaken to investigate the cause of energy collapse 
and eventually cell death in Aag-/- MEF cells although the PARylation was absent in these 
cells. 
So, PARP activation is expected to be the main cause for rapid bioenergetic failure and 
eventually cell death in wild-type MEFs after MMS treatment. While in the absence of 
PARylation, the increased of H2AX phosphorylation may explain the bioenergetic failure 
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seen in Aag-/- MEF cells. However, the next Figure (6-2) is showing the possible causes 
leading to bioenergetic failure in MEF cells after MMS treatment. 
 
Figure 6-2: Schematic showing the possible causes leading to energy collapse in BER initiated by AAG after 
alkylation treatment. PAR synthesis after PARP activation in response to MMS-induced DNA strand breaks 
will lead to rabid loss of NAD+ which can also in turn block the glycolysis leading to loss of ATP. 
Phosphorylation of H2AX resulted from MMS-induced DNA strand breaks require ATP which can also lead 
to consumption of the cellular ATP level. Moreover, accumulation of unrepaired DNA damages in 
mitochondrial DNA as a result of MMS treatment will lead to a severe mitochondrial dysfunction characterised 
by a decrease in ATP. In addition, ATP is consumed during the synthesis of NAD+ and vice versa (Fouquerel 
et al., 2014, Lans et al., 2012, Hassa et al., 2006, Prakash and Doublié, 2015).  
The results of this study are in line with previous studies which show that the initiation of 
BER by AAG is more lethal to the cell than leaving the damaged DNA bases unrepaired by 
AAG. This finding was observed in many cells such as retinal photoreceptor cells, pancreatic 
β-cells, splenocytes, thymocytes, cerebellar granule cells and bone marrow cells (Meira et 
al., 2009, Calvo et al., 2013, Roth and Samson, 2002). This increased sensitivity to alkylating 
agents in presence of AAG can be attributed to the PARP activation which was abrogated in 
Aag-/- MEF cells in this study. These findings are consistent with those of Calvo and co-
workers (2013) who found that evaluation of PARP activation by immunodetection of the 
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PAR polymer following MMS treatment indicated that increased PAR polymer staining in 
retinal photoreceptors was AAG-dependent. 
6.2 Conclusion 
This study characterises the temporal molecular steps preceding AAG-dependent alkylation-
induced cell death using wild-type and Aag-/- MEF cells. The work described here in this 
study shows that both wild-type and Aag-/- MEF cells are sensitive to the alkylating agent 
MMS and generate almost equal levels of AP sites and DNA strand breaks. However, this 
sensitivity to the alkylation treatment is exacerbated in presence of AAG-mediated initiation 
of BER. While, the absence of AAG activity in MEF cells delays MMS-induced cell death 
conferring initially more resistance to DNA-damaging agents compared to wild-type MEF 
cells. This conclusion is supported by the finding that PARP activation in wild-type MEFs 
results in rapid bioenergetic failure, whereas AAG deficiency in Aag-/- MEF cells abrogates 
the activation of PARP after MMS treatment, although the DNA strand breaks were formed, 
which results in a delay in bioenergetic failure. Therefore, initiation of BER by AAG can be 
harmful to the cells, although BER is essential and important in repairing many different 
types of DNA lesions caused by alkylating agents. 
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6.3 Future Work 
The results of this study provide several important directions for future studies and also some 
questions in need of further investigation. In order to validate that AAG is required for 
PARP-1 activation, further studies need to be carried out. One possible study is to investigate 
AIF nuclear translocation from mitochondria after MMS treatment in both genotypes of 
MEF cells. This is because it has been demonstrated the requirement of PAR polymer in 
release of AIF from the mitochondria and translocation in the nucleus (Yu et al., 2006, Yu 
et al., 2002). So, it is expected that AIF nuclear translocation from mitochondria will be 
present in wild-type but not in Aag-/- MEF cells. 
Also, another possible study to validate the requirement of AAG for PARP-1 activation is to 
investigate the effects of using PARP inhibitor on both genotypes of MEF cells after 
treatment with MMS. This is because using PARP inhibitor should rescue wild-type MEFs 
from MMS sensitivity but not in Aag-/- MEFs. Also, PARP-1 inhibition could attenuates the 
loss of ATP after MMS treatment in wild-type MEFs. 
In addition, it is suggested that the association of PARP activation and glycolysis blocking 
is investigated in future studies in both genotypes of MEF cells. A possible way is by 
measure the level of the glycolysis metabolites such as pyruvate after MMS treatment. Also, 
another possible way is to add a Krebs cycle substrate such as α-ketoglutarate and pyruvate 
and investigate if a glycolytic block can be rescued in wild-type MEF cells, while not in Aag-
/- MEF cells. 
Moreover, the data from this study will be used to construct a mathematical model to explain 
AAG-mediated alkylation-induced cell death process. The development of a mathematical 
model is useful in predicting the level of BER imbalance required to initiate the downstream 
cascade of events which lead to cell death. Also, this approach of computational and 
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mathematical tools will be useful in order to determine the cellular outcome after exposure 
to alkylating agents where experiments have to be done in-vivo using animals, so if the 
mathematical model can predict accurately the outcome and mimics the biological response, 
this will help to reduce using the animals in such investigations. However, generating the 
mathematical modelling will be done as collaboration with Dr Philip Aston from Department 
of Mathematics and Dr Ruan Elliott from Department of Nutritional Sciences at University 
of Surrey. The initial report entitled “Mathematical Model of in vivo Base Excision Repair” 
is included in the Appendices. 
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Appendix 1: Genotyping of MEF cells 
 
Figure 1: PCR-based analysis for genotyping of wild-type and Aag-/- MEF cells. Genomic DNA samples from 
each genotype of MEF cells were extracted and analysed by allele-specific PCR (specific to either the wild 
type or Aag null allele) in order to confirm the Aag genotype. The upper band, which is approximately 500 bp, 
corresponds to the presence of the Aag null allele (lanes 3, 5, 8 and 10), while the lower band, which is 
approximately 350 bp, indicates the presence of the wild-type allele (lanes 2 and 4). The presence of both bands 
identify Aag heterozygotes (lanes 6, 7 and 9). Lane 1 contains the molecular size markers. Lanes 11, 12 and 13 
contain control samples for the Aag null, heterozygotes and wild-type, respectively.  
Appendix 2: Olive Moment Results 
The third common parameter to present the results of comet assay is olive moment. The 
results of the olive moment in wild-type and Aag-/- MEFs are shown in the next pages. 
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Figure 2: Histographs illustrating the olive moment in wild-type MEFs. The (top) graph shows the olive 
moment with time after treatment with MMS (2.5 mM) comparing to their respective untreated control. The 
(bottom) graph shows the olive moment after treatment with H2O2 (1 mM) for 30 minutes at 37°C/5% CO2 as 
a positive control. The data shown are mean values ± SEM of three independent experiments and each time 
point was done in duplicate. One-way ANOVA test was performed (Dunnett's multiple comparisons test) and 
significance was assumed if p < 0.05. 
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Figure 3: Histographs illustrating the olive moment in Aag-/- MEFs. The (top) graph shows the olive moment 
with time after treatment with MMS (2.5 mM) comparing to their respective untreated control. The (bottom) 
graph shows the olive moment after treatment with H2O2 (1 mM) for 30 minutes at 37°C/5% CO2 as a positive 
control. The data shown are mean values ± SEM of three independent experiments and each time point was 
done in duplicate. One-way ANOVA test was performed (Dunnett's multiple comparisons test) and 
significance was assumed if p < 0.05. 
235 
 
c
o
n
tr
o
l
-  
0
.5
0 0
0
.5
0 1 2 4 6
1
2
2
4
4
8
0 .0
2 .5
5 .0
7 .5
1 0 .0
1 2 .5
1 5 .0
T im e  (H r )
O
li
v
e
 M
o
m
e
n
t
(M
e
a
n

 S
E
M
)
W ild - ty p e  M E F s
A a g
- / -
M E F s
c
o
n
tr
o
l
H
2
O
2
0 .0
2 .5
5 .0
7 .5
1 0 .0
1 2 .5
1 5 .0
T im e  (H r )
O
li
v
e
 M
o
m
e
n
t
(M
e
a
n

 S
E
M
)
W ild - ty p e  M E F s
A a g
- / -
M E F s
 
Figure 4: Histogram graph illustrating the temporal increase in olive moment after MMS treatment measured 
by comet assay in wild-type and Aag-/- MEFs. (Top) Time represents the number of hours when the MEFs were 
incubated in culture medium containing 2% serum after one hour treatment with MMS. The (bottom) graph 
shows the olive moment after treatment with H2O2 (1 mM) for 30 minutes at 37°C/5% CO2 as a positive control. 
No statistically significant difference was observed by two-way ANOVA test. 
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Appendix 3: Cell Cycle Results 
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Figure 5: Temporal cell cycle analysis of wild-type MEF cells. Time represents the number of hours when the 
wild-type MEFs were incubated in culture medium containing 2% serum after one hour treatment with MMS. 
The data shown are mean values of four independent experiments and each time point was done in triplicate. 
Table 1: The mean and SEM values of the temporal cell cycle analysis of wild-type MEF cells. 
Time represents the number of hours when the wild-type MEFs were incubated in culture medium 
containing 2% serum after one hour treatment with MMS. The data shown are mean values of four 
independent experiments and each time point was done in triplicate. 
Time 
(Hour) 
Sub-G1 Cells G0/G1 Phase S Phase G2/M Phase 
Mean SEM Mean SEM Mean SEM Mean SEM 
Control 1.54 0.73 72.02 0.76 5.39 0.43 21.05 1.51 
0 1.31 0.48 58.82 2.87 11.73 0.35 28.11 2.61 
2 1.63 0.46 59.06 2.33 14.17 0.55 25.15 2.13 
4 3.31 1.31 57.22 1.55 14.28 0.66 25.18 2.25 
6 4.83 1.99 54.18 1.20 13.45 0.58 27.51 0.57 
12 7.33 3.34 45.47 4.48 18.13 3.08 29.03 1.70 
24 10.63 3.17 29.45 3.61 20.41 1.43 39.50 4.66 
48 28.70 3.98 24.43 2.10 12.18 1.38 34.73 6.10 
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Figure 6: Temporal cell cycle analysis of wild-type MEF cells. Time represents the number of hours when the 
wild-type MEFs were incubated in 15% serum culture medium after one hour treatment with MMS. The data 
shown are mean values of four independent experiments and each time point was done in triplicate. 
Table 2: The mean and SEM values of the temporal cell cycle analysis of wild-type MEF cells. 
Time represents the number of hours when the wild-type MEFs were incubated in 15% serum 
culture medium after one hour treatment with MMS. The data shown are mean values of four 
independent experiments and each time point was done in triplicate. 
Time 
(Hour)  
Sub-G1 Cells G0/G1 Phase S Phase G2/M Phase 
Mean SEM Mean SEM Mean SEM Mean SEM 
Control 1.95 0.63 68.44 0.94 6.42 0.82 23.14 0.47 
0 1.22 0.46 59.17 1.74 12.10 0.42 27.45 1.59 
2 1.72 0.29 58.79 2.47 13.75 0.93 25.71 1.87 
4 3.17 1.06 57.99 1.47 14.60 1.23 24.23 1.10 
6 3.83 1.47 56.13 0.99 15.08 1.02 24.97 0.86 
12 5.66 2.52 45.23 6.53 20.43 3.91 28.63 3.64 
24 7.87 3.64 27.06 4.18 17.81 2.57 47.22 8.20 
48 18.04 8.68 22.19 2.47 9.84 1.60 49.91 10.65 
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Figure 7: Temporal cell cycle analysis of Aag-/- MEF cells. Time represents the number of hours when the Aag-
/- MEFs were incubated in culture medium containing 2% serum after one hour treatment with MMS. The data 
shown are mean values of three independent experiments and each time point was done in triplicate. 
Table 3: The mean and SEM values of the temporal cell cycle analysis of Aag-/- MEF cells. Time 
represents the number of hours when the Aag-/- MEFs were incubated in culture medium 
containing 2% serum after one hour treatment with MMS. The data shown are mean values of 
three independent experiments and each time point was done in triplicate. 
Time 
(Hour) 
Sub-G1 Cells G0/G1 Phase S Phase G2/M Phase 
Mean SEM Mean SEM Mean SEM Mean SEM 
Control 2.83 1.22 73.88 2.80 5.88 1.82 17.25 1.36 
0 2.12 0.92 67.92 2.94 9.60 2.69 20.13 0.89 
2 2.38 0.96 69.02 4.95 11.23 2.70 17.20 2.30 
4 3.52 0.78 71.60 3.66 8.48 2.70 16.17 1.36 
6 7.62 2.06 68.93 4.56 7.15 1.48 16.02 1.53 
12 14.15 6.75 47.60 2.31 14.08 3.91 23.78 0.43 
24 17.77 7.33 46.33 4.28 14.33 2.69 21.00 1.53 
48 20.77 8.29 44.08 4.81 10.53 2.19 24.03 4.07 
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Figure 8: Temporal cell cycle analysis of Aag-/- MEF cells. Time represents the number of hours when the Aag-
/- MEFs were incubated in 15% serum culture medium after one hour treatment with MMS. The data shown 
are mean values of three independent experiments and each time point was done in triplicate. 
Table 4: The mean and SEM values of the temporal cell cycle analysis of Aag-/- MEF cells. Time 
represents the number of hours when the Aag-/- MEFs were incubated in 15% serum culture 
medium after one hour treatment with MMS. The data shown are mean values of three independent 
experiments and each time point was done in triplicate. 
Time 
(Hour) 
Sub-G1 Cells G0/G1 Phase S Phase G2/M Phase 
Mean SEM Mean SEM Mean SEM Mean SEM 
Control 2.32 1.87 78.88 3.84 4.80 0.67 14.00 1.58 
0 1.77 0.86 71.35 4.21 8.68 2.30 18.20 1.35 
2 3.28 0.89 68.47 3.94 12.32 0.58 15.90 2.85 
4 3.83 0.58 70.33 4.17 10.18 0.70 15.68 3.09 
6 4.20 1.80 73.45 3.86 8.65 1.54 13.72 2.03 
12 10.47 6.64 54.50 7.44 13.07 5.57 21.98 1.38 
24 15.67 7.47 46.28 3.81 13.73 2.46 24.32 8.15 
48 17.53 7.43 44.43 3.32 11.53 0.61 26.50 5.38 
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Appendix 4: Mathematical Model of in vivo Base Excision Repair 
The generation of mathematical equations will be useful in identifying the determinants of 
cellular fate after DNA damage. The initial report written by Dr. Philip Aston from 
Department of Mathematics at University of Surrey to explain the mathematical model of in 
vivo BER is presented in the next page, followed by a report written by a summer student 
Ben Gerrey where my data was used to model AP site repair.  
 
 
 
 
 
 
 
 
 
 
Mathematical Models of in vivo Base-Excision Repair
Philip Aston, Ruan Elliott and Lisiane Meira
September 28, 2012
1 DNA Damage and Repair Process
The base excision repair pathway (BER) for repairing damaged DNA has been considered
in the past in vitro, in which the DNA has been extracted from cells [4, 5]. UDG was
added to the DNA together with the enzymes required for the BER process but without
any MgCl2, which is essential for the activation of the repair enzymes. The UDG created
the damage to the DNA. After 5 minutes, MgCl2 was added to start the repair process and
various measurements at several points in time were made in order to understand the repair
process [5]. Clearly, this is a very controlled environment from which interesting results were
obtained.
We consider the more difficult problem of in vivo DNA base excision repair that is occur-
ring in the natural environment of the cell where all the repair enzymes are present. We use
the alkylating agent MMS to produce the DNA damage, but then consider the same repair
pathway. We consider two possible models for the DNA damage and repair process.
2 First Model
2.1 DNA damage
When MMS is added to DNA, it causes alkylation base damage and is used up in the process.
In the experiments, any remaining MMS is removed after 1 hour. The enzyme Aag then acts
on this damaged DNA to produce apurinic (AP) sites.
There is also endogenous DNA damage that occurs all the time when there is no MMS
present and this can occur in several ways [1]. Spontaneous depurination results in AP sites
being formed directly. In human DNA, about 5,000 purine bases are lost every day from
the DNA of each human cell due to spontaneous depurination, and this is the most frequent
spontaneous reaction that creates DNA damage in cells [1].
To model the DNA damage process, we define the following variables:
• M : concentration of MMS (µM)
• Y : concentration of undamaged DNA (µM)
• y0: DNA with alkylation damage due to the action of MMS (µM)
• y1: AP sites (µM)
Remark: Experimental measurements of AP sites are done in units of sites per 100 kbp.
See Ruan’s email for conversion of these units to concentrations.
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2.2 Alkylation damage
Since the MMS is used up in the reaction with the DNA, we use a standard model of a
chemical reaction in which the rate of reaction is proportional to the product of the two
reactants. The equations for this reaction are given by
M˙ = −c˜0MY
Y˙ = −c˜0MY
y˙0 = c˜0MY
for some constant c˜0 (µM
−1h−1).
2.3 Aag activity
The enzyme Aag acts on the DNA with alkylation damage to produce the AP sites. We
model this enzymatic reaction with Michaelis-Menten kinetics and so the equations are given
by
y˙0 = −
k0e0y0
y0 +K0
y˙1 =
k0e0y0
y0 +K0
where k0 is the kcat (h
−1), K0 is the KM (µM) and e0 is the concentration of the enzyme Aag
(µM).
2.4 Spontaneous depurination
We assume that the DNA damage caused by spontaneous depurination occurs at a constant
rate per cell, which implies that the rate of damage is proportional to the amount of DNA
present. Thus we model this with the equations
Y˙ = −c1Y
y˙1 = c1Y
for some constant c1 (h
−1).
2.5 Combined equations for DNA damage
Combining the equations that model these two processes for DNA damage gives the equations
M˙ = −c˜0MY (1)
Y˙ = −c˜0MY − c1Y (2)
y˙0 = c˜0MY −
k0e0y0
y0 +K0
(3)
y˙1 = c1Y +
k0e0y0
y0 +K0
(4)
2
2.6 Model of DNA repair
Once the AP sites have been formed, we assume that the standard base excision repair
pathway is followed, as described by Srivastava et al. [5] and Sokhansanj et al. [4]. This
consists of the following steps:
AP site
↓ AP endonuclease
Gapped 5 dRp
↓ Polβ
Nicked 5 dRp
↓ Polβ
Nicked
↓ DNA ligase I
Repaired DNA
We model this process using the model equations of [4] which are given by
y˙1 = −v1(y1) (5)
y˙2 = v1(y1)− v2(y2) (6)
y˙3 = v2(y2)− v3(y3) (7)
y˙4 = v3(y3)− v4(y4) (8)
Y˙ = v4(y4) (9)
where y1–y4 are the number of sites of each type per 100 kbp at the first four stages of the
process which are respectively the AP site, gapped 5 dRp, nicked 5 dRp and nicked. The
variable Y , as used above, is the concentration of undamaged DNA which is the final product
of this repair process. The velocity functions are based on Michaelis-Menten kinetics and so
are given by
vi(yi) =
kieiyi
yi +Ki
, i = 1, 2, 3, 4 (10)
where ki is the kcat (h
−1), Ki is the KM (µM) and ei (µM) is the enzyme concentration for
each reaction.
3
2.7 Combined Model of DNA Damage and Repair
Combining our equations (1)–(4) for DNA damage with the equations (5)–(9) for DNA repair
gives the complete model
M˙ = −c˜0MY (11)
Y˙ = −c˜0MY − c1Y + v4(y4) (12)
y˙0 = c˜0MY − v0(y0) (13)
y˙1 = c1Y + v0(y0)− v1(y1) (14)
y˙2 = v1(y1)− v2(y2) (15)
y˙3 = v2(y2)− v3(y3) (16)
y˙4 = v3(y3)− v4(y4) (17)
2.8 Initial Conditions
The initial conditions for our equations consist of the steady state in the absence of the
MMS. Setting M = 0, equations (11)–(17) reduce to
Y˙ = −c1Y + v4(y4) (18)
y˙0 = −v0(y0) (19)
y˙1 = c1Y + v0(y0)− v1(y1) (20)
y˙2 = v1(y1)− v2(y2) (21)
y˙3 = v2(y2)− v3(y3) (22)
y˙4 = v3(y3)− v4(y4) (23)
We define the total of all the constituents as
T = Y + y0 + y1 + y2 + y3 + y4
Adding equations (18)–(23), we see that
T˙ = 0
which implies that T is constant for all time. Clearly, this is due to the fact that we have a
closed system where nothing is entering and nothing leaves. Thus, we have a conservation
law
Y + y0 + y1 + y2 + y3 + y4 = T0
for some constant T0 and, evaluating this at time t = 0, we have that
T0 = Y (0) + y0(0) + y1(0) + y2(0) + y3(0) + y4(0)
The initial conditions are the steady states of equations (18)–(23). Solving these equations
for yi, i = 0, 1, 2, 3, 4 in terms of Y (0) = Y0 gives
y0,s = 0, yi,s =
c1KiY0
kiei − c1Y0
, i = 1, 2, 3, 4
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Clearly, this solution is only physically meaningful provided that yi,s ≥ 0, i = 1, 2, 3, 4 and
this requires that
c1Y0 ≤ kiei, i = 1, 2, 3, 4
which implies that the inflow rate of AP sites (c1Y ) does not exceed the maximum flow rate
(kiei) of any of the steps. Also, the initial concentration Y0 of undamaged DNA must be
specified, which then determines the value of the constant T0.
2.9 Stability
It is reasonable to assume that this steady state is stable. To show this, we must find the
eigenvalues of the Jacobian matrix evaluated at the steady state, which is given by
J =


−c1 0 0 0 0 d4
0 −k0e0
K0
0 0 0 0
c1
k0e0
K0
−d1 0 0 0
0 0 d1 −d2 0 0
0 0 0 d2 −d3 0
0 0 0 0 d3 −d4


where
di =
(c1Y0 − kiei)
2
kieiKi
, i = 1, 2, 3, 4
However, this requires the eigenvalues of a 6×6 matrix, and the appearance of y4 in the first
equation stops the matrix being lower triangular. Now the sum of all the columns of the
matrix J is zero, and this implies that the determinant is zero and so there is an eigenvalue
λ1 = 0 which is due to the conservation law. It is easily seen that another eigenvalue is
λ2 = −k0e0/K0 with eigenvector v2 = [0, 1, 0, 0, 0, 0]
T . The remaining eigenvalues are found
as roots of the quartic polynomial
p4(λ) = λ
4 + a3λ
3 + a2λ
2 + a1λ+ a0
where
a0 = d1d2d3d4 + c1(d1d2d3 + d2d3d4 + d1d2d4 + d1d3d4)
a1 = d1d2d3 + d2d3d4 + d1d2d4 + d1d3d4 + c1(d1d2 + d1d3 + d1d4 + d2d3 + d2d4 + d3d4)
a2 = d1d2 + d1d3 + d1d4 + d2d3 + d2d4 + d3d4 + c1(d1 + d2 + d3 + d4)
a3 = d1 + d2 + d3 + d4
which is not easy to solve. However, all the coefficients of this polynomial are positive and so,
by Descartes’ rule of signs [2], there are no real positive solutions. Thus, the four eigenvalues
are either real and negative or complex. We now need to exclude the possibility of complex
eigenvalues with positive real part in order to establish stability.
To do this we first consider the special case c1 = 0. In this case, the remaining four
eigenvalues can be found and are given by
λi+2 = −di, i = 1, 2, 3, 4
and so all the eigenvalues are real and negative in this case.
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As c1 increases from zero, this stable steady state will become unstable if one real or
two complex eigenvalues cross the imaginary axis. However, the constant coefficient of the
quartic polynomial is always positive, and so there can never be an eigenvalue of zero.
For the complex case, substituting λ = iω into the quartic polynomial p4(λ) and equating
real and imaginary parts gives the two equations
ω4 − a2ω
2 + a0 = 0 (24)
−a3ω
3 + a1ω = 0 (25)
One solution of (25) is ω = 0 but this corresponds to a zero eigenvalue, which is a case we
have already considered. The other solution is ω2 = a1/a3. Substituting this into (24) gives
the equation
a21 − a1a2a3 + a0a
2
3 = 0
Substituting for the coefficients into this equation gives a complicated cubic equation for
c1 which has all positive coefficients. Thus, by Descartes’ rule of signs [2], it cannot have
any real positive solutions. Thus, we conclude, since c1 must be real and positive, that no
eigenvalue can cross the imaginary axis for positive values of c1, and since the eigenvalues
are all real and negative for c1 = 0, they must remain in the real negative half of the complex
plane for all positive values of c1 and so the steady state is stable. It would seem that as
c1 increases, some of the eigenvalues could collide giving complex eigenvalues with negative
real part, resulting in oscillatory transient motion.
2.10 Simplified Model
The model equations (11)–(17) could be linearised by replacing the nonlinear Michaelis-
Menten terms with a linear term, which gives a good approximation provided that yi is
small compared to Ki for i = 0, 1, 2, 3, 4. However, the matrix associated with this linear
system has the same structure as the matrix we considered in the previous section, and the
solution of the linear differential equations requires knowledge of the eigenvalues. We saw
previously that we could only find two eigenvalues explicitly, and so we cannot write down
the general solution of these equations, except for the special case of c1 = 0.
3 Second Model
3.1 The Model Equations
The second model that we consider is a modification of the first. The amount of undamaged
DNA (Y ) is assumed to be very large relative to the other components of the model and is
not significantly depleted. Thus, we can assume that this quantity is constant. The model
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equations for the DNA damage and repair are then given by
M˙ = −c0M (26)
y˙0 = c0M − v0(y0) (27)
y˙1 = c1 + v0(y0)− v1(y1) (28)
y˙2 = v1(y1)− v2(y2) (29)
y˙3 = v2(y2)− v3(y3) (30)
y˙4 = v3(y3)− v4(y4) (31)
y˙5 = v4(y4) (32)
where c0 has units h
−1 and y5 is the amount of DNA that has been repaired. Clearly, the
last equation decouples from the others as it represents the final product of the process and
so can be ignored.
The advantage of this model is that is it not a cyclic process, which makes it easier to
work with.
We also note that there is a clearly defined concentration of MMS that is added to
the cells at the start of the process, but that the remaining quantities are more naturally
measured in sites per 100 kbp (kilo base pairs). If we use these units for the variables y1–y5,
then there is no change required for equations (28)–(32), except that the constant c1 will
have units of sites per 100 kbp/hour. However, the term c0M in (27) will have to change
as it is now in the wrong units. We also note that the MMS results in alkylation damage
to the DNA but also has many other effects in the cell, and so the loss of concentration of
MMS will not be exactly matched by the gain in alkylation damage. This process is not
the same as the mass action model where one molecule of A reacts with one molecule of B
to give one molecule of C. However, we still assume that the alkylation damage produced is
proportional to the amount of MMS. For both of these reasons, we should have two different
constants in equations (26) and (27) and so we now have the model equations
M˙ = −c0M (33)
y˙0 = cˆ0M − v0(y0) (34)
y˙1 = c1 + v0(y0)− v1(y1) (35)
y˙2 = v1(y1)− v2(y2) (36)
y˙3 = v2(y2)− v3(y3) (37)
y˙4 = v3(y3)− v4(y4) (38)
y˙5 = v4(y4) (39)
where cˆ0 has units sites per 100 kbp h
−1 µM−1. Since c0 and cˆ0 are in different units, it is
not possible to make any meaningful comparison between the values of the two constants.
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3.2 Initial Conditions
The initial conditions for our equations again consist of the steady state in the absence of
the MMS. Setting M = 0, equations (34)–(38) (ignoring the final equation) reduce to
y˙0 = −v0(y0) (40)
y˙1 = c1 + v0(y0)− v1(y1) (41)
y˙2 = v1(y1)− v2(y2) (42)
y˙3 = v2(y2)− v3(y3) (43)
y˙4 = v3(y3)− v4(y4) (44)
These equations have a steady state solution which we denote by yi,s, i = 0, 1, 2, 3, 4, which
represents a constant flow of damaged DNA being repaired, and is given by
y0,s = 0, vi(yi,s) = c1, i = 1, 2, 3, 4
which is equivalent to
y0,s = 0, yi,s =
c1Ki
kiei − c1
, i = 1, 2, 3, 4
Clearly, this solution only exists provided that yi,s ≥ 0, i = 1, 2, 3, 4 and this requires that
c1 ≤ kiei, i = 1, 2, 3, 4
which implies that the inflow rate of AP sites (c1) does not exceed the maximum flow rate
(kiei) of any of the steps.
The initial value of y5 is given by y5(0) = 0 so that y5 measures the total amount of
repaired DNA.
3.3 Stability
The Jacobian matrix for these equations is given by
J =


−k0e0
K0
0 0 0 0
k0e0
K0
−b1 0 0 0
0 b1 −b2 0 0
0 0 b2 −b3 0
0 0 0 b3 −b4


where
bi =
(kiei − c1)
2
k1e1K1
, i = 1, 2, 3, 4
which is lower triangular, and hence the eigenvalues are the diagonal entries. Evaluating at
the steady state, the eigenvalues are found to be
−
k0e0
K0
, − bi, i = 1, 2, 3, 4
and clearly these are all negative, and so the steady state is stable, as expected. We note in
this model that it is not possible to have complex eigenvalues, and so oscillatory transient
motion is not possible.
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3.4 The Model Equations
Using these steady states as the initial conditions, the full model is now given by
M˙ = −c0M M(−T ) = M0 (45)
y˙0 = cˆ0M − v0(y0) y0(−T ) = 0 (46)
y˙1 = c1 + v0(y0)− v1(y1) y1(−T ) = y1,s (47)
y˙2 = v1(y1)− v2(y2) y2(−T ) = y2,s (48)
y˙3 = v2(y2)− v3(y3) y3(−T ) = y3,s (49)
y˙4 = v3(y3)− v4(y4) y4(−T ) = y4,s (50)
where M0 is the concentration of MMS that is added to the DNA and T is the time interval
that the MMS is present for. Once the MMS has been removed, the equations are then given
by
y˙0 = −v0(y0) y0(0) = Y0 (51)
y˙1 = c1 + v0(y0)− v1(y1) y1(0) = Y1 (52)
y˙2 = v1(y1)− v2(y2) y2(0) = Y2 (53)
y˙3 = v2(y2)− v3(y3) y3(0) = Y3 (54)
y˙4 = v3(y3)− v4(y4) y4(0) = Y4 (55)
where Yi = yi(0), i = 0, 1, . . . , 4 from equations (46)–(50).
An advantage of this model compared with the first is that it has only forward coupling
and is not cyclic. We will compare predictions of this model with experimental data for the
AP sites (y1) and so for this model, we then need consider only equations (45)–(47) and
(51)–(52).
3.5 Simplified Model
The model described above assumes Michaelis-Menten kinetics, and so involves the nonlinear
velocity functions vi(yi), i = 0, 1, 2, 3, 4. If yi is small compared to Ki, then these nonlinear
functions can be approximated by a linear function, given by
vi(yi) ' κiyi
where κi = kiei/Ki. Using this approximation, the saturation effect of the Michaelis-Menten
function is removed, and the full model, including the MMS, becomes
M˙ = −c0M M(−T ) = M0 (56)
y˙0 = cˆ0M − κ0y0 y0(−T ) = 0 (57)
y˙1 = c1 + κ0y0 − κ1y1 y1(−T ) = y1,s (58)
y˙2 = κ1y1 − κ2y2 y2(−T ) = y2,s (59)
y˙3 = κ2y2 − κ3y3 y3(−T ) = y3,s (60)
y˙4 = κ3y3 − κ4y4 y4(−T ) = y4,s (61)
The steady state values in the absence of MMS are now given by
yi,s =
c1
κi
, i = 1, 2, 3, 4
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Similarly, the equations once MMS has been removed are given by
y˙0 = −κ0y0 y0(0) = Y0 (62)
y˙1 = c1 + κ0y0 − κ1y1 y1(0) = Y1 (63)
y˙2 = κ1y1 − κ2y2 y2(0) = Y2 (64)
y˙3 = κ2y2 − κ3y3 y3(0) = Y3 (65)
y˙4 = κ3y3 − κ4y4 y4(0) = Y4 (66)
Since these equations are linear, they can be solved analytically. The solution to equations
(56)–(58) is given by
M = M0e
−c0t (67)
y0 =
cˆ0M0
c0 − κ0
(e−κ0t − e−c0t) (68)
y1 =
c1
κ1
+ cˆ0κ0M0
(
e−c0t
(c0 − κ1)(c0 − κ0)
+
e−κ0t
(κ0 − c0)(κ0 − κ1)
+
e−κ1t
(κ1 − c0)(κ1 − κ0)
)
(69)
Similarly, the solution to equations (62) and (63) is given by
y0 = Y0e
−κ0t
y1 =
c1
κ1
+
κ0Y0
κ1 − κ0
e−κ0t +
(
Y1 −
c1
κ1
−
κ0Y0
κ1 − κ0
)
e−κ1t
=
c1
κ1
(1− e−κ1t) +
κ0Y0
κ1 − κ0
(e−κ0t − e−κ1t) + Y1e
−κ1t
4 Comparison with Experimental Results
4.1 Parameter Estimates
Experimental results are available for the number of AP sites per 100 kbp (y1). In order to
study this quantity using the simplified model, we require only equations (56)–(58) during
treatment with MMS, and equations (62)–(63) once the MMS has been removed. These
equations involve the five constants c0, cˆ0, c1, κ0 and κ1.
We start by estimating these parameters and see how good a fit these estimated values
give to the experimental data. We obtain the following estimates:
• The half life of MMS is approximately 30 minutes (Lisi), or 0.5h and so the decay
constant is
c0 =
ln 2
0.5
= 1.386
• Once the MMS treatment has stopped, the alkylated base damage is repaired by the
Aag enzyme and the half life for the decay of the damage is approximately 18 hours
[3]. Thus, the decay constant is
κ0 =
ln 2
18
= 0.03851
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• In Smith and Engelward [3], in vivo DNA is treated with 200µM of MNU for 30 minutes
and was found to produce 4.32× 106 alkylated bases per cell (excluding O6MeG which
MMS does not make – Lisi). The half life of MNU is approximately 15 minutes which
is half that of MMS, and so we might expect that MMS produces the same amount of
damage in 1 hour that MNU produces in 30 minutes. However, the initial concentration
of MMS that Lisi used was 2,500µM, which is 12.5 times higher than the concentration
of MNU that was used. Thus, we might expect MMS to produce 5.4 × 107 alkylated
bases per cell in 1 hour, which gives that the number of alkylated bases per 100 kbp
in one hour is
5.4× 107
6.842× 109
× 1× 105 = 789.2
From (68), we see that
y0(1) =
cˆ0M0
c0 − κ0
(e−κ0 − e−c0)
Setting y0(1) = 789.2 and using the above estimates for M0, c0 and κ0, we can solve
for cˆ0 giving
cˆ0 = 0.5973
• The spontaneous depurination occurs at a rate of approximately 15,000 purine bases
per cell per day (estimate from Lisi). Each DNA base pair contains one purine, and
there are 6.842× 109 base pairs per cell (see Ruan’s notes) and so this corresponds to
a rate of accumulation of AP sites of
c1 =
15000× 105
6.842× 109 × 24
= 9.135× 10−3 sites per 100 kbp per h
• The number of AP sites per 100 kbp before treatment was measured experimentally to
be 12.1, and this corresponds to the steady state. In terms of parameters, the steady
state is c1/κ1 and so we can use this to find
κ1 =
c1
12.1
= 7.549× 10−4
The results from the model using these parameters are shown in Fig. 1.
By construction, y1 fits the data point at time t = −1, but the fit to the next two data
points at times t = −0.5 and t = 0 is quite good. Thereafter, the graph continues to rise
rapidly, rather than falling back as the data points do.
This suggests that we have reasonable values for the parameters c0, cˆ0 and κ0, but not
for c1 and κ1. Clearly κ1 must increase significantly to get a decline in the predicted curve.
Keeping the ratio c1/κ1 = 12.1 in order to keep the steady state but increasing c1, we find
that c1 = 19 (and so κ1 = 1.570) gives a reasonable fit to the data, as is shown in Fig. 2.
We note that c1 = 19 corresponds to a rate of spontaneous depurination of 3.12 × 10
7
sites per day! This is much too high.
This raises the question as to why the model is not giving good results for y1 with the
estimated parameter values?
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Figure 1: Results for y0 and y1 using estimated parameter values.
−5 0 5 10 15 20 25
0
100
200
300
400
500
600
700
800
time
y 0
−5 0 5 10 15 20 25
10
15
20
25
30
35
time
y 1
Figure 2: Results for y0 and y1 using estimated parameter values but with c1 = 19, κ1 =
1.570.
4.2 Modified Model
Ruan and Lisi suggested that the reason for this discrepancy could be that the rate of conver-
sion of AP sites to single strand breaks, which involves the enzyme AP-endonuclease, could
be much higher when the AP sites are produced from alkylated sites than from spontaneous
depurination.
To model this, we introduce two new variables, namely ya1 and y
s
1 which are the number
of AP sites produced from alkylated sites and spontaneous depurination respectively. We
also have two different clearance rates, κa1 and κ
s
1 respectively for these two variables. Our
model equations, up to the production of AP sites, can then be modified as
M˙ = −c0M M(−T ) = M0 (70)
y˙0 = cˆ0M − κ0y0 y0(−T ) = 0 (71)
y˙a1 = κ0y0 − κ
a
1y
a
1 y
a
1(−T ) = 0 (72)
y˙s1 = c1 − κ
s
1y
s
1 y
s
1(−T ) = y
s
1,s (73)
where ys1,s = c1/κ
s
1. Similarly, the equations once MMS has been removed are given by
y˙0 = −κ0y0 y0(0) = Y0 (74)
y˙a1 = κ0y0 − κ
a
1y
a
1 y
a
1(0) = Y
a
1 (75)
y˙s1 = c1 − κ
s
1y
s
1 y
s
1(0) = Y
s
1 (76)
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We note that (73) and (76) decouple from the other equations. Moreover, they start at
the steady state value and the addition of the MMS has no effect and so they must stay at
the steady state for all time, i.e. ys1(t) = y
s
1,s = c1/κ
s
1 for all t ≥ 0. Thus, we can remove
these equations and have therefore only to solve equations (70)–(72) with the MMS present
and equations (74)–(75) once the MMS is removed. The total concentration of AP sites y1
is then given by
y1 =
c1
κs1
+ ya1
The differential equation for y1 with and without MMS is therefore
y˙1 =
c1κ
a
1
κs1
+ κ0y0 − κ
a
1y1, y1(−T ) =
c1
κsa
which is essentially the same as in the previous model, but with the parameter substitutions
c1 →
c1κ
a
1
κs1
κ1 → κ
a
1
Thus, we define the new parameter
cˆ1 =
c1κ
a
1
κs1
This equation has the same steady state value of y1,s = c1/κ
s
1 = cˆ1/κ
a
1.
In essence, the model equations have stayed the same with this modification, but the
interpretation of the parameters has changed. Thus, the results shown in Fig. 2 hold also
for this modified model, but now with cˆ1 = c1κ
a
1/κ
s
1 = 19 and κ
a
1 = 1.570, which is a factor
of 2080 higher than κs1.
Using the above values as estimates, we can now use optimisation to improve the fit of
the curve to the data. The results from this process are shown in Fig. 3 and correspond to
the parameter values
c0 = 1.678, cˆ0 = 1.987, cˆ1 = 91.09, κ0 = 0.06068, κ
a
1 = 7.166
The R2 value for this fit is 0.7866. These values give corresponding values of the half life
of MMS as 25 minutes, the half life of the alkylated damage once MMS has been removed
of 11.4 h, and a steady state for the AP sites of 12.71 sites per 100 kbp, which all seem
reasonable values. However, the maximum of y0 at time t = 0 is 2,317 which corresponds to
1.585× 108 sites per cell or 2.3% of the sites in a cell. This may be a little too high, and so
we set an upper bound on the parameter cˆ0 of 0.65 (by trial and error). This then pushes
some other parameters out of acceptable ranges, and so we also set a lower bound on c0 of
1.3 and an upper bound on ys1 of 12.2. The results obtained from optimisation including
these constraints are shown in Fig. 4 and the parameter values are
c0 = 1.3 (lower bound), cˆ0 = 0.65 (upper bound), cˆ1 = 43.51, κ0 = 0.09191, κ
a
1 = 3.566
These values give corresponding values of the half life of MMS as 32 minutes, the half life of
the alkylated damage once MMS has been removed of 7.5 h, and a steady state for the AP
sites of 12.2 sites per 100 kbp (upper bound). The maximum of y0 at time t = 0 is now 860,
which is much closer to the estimated value. The R2 value for this fit is 0.7132 which is only
a little lower than the previous value.
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Figure 3: Results for y0 and y1 using optimised parameter values.
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Figure 4: Results for y0 and y1 using optimised parameter values but with bounds c0 ≥ 1.3,
cˆ0 ≤ 0.65, y
s
1 ≤ 12.2.
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Figure 5: Results for y0 and y1 using the model including Michaelis-Menten terms.
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Figure 6: A comparison of the Michaelis-Menten functions and their linear approximations.14
4.3 Including Michaelis-Menten Functions
The model we have been working with has involved only linear terms, as a simplification of
the Michaelis-Menten functions that have saturation. We now generalise the modified model
to include Michaelis-Menten functions. Thus, equations (70)–(73) now become
M˙ = −c0M M(−T ) = M0 (77)
y˙0 = cˆ0M − v0(y0) y0(−T ) = 0 (78)
y˙a1 = v0(y0)− v
a
1(y
a
1) y
a
1(−T ) = 0 (79)
y˙s1 = c1 − v
s
1(y
s
1) y
s
1(−T ) = y
s
1,s (80)
where the velocity function vi(y) is given by (10) and y
s
1,s = c1K
s
1/(k
s
1e
s
1− c1). Similarly, the
equations once MMS has been removed are now given by
y˙0 = −v0(y0) y0(0) = Y0 (81)
y˙a1 = v0(y0)− v
a
1(y
a
1) y
a
1(0) = Y
a
1 (82)
y˙s1 = c1 − v
s
1(y
s
1) y
s
1(0) = Y
s
1 (83)
Again, the equation for ys1 starts at steady state and stays there for all time and decouples
from the other equations, and so we have
y1 = y
s
1,s + y
a
1
Adding equations (79) and (80) (or equivalently (82) and (83)), we obtain a differential
equation for y1 given by
y˙1 = v0(y0)− v
a
1(y1 − y
s
1,s)
There are now two extra parameters in the model, since the functions v0 and v
a
1 each contain
an extra parameter. For easy comparison with the previous parameter values, we write
vi(y) =
κiKiy
y +Ki
which involves κi, which is the same parameter as was used before, and the new parameter
Ki. Fitting this model to the data using optimisation, we obtain the parameter values
c0 = 1.455, cˆ0 = 0.8432, y1,s = 12.13,
κ0 = 0.07190, κ
a
1 = 3.593, K0 = 187, 494, K1 = 1, 405
The R2 value for this fit is 0.7290. These values give corresponding values of the half life of
MMS as 29 minutes, the half life of the alkylated damage once MMS has been removed of 9.6
h, and the maximum of y0 at time t = 0 is 1,063 which corresponds to 7.273× 10
7 sites per
cell or 1.1% of the sites in a cell. These all seem reasonable values and are obtained without
having to put lower or upper bounds on any of the parameters. The results are shown in
Fig. 5. We also note that the extra parameters K0 and K1 have only a small effect on the
velocity functions compared with the linear case used previously, as can be seen from Fig. 6.
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4.4 Prediction of Enzyme Concentration
The linearised approximation to the Michaelis-Menten function is v(y) = κy and this is
the dominant aspect of the function. The inclusion of the extra KM parameter typically
only results in a small variation from this linear function. The parameter κ is given by
κ = kcatE0/KM. From our data fitting, we have an estimate for the parameter κ and in
the literature, there are estimates for the parameters kcat and KM derived from in vitro
experiments. Assuming that the same kcat and KM values hold for the reaction in vivo, we
should be able to estimate the concentration E0 of an enzyme in the cell.
For the action of the enzyme AP-endonuclease, which converts AP sites into single strand
breaks, the parameters are estimated in Sokhansanj et al. [4] to be kcat = 3.08s
−1 and
KM = 32.5nM. Thus,
kcat
KM
=
3.08× 3600
0.0325
= 3.412× 105 µM−1 h−1
Now in Appendix A, we show that 1 site per 100 kbp is equivalent to a concentration in the
cell of 1µM and so we can regard our equations as also being in concentrations of µM. Thus,
we can estimate the concentration of AP-endonuclease in the cell as
E0 =
κa1KM
kcat
=
3.593
3.412× 105
= 1.053× 10−5µM = 0.01053nM
Alternative values for kcat and KM from Srivastava et al. [5] are kcat = 10s
−1 and KM =
100nM. Using these values gives a value of E0 = 0.00998nM, which is very close to the
previous estimate.
To assess how realistic this figure is, we note that n molecules per nucleus corresponds
to a concentration in the nucleus of
n
1.131× 10−13 × 6.022× 1023
= 1.468× 10−11n M = 1.468× 10−2n nM
Thus, the concentration E0 = 0.01053nM corresponds to 0.72 molecules per nucleus, which
does not seem at all reasonable.
From our fitting process, we obtained a KM value for this step given by K1 = 1, 405µM =
1.405 × 106nM, which is much larger than the values from the literature. Keeping the
kcat value of 10s
−1 from the literature, but using this value of KM, would give a predicted
concentration of the enzyme of 147nM which corresponds to 10,116 molecules per nucleus,
which would seem to be a much more reasonable value.
Thus, it appears that the linearised coefficient that determines the reaction rate, kcat/KM,
is much smaller in vivo than in vitro and so, for a given concentration of the enzyme, the
reaction will proceed much more slowly in the cell.
If kcat and KM values are available for Aag, then a similar calculation could be done for
this enzyme.
4.5 Aag-Null
Experimental results were also obtained with Aag-null, in which the Aag enzyme does not
act to convert alkylated sites into AP sites. However, AP sites still form and so we assume
that this occurs spontaneously. The rate of loss of alkylated sites and formation of AP sites is
assumed to be proportional to the number of alkylated sites, and so the model for this is the
16
−5 0 5 10 15 20 25
0
500
1000
1500
2000
2500
3000
3500
4000
4500
5000
time
y 0
Wild Type
−5 0 5 10 15 20 25
10
15
20
25
30
35
time
y 1
Wild Type
−5 0 5 10 15 20 25
0
500
1000
1500
2000
2500
3000
3500
4000
4500
5000
time
y 0
Aag−Null
−5 0 5 10 15 20 25
5
10
15
20
25
30
time
y 1
Aag−Null
Figure 7: Results for y0 and y1 for both wild type and aag-null.
same as the simple model considered previously, but with a smaller value of the parameter
κ0 in equations (57), (58), (62) and (63).
We now find the best fit to both datasets simultaneously, with all the parameters the
same except for the addition of a separate value of κ0 for the Aag data, which we will denote
by κˆ0. The results for this are shown in Fig. 7 with parameter values given by
c0 = 0.9918, cˆ0 = 3.006, y1,s = 14.22,
κ0 = 0.07407, κ
a
1 = 18.50, K0 = 187, 000, K1 = 1, 400, κˆ0 = 0.01038
A Conversion Factor
For the experimental measurements, the MMS is given as a concentration in µM and the
other variables are given as sites per 100 kbp (kilo base pairs). We now consider how to
convert number of sites per 100 kbp to concentrations.
There are 6.842 × 109 base pairs of genomic DNA in the nucleus of one cell and each
normal cell has precisely one nucleus. Each base pair contains two bases, each of which could,
in principle, be alkylated or converted into an AP site or the site of a single strand break.
Therefore, you might consider that the DNA in each cell nucleus contains 2 × 6.842 × 109
(= 1.3684× 1010) potential damage sites. The nucleus is typically spherical, so if we assume
that this has a radius of 3× 10−6m, then the volume is 1.131× 10−16m3. Now 1 cubic metre
has a volume of 103 litres and so 1.131× 10−16m3 has a volume of 1.131× 10−13l. So within
the nucleus the potential damage sites of the DNA are at a concentration of 1.3684 × 1010
17
sites per 1.131 × 10−13l= 1.210 × 1023 sites per litre. One mole of potential damage sites
would be 6.022× 1023 sites and so the concentration of potential DNA damage sites within
a nucleus is 1.210× 1023/6.022× 1023 moles/litre = 0.201M.
One AP (or alkylated) site per 105 base pairs is therefore equivalent to 6.842× 104 sites
per cell nucleus and this equates to 6.842× 104/1.131× 10−13 = 6.050 × 1017 sites per litre
or 1.005 × 10−6 moles/litre (M) or equivalently, 1.005µM. We round this conversion factor
to 1µM, so that one site per kbp is equivalent to a concentration of 1µM.
The concentration of MMS used in the experiments was 2.5mM or 2,500µM. The mea-
sured sites per 100 kbp can also be thought of as concentrations in units of µM, using the
above conversion.
Thanks to Ruan for these calculations!
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1 Introduction
Models have been created for the in vivo base excision repair pathway for repairing damaged DNA [?]. The
alkylating agent MMS was used to produce the DNA damage for one hour, with measurements of the AP
Sites taken during this hour and then at intervals over a 24 hour period.
We now consider ways of improving the model, with new data taken at more data points over a larger
time interval (48 hours).
2 First Fitting
We first used the previous model, which is presented in two parts. The first part models the process for the
hour with MMS.
M˙ = −c0M M(−T ) =M0 (1)
y˙0 = cˆ0M − κ0y0 y0(−T ) = 0 (2)
y˙1 = cˆ1 − κ0y0 − κa1y1 y1(0) = ys1,s (3)
The second part models the repair after the MMS has been removed.
y˙0 = cˆ0M − κ0y0 y0(0) = Y0 (4)
y˙1 = cˆ1 − κ0y0 − κa1y1 y1(0) = Y1 (5)
In these equations :
• M : concentration of MMS (µM)
• y0: DNA with alkylation damage due to the action of MMS (µM)
• y1: AP sites produced from alkylated sites and spontaneous depurination (µM)
• c0: decay constant of MMS
• cˆ0: amount of damage caused by MMS
• cˆ1: rate of accumulation of AP sites
• κ0: decay constant of damage
• κ1: c1’s divisor for the steady state
• −T : the starting time, -1 hours
Using this model, and the initial data analysed by Dr Aston, I managed to achieve the following fit:
c0 cˆ0 cˆ1 κ0 κ1
1.3027 0.65 67.4674 0.0976 4.4937
This gave me an R-squared value of 0.6859, a relatively good fit.
2
Figure 1: Data fit with original 24 hour data.
Figure 2: Average data across 3 experiments, no normalisation, no outliers removed.
3
3 Finding the Right Data
(The graphs in this section are based on the averages of the first three sets of experimental data, as at the
time of writing the fourth was not available to me.)
We decided to put the data through various forms of normalisation and outlier removal, then determine which
data sets would be best to use. For the sake of comparison, below is the graph of the undoctored data.
First of all we looked at how normalising it by various points would change the graph, we looked at
normalisation by:
• The first point
• The last point
• The peak
• The average of the area under the graph
Figure 3: Normalised by start and by end.
Figure 4: Normalised by peak and average.
After looking at the various normalisations, none of them looked very similar in shape from the main
graph, so we decided not to include any normalisations in the final selection of graphs. So we next removed
some outliers, which we did in two stages.
In stage one, we only removed outliers if they were anomalous both along the line of the graph and
compared to the other values of their experiment at that time point.
In stage two, we removed any outliers that were anomalous when compared to the other values of the
experiment.
4
Figure 5: After first stage of outlier removal.
Figure 6: After second stage of outlier removal.
5
Even with these graphs, there is still very little difference to be found between them. We decided to have
a more analytical look to decide what combination of the four experiments and what stage of outlier removal
would work. From a total of 45 possibilities, we subjected them to three criteria.
• Each graph must be a combination of at least three experiments.
• The starting point on the graph is defined as the steady state and must therefore be the lowest.
• The peaks must be distinct, they cannot be jagged, this was tested by checking that the two points
either side sloped away.
This left us with only four options, which we reduced to one from a visual comparison of the best fit
found from the improved model. This option was to take the average of all four experiments after the first
stage of outlier removal.
4 New Model
From looking at the previous graphs, it can clearly be seen that our data actually has two peaks, one high,
sharp peak around time point 0.5 and one lower, duller peak around time point 4 or 6. After a number
of discussions with our coworkers in the biology department, it was determined that the second peak was
likely caused by the MMS producing two different types of damage. This meant that we had to add another
damage pathway to our model, leading to a 3MeA damage pathway and a 7MeG damage pathway [2]:
M˙ = −c0M M(−T ) =M0 (6)
y˙70 = cˆ
7
0M − κ70y70 y70(−T ) = 0 (7)
y˙71 = cˆ
7
1 − κ70y70 − κa,71 y71 y71(0) = ys,71,s (8)
y˙30 = cˆ
3
0M − κ30y30 y30(−T ) = 0 (9)
y˙31 = cˆ
3
1 − κ30y30 − κa,31 y31 y31(0) = ys,31,s (10)
We were then further advised that we should change the steady state value to 0, by taking our previous
steady state value from each data point and removing cˆ1 from the equation completely, which lead to our
updated model:
M˙ = −c0M M(−T ) =M0 (11)
y˙70 = cˆ
7
0M − κ70y70 y70(−T ) = 0 (12)
y˙71 = −κ70y70 − κa,71 y71 y71(0) = 0 (13)
y˙30 = cˆ
3
0M − κ30y30 y30(−T ) = 0 (14)
y˙31 = −κ30y30 − κa,31 y31 y31(0) = 0 (15)
5 Final Fit
To get the final fit, we started by finding a solution for our differential equations down one pathway. This
allowed us to force the model to fit at the peak, by finding an equation for cˆ0. Then we made an initial fit
with this restriction to get initial guesses for our other variables, and used the equation to get our initial
guess for cˆ0. From there we managed to get out intial fit onto the data 7 which still strays a little. So we
then weighted the data around the peaks to bring it down which resulted in a much better fit 8.
The values we found for this fit are as follows:
6
Figure 7: First fitting with the new model.
Figure 8: Second fitting after the data was weighted.
7
c0 cˆ
7
0 κ
7
0 κ
7
1 cˆ
3
0 κ
3
0 κ
3
1
0.73335 0.0707 1.1977 1.9004 1345.233 0.066283 0.266283
It has a relatively low R-squared value of 0.403, but the graph looks good enough for our purposes.
We theorised that the second peak may coincide with a peak found in Aag-KO cells, implying that the
second type of damage is unaffected by Aag. Unfortunately a brief look at the data showed the peak to be
at a much larger magnitude as well as occuring a significant time period earlier.
Figure 9: Fitted data with fitted Aag-KO overlay.
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